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Preface		
This	 thesis	 is	 presented	 as	 a	 ‘Research	 Paper	 Style	 Thesis’	 in	 accordance	 with	 submission	
guidance	 provided	 by	 the	 London	 School	 of	 Hygiene	 and	 Tropical	 Medicine.	 Six	 of	 the	
chapters	 comprise	 a	 total	 of	 eight	 papers	 that	 have	 been	 published,	 submitted	 for	
publication	 or	 that	 are	 in	 preparation	 for	 submission	 to	 particular	 peer-reviewed	 journals.	
These	are	highlighted	in	italics	in	the	Table	of	Contents.	In	view	of	the	differing	requirements	
of	the	journals	in	which	the	work	has	been	published	there	is	by	necessity	some	repetition	of	
material	 and	 variation	 in	 the	 formatting	 of	 these	 chapters.	 Publication	 details	 and	
acknowledgement	of	co-	author	contributions	are	included	on	the	individual	cover	sheets	for	
each	paper.	 The	 remainder	 of	 the	 thesis	 is	 comprised	of	 ‘linking	material’	 and	 includes	 an	
introduction	to	the	overall	research	project.		
All	material	within	this	thesis	was	written	by	Michael	Marks.		
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Abstract	
Yaws	is	a	re-emerging	endemic	treponemal	infection.	The	Pacific	Islands	are	believed	
to	be	a	major	 focus	of	yaws	worldwide.	WHO	has	 recently	developed	a	 strategy	 for	global	
yaws	eradication	based	predominantly	on	community	mass	treatment	with	azithromycin	at	a	
dose	of	30mg/kg	(max	2g).	Mass	treatment	with	azithromycin	is	also	key	to	the	WHO	strategy	
for	 trachoma	 elimination,	 although	 the	 dose	 used	 is	 lower	 (20mg/kg	 –	 max	 1g).	 In	 areas	
where	 trachoma	 and	 yaws	 are	 co-endemic,	 mass	 treatment	 of	 populations	 as	 part	 of	
trachoma	 control	 programmes	 might	 aid	 yaws	 eradication	 efforts,	 but	 could	 also	 have	
negative	consequences	if	drug	resistance	were	to	be	encouraged.		
Prior	to	mass	treatment	with	azithromycin,	the	prevalence	of	clinical	and	serological	
evidence	 of	 yaws	 in	 the	 Solomon	 Islands	was	 found	 to	 be	 high.	Household	 contact	with	 a	
seropositive	individual	was	a	strong	risk	factor	for	infection,	especially	if	the	contact	also	had	
an	active	skin	lesion.	Village	level	seroprevalence	was	shown	to	be	the	strongest	risk	factor	
for	infection.		Haemophilus	ducreyi	was	identified	as	the	likely	cause	of	a	large	proportion	of	
ulcerative	skin	lesions	amongst	children,	which	were	clinically	indistinguishable	from	those	of	
yaws.	
A	single	round	of	mass	treatment	with	azithromycin	at	a	dose	of	20mg/kg	significantly	
decreased	 the	 prevalence	 of	 both	 clinical	 signs	 of	 yaws	 and	 serological	 evidence	 of	 active	
infection.	This	effect	was	shown	to	extend	to	at	least	18	months	after	mass	treatment	in	the	
absence	 of	 any	 further	 intervention.	 Not	 receiving	 treatment	 with	 azithromycin	 was	 the	
major	risk	factor	for	seropositivity	following	MDA	at	both	6	and	18	months	of	follow-up.		
		A	rapid	diagnostic	test	for	syphilis	was	shown	to	also	have	potential	value	for	use	in	
yaws.	 The	 sensitivity	 of	 the	 test	 was	 strongly	 associated	 with	 the	 antibody	 titre	 on	 gold	
standard	 testing,	 suggesting	 the	 test	may	 be	most	 appropriate	 for	 testing	 individuals	with	
suspected	active	yaws	where	antibody	titres	are	higher.		
Mathematical	modelling	data	were	used	to	establish	the	minimum	number	of	rounds	
and	 coverage	 that	 are	 likely	 to	 be	 required	 to	 interrupt	 transmission.	 Consistent	with	 the	
findings	 of	 the	 post-MDA	 prevalence	 surveys,	 the	 model	 predicted	 that	 high	 coverage	 –	
ideally	above	80%	-	is	likely	to	be	required	to	interrupt	transmission.	
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This	PhD	has	addressed	several	key	questions	about	the	epidemiology	of	yaws.	Even	
within	endemic	populations,	the	disease	is	highly	focal.	 Integration	of	rapid	diagnostic	tests	
into	routine	surveillance	may	help	improve	data	quality	and	guide	yaws	elimination	efforts	at	
a	national	level.	Given	the	strong	association	between	coverage	of	mass	treatment	and	risk	
of	infection,	new	strategies	to	increase	the	reach	of	yaws	eradication	strategies	are	needed.	
Mathematical	modelling	may	be	of	use	in	informing	the	design	of	these	interventions.		
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Thesis	outline	
 
The	 thesis	 consists	of	a	mixture	of	explanatory	material,	data	chapters	based	on	published	
and	 submitted	 manuscripts	 and	 relevant	 linking	 material.	 Chapters	 highlighted	 in	 italics	
consist	of	papers	that	have	been	published	or	submitted	for	publication.	The	other	chapters	
are	linking	material	prepared	for	this	thesis.	
	
Chapter	1	is	a	review	of	the	epidemiology,	clinical	features	and	management	of	yaws.		
	
Chapter	 2	 provides	 an	 overview	 of	 the	 components	 of	 the	 PhD	 project	 and	 the	 scientific	
rationale	for	the	study.		
	
Chapter	3	addresses	the	first	 two	objectives	of	my	PhD	and	presents	data	on	the	pre-MDA	
epidemiology	of	yaws	in	the	Solomon	Islands	
	
Chapter	 4	 addresses	 the	 third	 and	 fourth	 objectives	 of	 my	 PhD	 and	 includes	 two	 papers	
presenting	data	on	the	impact	of	community	mass	treatment	with	azithromycin	on	yaws.		
	
Chapter	 5	 presents	 data	 on	 the	 validation	 of	 a	 rapid	 diagnostic	 serological	 test	 for	 yaws,	
addressing	the	fifth	objective	of	my	PhD.	
	
Chapter	 6	 presents	 a	 mathematical	 modelling	 study	 undertaken	 to	 explore	 the	 likely	
programmatic	requirements	of	a	yaws	eradication	campaign,	addressing	the	final	objective	of	
my	PhD.		
	
Chapter	7	provides	an	overall	summary	of	the	PhD	in	relation	to	my	objectives.	
	
Chapter	8	provides	a	commentary	on	the	progress	towards	yaws	eradication	that	has	been	
made	over	the	course	of	my	PhD	
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Chapter	9	provides	an	overview	of	future	research	questions	raised	by	the	PhD.	
	
Chapter	10	contains	relevant	appendices	from	the	studies	conducted	during	the	PhD.   
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Introduction: Yaws, caused by Treponema pallidum ssp. pertenue, is
endemic in parts of West Africa, Southeast Asia and the Paciﬁc. The WHO
has launched a campaign based on mass treatment with azithromycin, to
eradicate yaws by 2020.
Sources of data: We reviewed published data, surveillance data and data
presented at yaws eradication meetings.
Areas of agreement: Azithromycin is now the preferred agent for treating
yaws. Point-of-care tests have demonstrated their value in yaws.
Areas of controversy: There is limited data from 76 countries, which previ-
ously reported yaws. Different doses of azithromycin are used in community
mass treatment for yaws and trachoma.
Growing points: Yaws eradication appears an achievable goal. The pro-
gramme will require considerable support from partners across health and
development sectors.
Areas timely for developing research: Studies to complete baseline
mapping, integrate diagnostic tests into surveillance and assess the impact
of community mass treatment with azithromycin are ongoing.
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Introduction
Yaws is an infectious disease caused by Treponema
pallidum ssp. pertenue and is one of the four trepo-
nemal diseases affecting humans.1,2 Unlike syphilis,
which is caused by the almost identical T. pallidum
pallidum, it is not sexually transmitted, but is
thought to be spread by skin to skin contact in warm
humid environments, and mother to child transmis-
sion is not seen. As with other treponemal infections,
yaws causes primary, secondary and tertiary lesions,
which predominantly affect the skin, bones and
cartilage. Yaws was the ﬁrst disease to be targeted
for eradication by the World Health Organization
(WHO), and mass screening and treatment pro-
grammes led by WHO reduced the global prevalence
by >95% between 1950 and 1964, but it has re-
emerged as an important public health problem in
West Africa, Southeast Asia and the Paciﬁc in recent
years.3 The recent demonstration that a single oral
dose of azithromycin is as effective as injectable
penicillin in the treatment of yaws4 has prompted
renewed interest in the possibility of yaws eradica-
tion, but barriers such as funding and access to
azithromycin have to be overcome before this goal
can be realized.
Epidemiology
Yaws is found in warm and humid environments5
and affects mostly children between 2 and 15 years
old, who are considered as the reservoir for infec-
tions. The disease is spread by direct skin-to-skin,
non-sexual, contact often after a cut or abrasion in
the lower legs.6 There have been suggestions that
ﬂies may act as a vector for yaws,6 but there is no
deﬁnitive proof that this occurs. Treponemal infec-
tions closely related to yaws and syphilis have been
identiﬁed in primates, but there is no evidence to
suggest that zoonotic transmission between humans
and non-human primates occurs.7 Children born to
mothers affected with yaws are generally unaffected,
and most evidence seems to indicate that the disease
is not acquired congenitally.
The early lesions of yaws are most infectious. It is
estimated that patients are infectious for up to 12–18
months following primary infection,6 but relapsing
disease can extend this period. The destructive
lesions of late yaws are not infectious. In studies in
both Papua New Guinea and the Solomon Islands,
endemicity at the village level has been identiﬁed as
the major risk factor for infection and re-infection
following treatment.8,9 The disease primarily affects
rural communities with low standards of hygiene,
with incidence declining as social and economic
status rise.
In the mid-20th century, yaws was reported to
affect ∼50 million individuals and to be endemic in
at least 90 countries10 in South America, the Carib-
bean, Africa, Asia and the Paciﬁc. The WHO
launched a major eradication effort in the 1950s
based on mass screening and treatment with inject-
able penicillin. The campaign examined some 300
million individuals of whom 50 million were treated.
Although yaws was not eradicated, by the end of the
major campaign in 1964, the burden of yaws had
been signiﬁcantly reduced to ∼2.5 million cases.3
Following this initial success of the WHO cam-
paign, yaws dropped down the public health agenda
internationally and domestically in many countries.
In the 1970s and 1980s, there was a resurgence
of cases in some countries in West and Central
Africa.11,12 This led to a renewal of control efforts,
which again reduced the burden of the disease but
did not eradicate it.
Over the past 20 years, there has been a further
resurgence of yaws in previously endemic countries,
and the disease is now thought to be endemic in at
least 12 countries in West Africa, Southeast Asia and
the Paciﬁc. There are a further 76 countries that
previously reported yaws, throughout Africa, the
Americas, Asia and the Paciﬁc, for which adequate
up-to-date surveillance data are not currently avail-
able (Fig. 1).10 Most yaws cases are concentrated in
just three countries: Ghana, Papua New Guinea and
the Solomon Islands have each reported >15 000
cases annually within the last 3 years. In another
eight countries, transmission occurs in focal com-
munities. Despite being deprioritized in inter-
national health fora, both India and Ecuador have
reported eliminating yaws in recent years with pro-
longed campaigns based on case identiﬁcation,
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contact tracing and treatment with injectable penicil-
lin,13 demonstrating that sustained efforts can be
successful.
Bacteriology
Treponema pallidum is a spirochaete that cannot be
cultured in vitro.6 They divide slowly (every 30 h),
have a characteristic corkscrew-like motility and can
move through gel-like environments such as connect-
ive tissue. They are rapidly killed by drying, oxygen
exposure or heating, and they cannot survive outside
the mammalian host. The four pathogenic trepo-
nemes are morphologically and serologically indis-
tinguishable, and share at least 99% DNA sequence
homology.14 Whole-genome sequencing has demon-
strated that the genome of T. p ssp. pertenue differs
by only 0.2% from that of T. p ssp. pallidum,14 the
causative organism of venereal syphilis. The phylo-
genetic relationship between different subspecies of
treponemes is not clear, as very few isolates of the
non-venereal subspecies are available.15
Clinical features
As with other treponemal diseases, the clinical features
of yaws may be conveniently divided into primary, sec-
ondary and tertiary disease.2,6,16 Although this classiﬁ-
cation is clinically useful, it should be remembered that
patients may present with a mixture of clinical signs.
Primary yaws
The initial lesion of primary yaws is a papule ap-
pearing at the site of inoculation after ∼21 days
(range 9–90 days).6 This ‘Mother Yaw’ may evolve
either into an exudative papilloma, 2–5 cm in size,
or degenerate to form a single, crusted, non-tender
ulcer (Fig. 2). The lower limbs are the commonest
site for primary yaws lesions, but other parts of the
body may all be affected. Unlike venereal syphilis,
genital lesions are extremely uncommon. In untreated
individuals, primary lesions may heal spontaneously
over a period of 3–6 months, leaving a pigmented
scar.17 Primary lesions may still be present in patients
who present with secondary yaws.
Fig. 1 Worldwide distribution of yaws. Data taken from the World Health Organization. Global Health Observatory Data
Repository. http://apps.who.int/gho/data/node.main.NTDYAWSEND?lang=en (2 October 2014, date last accessed).
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Secondary yaws
After a period of 1–2 months (sometimes up to 24
months), haematogenous and lymphatic spread of tre-
ponemes may result in progression to secondary yaws,
which predominantly affects the skin and bones,18,19
often with general malaise and lymphadenopathy.
As with venereal syphilis, a wide range of skin
manifestations has been described in secondary yaws
(Fig. 3). Patients may develop disseminated papillo-
matous or ulcerative lesions, scaly macular lesions or
hyperkeratotic lesions on the palms and soles.6,19
Hyperkeratotic lesions can crack and become sec-
ondarily infected, resulting in severe pain and a crab-
like gait (crab-yaws).20 Mucous membrane involve-
ment is uncommon in secondary yaws.21
Alongside the skin, involvement of the bones is
one of the cardinal features of secondary yaws. The
most common manifestation is osteoperiostitis,
involving the ﬁngers (resulting in dactylitis) or long
bones (forearm, ﬁbula and tibia) which results in
bony swelling and pain (Fig. 4).18 In most patients,
multiple bones can be affected. In a study from
Papua New Guinea,19 75% of children with second-
ary yaws had joint pain. Following treatment of
primary or secondary yaws, skin lesions usually
resolve within 2–4 weeks and bone pain may begin
to resolve in as little as 48 h.1,2
As in all treponemal infections, untreated patients
may develop latent infection, with positive serology
but no clinical signs. Latent cases can relapse,
usually in the ﬁrst 5 years (rarely up to 10 years)
after infection.6 Relapsing lesions tend to occur
around the axillae, anus and mouth.
Tertiary yaws
The destructive lesions of tertiary yaws were previ-
ously reported to occur in up to 10% of untreated
patients but are now rarely seen. As in other stages of
the disease, the skin is most commonly affected.
Nodular lesions may occur near joints and ulcerate,
causing tissue necrosis.5 Destructive lesions of the
face were one of the most marked manifestations of
late-stage yaws. Gangosa, a destructive osteitis of the
palate and nasopharynx, results in mutilating facial
Fig. 2 Lesions of primary yaws. A, typical ulcer of primary yaws. B, papilloma of primary yaws (Images
reproduced with permission of M.M. and O.M.).
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ulceration. Goundou, which was rarely reported
even when yaws was hyperendemic, is characterized
by exostoses of the maxillary bones.2
Unlike syphilis, yaws is not thought to cause car-
diovascular or neurological disease.2 Post-mortem
studies in a yaws-endemic community in Ghana
found that aortitis, histologically similar to that
found in tertiary syphilis, was the most common
cardiovascular abnormality, but deﬁnitive evidence
that this was due to yaws is lacking.
Attenuated disease
The manifestations of yaws appear to be less ﬂorid
than previously described.22 In particular, tertiary
manifestations are now rarely seen. There is no
agreed deﬁnition of attenuated yaws, nor a clear
explanation for why the clinical features of the
disease may have changed, although improvements
in living standards, use of treponemocidal antibiotics
for other infections and mutations in T. p ssp. perte-
nue have all been proposed.22
Diagnosis
Treponema pallidum is not viable ex vivo, which has
limited the value of direct diagnostic methods. While
dark ﬁeld microscopy allows direct visualization of
spirochaetes,6 the skills and equipment required are
not available in most locations even in relatively
high-income settings. Instead diagnosis has rested on
Fig. 3 Skin lesions of secondary yaws. A, Crusted maculopapular lesion of secondary yaws. B, Multiple
ulcers of secondary yaws (Images reproduced with permission of M.M. and O.M.).
Fig. 4 Bony lesions of secondary yaws. Dactylitis due to
secondary yaws (Images reproduced with permission of O.M.).
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combinations of serological assays and, more
recently, nucleic acid ampliﬁcation tests (NAATs).
As with venereal syphilis, serology has been the
mainstay of laboratory diagnosis.23 Serological
detection of yaws requires detection of two distinct
antibodies: one against a treponemal antigen and
one against a non-treponemal antigen. Treponema
pallidum particle agglutination (TPPA) and haem-
agglutination (TPHA) assays are used to detect
Treponema-speciﬁc antibodies. Once positive, these
tests usually remain positive for life. The venereal
disease research laboratory (VDRL) and rapid
plasma reagin (RPR) tests are non-treponemal tests,
which may give rise to biological false positives, but
more accurately reﬂect active disease and can be used
as a test of cure, since titres fall following successful
treatment.
A major challenge for clinicians and epidemiolo-
gists has been that the pathogenic treponemes are
serologically indistinguishable. Given the consider-
able epidemiological and clinical overlap between
the syndromes, this continues to represent a barrier
to accurate data on the incidence and prevalence of
yaws.
While serological assays do not require sophisti-
cated equipment, they do require access to labora-
tory facilities, which are rarely available to the
remote communities where yaws is endemic. Rapid
diagnostic tests (RDTs) have proved effective in the
diagnosis of syphilis,24 and a number of evaluations
of their performance in diagnosing yaws have
recently been undertaken. In Papua New Guinea, an
RDT (Chembio Diagnostic System, Inc., New York,
NY, USA) that detects both treponemal and non-
treponemal antibodies was shown to be valuable in
providing serological conﬁrmation of clinically sus-
pected cases.25 In the Solomon Islands, the same
RDT was shown to be of use for community surveil-
lance and mapping.26 These tests may help to
improve reporting practices for yaws worldwide.
Polymerase chain reaction (PCR) tests have been
commonly adopted for the diagnosis of venereal
syphilis, but distinguishing between subspecies of T.
pallidum currently relies on combined PCR and
sequencing27 and is only available at research labora-
tories. PCR has also emerged as a tool for diagnosing
other causes of skin lesions in yaws-endemic popula-
tions, including Haemophilus ducreyi.28,29 Wider
access to NAAT-based diagnostics, including pos-
sible point-of-care tests, will be required as part of
the WHO yaws eradication programme.
Diagnostic quandaries
The differential diagnosis of tropical ulcerative
lesions is broad30 and varies depending on the stage
and type of lesion. As examples, the primary lesions
of yaws may be mistaken for cutaneous leishmania-
sis, tropical ulcer caused by fusobacteria and
Treponema vincentii, or pyoderma. Of particular
importance is the emergence of H. ducreyi, the
causative organism of the sexually transmitted
disease chancroid, as a common cause of non-genital
skin lesions in a number of countries where yaws is
endemic. There are now reports of H. ducreyi as
a cause of non-genital skin lesions from Papua
New Guinea, the Solomon Islands, Ghana and
Vanuatu.28,29 Data from experimental models of
chancroid suggest that these lesions should be
responsive to azithromycin,31 and therefore, that
mass distribution of azithromycin for yaws (and pos-
sibly trachoma) could also be effective in treating
lesions resulting from infection withH. ducreyi.
Treatment
Long acting, injectable penicillin has been the
mainstay of treatment for yaws for over 50 years6
and was the cornerstone of all previous yaws control
and eradication programmes. Despite extensive use,
T. pallidum remains exquisitely sensitive to penicil-
lin, with no evidence that resistance has emerged.
There have been rare reports of treatment failure fol-
lowing treatment with penicillin, but the difﬁculty of
distinguishing treatment failure from reinfection
makes the signiﬁcance of these ﬁndings uncertain.32
The major drawback of injectable penicillin has been
the requirement for trained medical staff to adminis-
ter treatment, the risk of transmitting blood-borne
infections and the possible risk of anaphylaxis. The
recommended doses of benzathine penicillin for the
treatment of yaws (1.2 MU for adults, 0.6 MU for
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children) are lower than those used in venereal syph-
ilis,6 and in situations where the diagnosis is unclear,
clinicians are advised to treat for syphilis.16
Before 2012, no other agents had been evaluated
against yaws in randomized controlled trials, but
there are published observational data suggesting
prolonged courses of oral penicillin or tetracyclines
could be effective.33,34 Erythromycin has also been
recommended based on its efﬁcacy in the treatment
of venereal syphilis. These treatment options are of
less relevance since the emergence of azithromycin as
an effective treatment for yaws.
The macrolide antibiotic azithromycin was previ-
ously shown to be effective in treating venereal syph-
ilis.35 A landmark paper published in 2012 compared
a single oral dose of azithromycin (30 mg/kg) to
benzathine penicillin in the treatment of primary
and secondary yaws.4 Azithromycin was non-
inferior to penicillin, with clinical and serological
cure in 96% of individuals randomized to treatment
with azithromycin.
Azithromycin has a number of advantages as
an agent in the treatment of yaws. It is orally admi-
nistered and has a favourable safety proﬁle. It has
been widely and successfully used in mass drug
administration programmes for the control and elim-
ination of trachoma.36 One area of concern is the
possibility of resistance to azithromycin, which is
now widespread in sexually transmitted strains of
T. pallidum.37,38 Monitoring for the development of
resistance in T. p ssp. pertenue will be an extremely
important component of the WHO yaws eradication
strategy.
Eradication efforts
The emergence of azithromycin as an effective,
single-dose oral agent for the treatment of yaws has
led to renewed interest in the disease. In 2012, the
WHO outlined a new strategy (the Morges strategy)
for yaws eradication.39 This strategy is based on
community mass treatment with single-dose oral
azithromycin, with subsequent clinical case detection
to direct further rounds of mass or targeted treat-
ment with azithromycin. The WHO is aiming to
eradicate the disease by 2020.39
The previous WHO programmes in the 1950s to
1960s resulted in signiﬁcant reductions in the world-
wide burden of yaws3 but did not successfully eradi-
cate it. It is thought that a failure to adequately
identify and treat contacts and latent cases alongside
a lack of integration of yaws surveillance in to
national health programmes were responsible for
thisfailure.40
Both India and Ecuador have reported eliminat-
ing yaws since 2000, and their experiences are
informative for the current global eradication cam-
paign. Ecuador experienced a large drop in yaws
incidence and prevalence following the initial WHO
campaigns of the 1950s,13 but further control efforts
were complicated by the anecdotal nature of case
reporting. Ecuador instituted a more sustained sur-
veillance programme in the late 1980s, combining
continuous village-level monitoring for skin lesions
with formal surveys conducted every 5 years that
included clinical and serological screening. Indivi-
duals identiﬁed as having yaws (active or latent) were
treated with injectable benzathine penicillin. In
surveys conducted between 1988 and 1993, the
prevalence of yaws dropped by over 90%, and in a
follow-up survey conducted in 1998, no new cases
were been detected.13
In India, initial eradication efforts were launched
in the 1950s, but the disease rebounded in the 1970
and 1980’s. In 1996, the government launched a
yaws eradication programme.41 As in Ecuador, the
programme involved a combination of clinical
screening and treatment with intermittent serological
surveys. A notable aspect was the provision of ﬁnan-
cial incentives for individuals to report suspected
cases to the control programme.41 As in Ecuador,
the programme drove a sustained reduction in yaws
incidence from 3571 cases in 1996 to 0 cases in
2004.
Despite optimism surrounding mass distribution
of azithromycin, there remain major barriers to a
successful eradication programme. Notably, there
are limited accurate epidemiological data from many
countries where yaws is currently reported. Most
national surveillance systems report clinically sus-
pected cases only, without serological or PCR con-
ﬁrmation. Given the wide range of phenotypically
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similar skin lesions that may occur, it is likely that
these ﬁgures are inaccurate. Capacity building to
support improved surveillance is a central compo-
nent of the current eradication campaign. This is
compounded by the absence of recent data from
many countries where yaws was previously reported
to be endemic.10 Signiﬁcant investment in mapping
and epidemiology will be required to go along with
the eradication programme. Given the ambitious
timescales involved, innovative approaches combin-
ing mapping with other NTD or disease mapping
activities should be considered.
The eradication programme also lacks dedicated
funding and a drug donation programme. The cost
of eradication has been estimated to be in the region
of $112 million dollars, excluding drug costs, with a
cost of ∼$21 per DALY saved42 that compares
favourably to many other public health interven-
tions. As data from a larger number of previously
endemic countries become available, it is possible
that the total cost of the eradication programme may
be revised upwards substantially, although efﬁcien-
cies of scale may bring the cost per DALY down.
Yaws is known to be endemic in several countries
where trachoma is also found, including the Solomon
Islands and Vanuatu, and co-ordinated mapping
efforts have been undertaken or proposed in some of
these countries. As both diseases are controlled by
mass distribution of azithromycin, and there is
already a dedicated drug donation scheme for trach-
oma elimination, the possibility of integrating yaws
and trachoma control efforts warrants further study.
Particular attention will need to be paid to the efﬁ-
cacy of the lower dose of azithromycin (20 mg/kg)
used in trachoma control programmes for the treat-
ment of yaws.
Conclusions
Yaws remains a problem for poor, rural commu-
nities in many countries and places a signiﬁcant
burden on national health-care systems. As with the
other treponemal diseases, it has a multi-stage
disease course predominantly involving the skin and
bones. Yaws remains sensitive to penicillin, but
azithromycin has emerged as an effective treatment
that will be the cornerstone of the WHO-led eradica-
tion efforts, providing that it can be delivered to the
populations that need it.
The eradication of yaws will require considerable
support from partners across the health and develop-
ment sectors, and a number of challenges need to be
overcome for this effort to be successful. Accurate
epidemiological data are lacking from both currently
and formerly endemic countries, and a signiﬁcant
investment to improve this situation is urgently
needed. The development and validation of near-
patient and laboratory tests speciﬁc for treponemal
subspecies are urgently required, in view of the
increasing recognition that other bacteria can cause
phenotypically indistinguishable skin lesions. Inte-
gration of these tools, and monitoring for the emer-
gence of macrolide resistance, will be of critical
importance as the programme moves forward.
Despite these concerns, signiﬁcant progress has been
made in the last 5 years, raising hopes that yaws
eradication may ﬁnally become possible.
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Chapter	2:	Overview	of	PhD	objectives	and	study	design	
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2.1	Project	summary	
	
Yaws	is	a	re-emerging	endemic	treponemal	infection[1,2]	and	is	recognized	by	WHO	
as	a	Neglected	Tropical	Disease	(NTD).	The	Pacific	Islands	are	believed	to	be	a	major	focus	of	
yaws	worldwide,	though	accurate	population-based	data	on	infection	prevalence	are	lacking	
from	most	countries[2].	In	a	randomized	controlled	trial	published	in	2012,	azithromycin	at	a	
dose	of	30mg/kg	 (max	2g)	was	 shown	 to	be	non-inferior	 to	 the	previous	 standard	of	 care,	
benzathine-penicillin,	with	a	cure	rate	of	96%	for	primary	and	secondary	yaws[3].	Based	on	
this	 finding,	 WHO	 developed	 a	 strategy	 for	 worldwide	 yaws	 eradication	 by	 2020,	 based	
predominantly	on	community	mass	treatment	with	azithromycin[4].		
	
Mass	 treatment	with	 azithromycin	 is	 also	 key	 to	 the	 “SAFE”	 strategy	 for	 trachoma	
elimination[5];	however	 the	dose	used	 in	 trachoma	mass	 treatment	 (20mg/kg	–	max	1g)	 is	
lower	than	that	which	was	demonstrated	to	be	effective	against	yaws.	Although	resistance	
has	not	been	documented	in	yaws,	azithromycin	resistance,	mediated	by	point	mutations	in	
23s	rRNA,	has	emerged	in	other	treponemal	infections,	notably	syphilis[6–8].	Both	trachoma	
and	yaws	are	believed	 to	be	endemic	 in	 a	number	of	 countries,	 in	particular	 in	 the	Pacific	
region[9].	In	areas	where	trachoma	and	yaws	are	co-endemic,	mass	treatment	of	populations	
as	part	of	 trachoma	control	programmes	might	aid	yaws	eradication	efforts,	but	could	also	
have	negative	consequences	if	drug	resistance	were	to	be	encouraged.		
	
The	 aim	 of	 this	 PhD	was	 to	 answer	 several	 questions	 about	 the	 epidemiology	 and	
control	of	 yaws.	A	 central	 component	was	a	 series	of	 cross-sectional	 surveys	 conducted	 in	
the	Solomon	Islands,	which	were	used	to	provide	insights	in	to	the	epidemiology	of	yaws	and	
assess	the	 impact	of	community	mass	treatment	with	azithromycin,	conducted	as	part	of	a	
trachoma	 control	 programme,	 on	 yaws.	 It	 was	 intended	 that	 these	 data	 would	 provide	
particular	 insights	 into	 the	 potential	 effectiveness	 of	 a	 lower	 dose	 of	 azithromycin	 for	
treating	yaws.		
The	 samples	and	data	 collected	during	 these	 surveys	 formed	 the	basis	of	 the	other	
major	components	of	 this	PhD	–	a	validation	of	a	 rapid	diagnostic	serological	 test	 for	yaws	
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and	a	mathematical	modelling	study	designed	to	understand	the	programmatic	requirements	
for	yaws	eradication.		
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2.2	Aims	and	objectives	
	
2.2.1	Objectives	
	
1. Establish	accurate	data	on	epidemiology	of	yaws	in	Solomon	Islands	
2. Identify	risk	factors	in	pre-MDA	setting	for	both	yaws	disease	and	infection	
3. Assess	the	impact	of	azithromycin	MDA	on	yaws	prevalence	
4. Identify	risk	factors	for	treatment	failure	following	MDA	
5. Evaluate	diagnostic	tests	for	use	in	yaws	eradication	programmes	
6. Identify	programmatic	requirements	for	yaws	eradication	programmes	
	
2.2.2	Specific	aims	
	
1. To	examine	a	population-based	sample	of	individuals	for	clinical	signs	of	disease	and	
capture	their	clinical	phenotype	accurately		
2. To	use	a	population-based	survey	methodology	to	establish	risk	factors	for	disease	at	
an	individual	and	community	level	
3. To	evaluate	the	effect	of	mass	drug	treatment	by	mapping	the	distribution	of	active	
disease	and	infection	at	follow-up,	post	mass	drug	administration	
4. To	 establish	 the	 sensitivity	 and	 specificity	 of	 a	 rapid	 diagnostic	 serological	 test	 for	
yaws	in	a	community	surveillance	setting	
5. To	build	a	mathematical	model	of	yaws	transmission	dynamics	and	investigate,	using	
the	model,	the	predicted	impact	of	MDA	on	transmission	
	
2.3	Hypotheses	
1. Household	and	community	level	factors	will	be	associated	with	risk	of	yaws	in	a	pre-
MDA	environment	
2. Treatment	 with	 20mg/kg	 of	 azithromycin	 will	 effectively	 treat	 yaws	 resulting	 in	 a	
decreased	prevalence	of	active	and	latent	yaws	in	the	community	
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3. Failure	to	participate	in	MDA	will	be	one	of	the	predominant	risk	factors	for	yaws	in	a	
post-MDA	environment	
4. Diagnostic	tests	developed	for	syphilis	will	have	adequate	test	characteristics	for	use	
in	yaws	eradication	campaigns	
5. Thresholds	for	interruption	of	yaws	transmission	will	be	definable	using	mathematical	
modelling	
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2.4	Study	site	
	
2.4.1	The	Solomon	Islands	
The	Solomon	 Islands	 is	 an	archipelago	of	approximately	1,000	 islands	 in	 the	Pacific,	with	a	
population	at	 the	time	of	 the	2009	census	of	515,870	[10].	Administratively,	 the	country	 is	
divided	into	ten	provinces,	including	the	capital	city,	Honiara.	The	majority	of	the	population	
live	 in	 rural	 communities	 with	 only	 approximately	 20%	 of	 individuals	 residing	 in	 an	 urban	
area.	In	rural	communities	most	people	are	subsistence	farmers	although	logging,	mining	and	
tourism	are	sources	of	income	in	some	settings.	
	
The	 mean	 temperature	 is	 27°C	 with	 minimal	 seasonal	 variation,	 and	 the	 average	 annual	
rainfall	 is	 between	 3,000	 and	 5,000	 mm	 per	 year[11].	 Tropical	 cyclones	 typically	 occur	
between	 November	 and	 April.	 The	 country	 is	 ranked	 156th	 in	 the	 world	 by	 the	 Human	
Development	 Index	 [12]	with	 a	 life	 expectancy	 at	 birth	 of	 67.9	 years	 and	 a	 gross	 national	
income	per	capita	of	$1,540.	Healthcare	is	provided	free	at	the	point	of	care	by	the	Solomon	
Islands	Ministry	of	Health	and	Medical	Services	(MHMS).	Most	healthcare	is	provided	by	rural	
health	clinics	and	nurse	aid	posts	staffed	by	registered	nurses	and	nurse	aids.	These	clinics	
normally	have	access	to	either	microscopy	or	rapid	diagnostic	tests	for	malaria,	but	no	other	
diagnostic	 facilities.	Each	province	 is	 served	by	at	 least	one	provincial	hospital	where	basic	
diagnostic	tests,	including	blood	tests,	are	normally	available.	Referral	services	are	located	at	
the	National	Referral	Hospital	in	the	capital,	Honiara.		
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Figure	1:	Map	of	the	Solomon	Islands	
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2.4.2	Western	and	Choiseul	province	
The	fieldwork	for	this	PhD	was	conducted	in	Western	and	Choiseul	provinces	of	the	Solomon	
Islands.	These	are	the	northernmost	provinces	of	the	country	and	are	close	to	Bougainville 
in	Papua	New	Guinea.		
	
Western	 Province	 is	 an	 archipelago	 made	 up	 of	 a	 number	 of	 distinct	 island	 groups.	 The	
administrative	capital	 is	Gizo	and	 the	province	 is	 served	by	 two	hospitals	and	a	number	of	
clinics	 (Figure	 3).	 At	 the	 time	 of	 the	 last	 census,	 the	 population	 of	Western	 Province	was	
76,649	individuals.		
	
Choiseul	 Province	 is	 comprised	 of	 one	 major	 island	 and	 a	 small	 number	 of	 surrounding	
islands.	The	administrative	capital	 is	Taro	and	the	province	 is	 served	by	one	hospital	and	a	
number	 of	 clinics	 (Figure	 3).	 At	 the	 time	 of	 the	 last	 census	 the	 population	 of	 Choiseul	
Province	was	26,372	individuals.	
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Figure	2:	Map	of	Western	and	Choiseul	provinces	
	
	
	
2.4.3	Yaws	in	the	Solomon	Islands	
	
Yaws	is	endemic	in	the	Solomon	Islands	and	the	country	reported	17,043	cases	in	2011	(Table	
1	and	2).	Previous	surveys,	conducted	in	the	1980s	in	the	Western	Province	had	reported	a	
prevalence	of	active	primary	and	secondary	yaws	of	8.5%[13].	 	Since	that	study,	no	further	
epidemiological	 surveys	 had	 been	 conducted	 in	 the	 Solomon	 Islands.	 The	 high	 number	 of	
cases	 of	 yaws	 places	 a	 substantial	 burden	 on	 the	 health	 system	 and	 results	 in	 substantial	
morbidity.	
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Table	1:	Absolute	number	of	reported	yaws	cases	by	age	group	and	province,	2011	
Province	 1-4	yrs	 5-14yrs	 15-49yrs	 50yrs+	 Total	
Central	Islands	 71	 237	 180	 60	 548	
Choiseul	 86	 475	 248	 48	 857	
Guadalcanal	 384	 1159	 768	 215	 2526	
Honiara	 180	 571	 360	 59	 1170	
Isabel	 30	 177	 134	 13	 354	
Makira/Ulawa	 201	 569	 323	 78	 1171	
Malaita	 546	 1541	 1042	 282	 3411	
Renbel	 21	 144	 64	 27	 256	
Temotu	 181	 544	 288	 115	 1128	
Western	 1068	 3089	 1206	 259	 5622	
Solomon	Islands	 2840	 8506	 4613	 1156	 17043	
(Data	from	Solomon	Islands	MHMS,	Health	Information	System)	
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Table	2:	Reported	yaws	cases	per	1,000	population	by	age	group	and	province	2011	
Province	 1-4	yrs	 5-14yrs	 15-49yrs	 50yrs+	 Total	
Central	Islands	 19	 35	 15	 21	 22	
Choiseul	 22	 67	 21	 17	 33	
Guadalcanal	 27	 48	 17	 27	 27	
Honiara	 24	 44	 10	 13	 19	
Isabel	 8	 27	 11	 4	 14	
Makira/Ulawa	 30	 54	 21	 12	 29	
Malaita	 26	 41	 17	 19	 25	
Renbel	 55	 173	 52	 48	 85	
Temotu	 62	 97	 30	 39	 53	
Western	 97	 158	 33	 31	 74	
Solomon	Islands	 38	 64	 18	 22	 33	
(Data	from	Solomon	Islands	MHMS,	Health	Information	System)	
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2.4.4	Trachoma	in	the	Solomon	Islands	
Trachoma,	 caused	 by	 ocular	 infection	 with	 Chlamydia	 trachomatis,	 is	 also	 endemic	 in	 the	
country.	 The	 WHO	 SAFE	 strategy	 [5]	 for	 the	 elimination	 of	 blinding	 trachoma	 combines	
surgery	 for	 trachomatous	 trichiasis	 (S),	 	 azithromycin	mass	 drug	 administration	 (MDA)	 (A),	
facial	cleanliness	(F)	and	environmental	improvement	(E).		
	
Current	WHO	guidelines	for	trachoma	recommend	that	a	minimum	of	three	annual	rounds	of	
azithromycin	 MDA,	 at	 a	 dose	 of	 20mg/kg,	 should	 be	 conducted	 in	 districts	 in	 which	 the	
prevalence	of	trachomatous	inflammation—follicular	(TF)	is	greater	than	10%	in	the	1-9	year	
old	population.		
	
Between	2011	and	2013,	the	Solomon	Islands	MHMS	completed	baseline	prevalence	surveys	
for	 trachoma	 in	 all	 ten	 provinces	 of	 the	 country.	 These	 surveys	 demonstrated	 that	 the	
prevalence	 of	 TF	 was	 above	 the	 threshold	 for	 undertaking	MDA	 in	 nine	 of	 ten	 provinces.	
These	provinces	were	therefore	due	to	undertake	three	annual	rounds	of	azithromycin	MDA	
between	2014	to	2016.	The	prevalence	of	TF	in	Choiseul	province	was	found	to	be	below	the	
threshold	 for	 conducting	 azithromycin	MDA,	 according	 to	 international	 guidelines	 then	 in	
use,	 and	 therefore	 only	 the	 other	 elements	 of	 the	 SAFE	 strategy	 were	 recommended	 for	
implementation	in	this	province.	
	
	
	
	 	
42
		
	
	
	
Table	3:	Prevalence	of	trachoma	by	province	in	the	Solomon	Islands	
Province	 Year	of	
Prevalence	
Survey	
TF	
Prevalence	
(%)*	
TT	
Prevalence	
(%)^	
Recommendations	 for	 SAFE	
Intervention	
Central	Islands	 2011	 19.2	 1.5	 Full	SAFE	intervention	
Choiseul	 2013	 7.0	 0.0	 -	Implement	S,	F	&	E.		
-	Sub-district	survey	is	needed		
Guadalcanal	 2012	 15.3	 0.0	 Full	SAFE	Intervention	
Honiara		 2012	 12.0	 0.0	 Full	SAFE	Intervention	
Isabel	 2012	 24.3	 1.2	 Full	SAFE	Intervention	
Makira/Ulawa	 2012	 22.3	 0.0	 Full	SAFE	Intervention	
Malaita	 2012	 19.2	 0.0	 Full	SAFE	intervention	
Western		 2013	 23.0	 0.3	 Full	SAFE	Intervention	
Temotu	 2013	 25.0	 0.0	 Full	SAFE	Intervention	
Renbel	 2013	 25.0	 0.0	 Full	SAFE	Intervention	
		(Data	from	Solomon	Islands	MHMS)	
*In	children	aged	1-9	years	
^	In	individuals	aged	>	14	years		 	
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2.5	Study	components:	
	
The	project	consisted	of	four	main	components,	which	aimed	to	address	the	six	objectives	of	
the	PhD.		
1. Epidemiology	of	yaws	pre-MDA	(Objectives	1	&	2)	
2. Evaluation	of	impact	of	azithromycin	MDA	on	yaws	(Objectives	3	&	4)	
3. Evaluation	of	point-of-care	diagnostic	tests	in	yaws	(Objective	5)	
4. Modelling	of	yaws	transmission	and	interventions	(Objective	6)	
	
An	 overview	 of	 each	 component	 of	 the	 PhD	 is	 given	 below.	 Detailed	 introductions	 and	
methodologies	 for	 each	 component	 are	 reported	 in	 the	 respective	 Research	 Papers	
addressing	each	objective.	
	
2.5.1	Epidemiology	of	yaws		
(Detailed	methodology	and	results	reported	in	Research	Paper	–	Chapter	3)	
	
There	are	limited	data	on	the	risk	factors	for	yaws	infection	and	disease	at	a	community	and	
individual	 level.	The	most	recent	survey	data	from	the	Solomon	Islands	are	from	the	1980s	
[13]	 but	 national	 reporting	 data	 and	 recent	 studies	 from	 Papua	New	Guinea	 and	 Vanuatu	
suggest	 that	 the	prevalence	of	yaws	 remains	high	 in	 the	Pacific	 [14,15].	Whilst	 rainfall	 and	
temperature	 have	 been	 reported	 to	 be	 important	 factors	 in	 the	 distribution	 of	 yaws	
worldwide	[16,17]	there	are	extremely	limited	data	on	risk	factors	for	infection	and	disease	
within	endemic	populations.		
	
This	element	of	the	PhD	aimed	to	broaden	our	understanding	of	the	pre-MDA	epidemiology	
of	yaws	in	the	Solomon	Islands	and	to	identify	risk	factors	for	infection	and	disease.		
	
The	 fieldwork	 for	 this	 component	 of	 the	 study	 was	 a	 cross-sectional	 survey	 conducted	 in	
Western	and	Choiseul	provinces	of	the	Solomon	Islands	in	2013.	An	outline	of	the	fieldwork	
methodology	 for	 the	 study	 is	 given	 below	 (Section	 2.6	 –	 Fieldwork	 Protocol).	 Logistic	
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regression	was	used	to	assess	for	associations	at	both	the	individual	and	household	level.	At	
the	 individual	 level,	 age,	 gender,	 clinical	 phenotype	 (including	 presence	 of	 skin	 and	 bone	
lesions),	and	reported	treatment	history	were	considered.	At	the	household	level,	household	
size,	WASH	variables,	 and	presence	of	 contacts	with	 infection	or	 disease	were	 considered.	
For	 both	 infection	 and	 active	 disease,	 unadjusted	 and	 adjusted	odds	 ratios,	 controlling	 for	
potential	 confounders,	are	presented.	Clustering	was	adjusted	 for	at	 the	 level	of	 the	 study	
cluster	using	robust	standard	errors.		
	
2.5.2:	Evaluation	of	azithromycin	MDA	on	yaws		
(Detailed	methodology	and	results	reported	in	Research	Paper	–	Chapter	4)	
	
The	 WHO	 yaws	 eradication	 strategy	 is	 based	 on	 community	 mass	 treatment	 with	
azithromycin[4].	 This	 element	 of	 the	 PhD	 aimed	 to	 asses	whether	MDA,	 using	 lower	 dose	
azithromycin,	conducted	for	trachoma	control,	would	be	effective	in	reducing	the	prevalence	
of	yaws	and	whether	it	might	be	sufficient	to	interrupt	transmission.		The	fieldwork	for	this	
component	of	the	study	was	two	cross-sectional	surveys	conducted	in	Western	provinces	of	
the	 Solomon	 Islands	 in	 2014	 and	 2015	 following	 azithromycin	 MDA,	 conducted	 by	 the	
Solomon	Islands	MHMS.		
	
This	 component	 of	 the	 PhD	 used	 two	 approaches	 to	measure	 the	 impact	 of	 azithromycin	
MDA	on	prevalence	and	transmission	of	yaws	at	the	community	level.	Firstly	a	nested	case-
control	 design	was	 used,	 in	 the	 initial	 post-MDA	 cross-sectional	 survey,	 by	 comparing	 the	
seroprevalence	 of	 yaws	 between	 individuals	 receiving	 MDA	 and	 individuals	 not	 receiving	
MDA.	 This	 methodology	 has	 been	 used	 before	 to	 measure	 the	 impact	 of	 public	 health	
interventions,	 such	 as	 bed	 net	 distribution,	 at	 the	 individual	 level[18].	 	 Secondly,	 children	
aged	 <5	 years	 were	 included	 in	 the	 second	 post-MDA	 surveys.	 If	 transmission	 had	 been	
interrupted	by	MDA	then	individuals	would	remain	seronegative	for	infection.	Testing	of	this	
age	group	is	specifically	recommended	by	WHO	to	assess	for	interruption	of	transmission[4].	
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Logistic	regression	was	used	to	calculate	unadjusted	and	adjusted	odds	ratios	for	risk	factors	
for	 both	 infection	 and	 disease.	 At	 the	 individual	 level,	 demographic	 data,	 as	 well	 as	
household	 (contact)	 and	 village	 (contacts)	 level	 data,	 alongside	 MDA	 compliance	 data	
(individual,	 household	 and	 village	 coverage)	were	used	 to	 assess	 risk-factors	 for	 treatment	
failure	/	disease	post-MDA.	Clustering	was	adjusted	for	at	the	level	of	the	study	cluster,	using	
robust	standard	errors.	
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2.5.3	Diagnostics:	Validation	of	Chembio-DPP	for	use	in	yaws			
(Detailed	methodology	and	results	reported	in	Research	Paper	–	Chapter	5)	
	
Serology	 has	 remained	 the	 mainstay	 of	 laboratory	 testing	 for	 yaws	 [19].	 As	 with	 syphilis,	
laboratory	 diagnosis	 of	 yaws	 is	 based	 on	 detection	 of	 two	 distinct	 sets	 of	 antibodies:	 one	
against	 a	 treponemal	 antigen	 and	 one	 against	 a	 non-treponemal	 antigen.	 The	 Treponema	
pallidum	 particle	 agglutination	 (TPPA)	 and	 haem-agglutination	 (TPHA)	 assays	 detect	
Treponema-speciﬁc	antibodies.	These	tests	are	more	specific	than	the	non-treponemal	tests	
but	once	positive,	they	usually	remain	positive	for	life.	Commonly	used	non-treponemal	tests	
include	the	venereal	disease	research	laboratory	(VDRL)	and	rapid	plasma	reagin	(RPR)	tests.	
These	are	less	specific	than	the	treponemal	antibody	tests	but	more	accurately	reﬂect	active	
disease,	with	titres	rising	in	active	infection	and	falling	following	successful	treatment.		
	
Access	to	these	tests	remains	limited	in	many	of	the	remote,	rural	communities	where	yaws	
is	 found,	 suggesting	 that	 a	 point	 of	 care	 test	 may	 be	 of	 value.	 Syphilis	 and	 yaws	 are	
indistinguishable	using	standard	serological	approaches	[20]	and	therefore	a	rapid	diagnostic	
test	developed	for	syphilis	could	potentially	provide	a	valuable	point-of-care	diagnostic	tool	
in	countries	where	yaws	is	endemic.	The	majority	of	rapid	diagnostic	tests	for	syphilis	detect	
only	treponemal	antibodies	and	cannot	distinguish	between	current	and	past	infection.	Such	
tests	are	therefore	not	suitable	for	use	during	a	yaws	eradication	campaign.	A	novel	point	of	
care	 test	 platform	 (the	 Dual	 Path	 Platform,	 DPP)	 was	 developed	 by	 the	 CDC	 [21]	 for	 the	
detection	 of	 both	 treponemal	 and	 non-treponemal	 antibodies	 in	 patients	 being	 tested	 for	
syphilis	(Figures	4	and	5).	The	platform	has	been	shown	to	be	both	highly	sensitive	(92-95%)	
and	 specific	 (95-99%)	 for	 the	 diagnosis	 of	 syphilis	 [22,23],	 as	 compared	 to	 traditional	
serology.		
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Figure	3:	Internal	structure	of	the	Dual	Path	Platform-Syphilis	test	kit	
	
	
Sample	 and	 running	 buffer	 are	 added	 at	 point	 1	 and	 migrate	 to	 the	 detection	 strip	 2.	 If	
treponemal	or	non-treponemal	antibodies	are	present	 they	bind	a	 recombinant	T.pallidum	
antigen	 and	 a	 non-treponemal	 antigen	 respectively.	 	 Additional	 running	buffer	 is	 added	 at	
point	3.	This	causes	colloidal	gold-particles	conjugated	to	protein-A	and	anti-IgM	antibodies	
to	migrate	into	the	detection	strip.	If	antibodies	to	treponemal	and	non-treponemal	antigens	
are	present,	visible	 lines	appear	within	15	minutes.	Typical	results	of	the	RDT	are	shown	in	
Figure	5.		
	
Figure	4:	Typical	results	from	the	Dual	Path	Platform-Syphilis	test	kit	
	
	
Samples	 collected	 as	 part	 of	 the	pre-MDA	 survey	were	utilized	 for	 the	DPP-RDT	 validation	
48
		
	
	
	
study	 component	 of	 this	 PhD.	 TPPA	 and	 quantitative	 RPR	 were	 considered	 the	 ‘gold	
standard’	diagnostic	test.	The	sensitivity	and	specificity	for	the	DPP-syphilis	kit	was	calculated	
for	the	presence	of	treponemal	antibodies	and	non-treponemal	antibodies.	For	the	purposes	
of	this	study,	simple	random	sampling	was	used	to	select	samples	to	undergo	parallel	testing	
with	both	the	DPP	kit	and	traditional	serology.		
	
2.5.4:	Programmatic	requirements	for	yaws	eradication		
	(Detailed	methodology	and	results	reported	in	Research	Paper	–	Chapter	6)	
The	current	WHO	yaws	eradication	strategy	is	based	on	an	initial	round	of	total	community	
treatment	(TCT)	followed	by	subsequent	regular	active	case	finding	surveys	and	treatment	of	
any	 cases	 identified	 and	 their	 contacts	 (Total	 Targeted	 Treatment,	 TTT)	 [4].	 Once	 zero	
incident	 cases	 are	 detected,	 annual	 surveys	 are	 proposed	 for	 a	 period	 of	 three	 years,	
including	 serological	 surveillance	 of	 children	 aged	 under	 5	 years.	 If	 no	 incident	 cases	 are	
detected	 during	 this	 period	 then	 yaws	 elimination	 will	 be	 declared.	 There	 are	 limited	
empirical	 data	 to	 inform	 the	optimum	number	of	 rounds	 and	 coverage	of	mass	 treatment	
and	case	finding	that	will	be	required	to	interrupt	transmission	of	yaws	and	make	eradication	
a	possibility.	
	
A	cost-effectiveness	analysis	conducted	by	WHO	suggested	that	implementation	of	the	yaws	
eradication	strategy	was	likely	to	be	cost-effective	with	a	cost	per	DALY	averted	of	$324	[24].	
This	 analysis	 assumed	 that	 initial	 treatment	 coverage	 would	 be	 close	 to	 100%	 and	 that	
transmission	 would	 be	 interrupted	 by	 a	 limited	 number	 of	 rounds	 of	 high	 coverage	
treatment.	As	noted,	there	are	limited	empirical	data	to	support	these	assumptions.	Firstly,	
data	from	Papua	New	Guinea	indicates	that	even	within	a	research	setting,	an	initial	round	of	
mass	 treatment	 followed	 by	 active	 case	 finding	 is	 not	 sufficient	 to	 completely	 interrupt	
transmission[25].	 Secondly,	 data	 from	a	wide	 variety	of	 other	NTD	programmes	 show	 that	
high	MDA	coverage	(>90%)	is	rarely	achieved	at	the	programmatic	 level	[26].	Mathematical	
models	have	proven	effective	in	providing	guidance	on	the	likely	programmatic	requirements	
for	 other	NTD	programmes	 and	 could	provide	 similarly	 useful	 insights	 into	 the	 scale	 up	of	
yaws	eradication	efforts.		
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For	this	component	of	the	PhD,	a	stochastic	Markov	model	of	community-level	transmission	
of	yaws	was	developed.	Community	mass	treatment	interventions	were	modelled	in	line	with	
the	WHO	 eradication	 strategy,	 varying	 the	 coverage	 and	 number	 of	 rounds	 of	 community	
mass	 treatment.	 Each	 combination	 of	 disease	 and	 intervention	 parameters	 was	 simulated	
1,000	 times	 and	 the	 eradication	 probability	was	 defined	 as	 the	 percentage	 of	 runs	within	
each	combination	of	model	characteristics	where	interruption	of	transmission	was	achieved.	
Sensitivity	 analysis	 was	 used	 to	 explore	 how	 the	 elimination	 probability	 was	 affected	 by	
variation	in	both	treatment	and	disease	parameters.	
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2.6	Fieldwork	protocol	
The	 data	 for	 the	 first	 two	 components	 of	 this	 PhD	 were	 derived	 from	 community	 level	
surveys	 in	the	Solomon	Islands,	both	preceding	and	following	azithromycin	MDA.	The	MDA	
itself	was	conducted	by	the	Solomon	Islands	MHMS	as	part	of	the	national	trachoma	control	
programme.		
	
An	overview	of	the	fieldwork	methodology	used	in	these	surveys	is	provided	below.	Detailed	
methodologies	 of	 the	 fieldwork	 are	 provided	 in	 the	 Research	 Papers	 (Chapters	 3	 and	 4),	
which	report	on	the	findings	of	these	studies.	
	
The	 pre-MDA	 surveys	 were	 conducted	 in	 both	 Western	 province	 and	 Choiseul	 province	
alongside	 national	 trachoma	 prevalence	 surveys.	 Independent	 of	 the	 PhD,	 the	 pre-MDA	
prevalence	of	Trachomatous	Inflammation	–	Follicular	(TF)	in	1-9	year	old	children	was	found	
to	be	greater	than	10%	in	Western	province	and	below	10%	in	Choiseul	province.	In	line	with	
then-current	 WHO	 recommendations,	 azithromycin	 MDA	 was	 therefore	 only	 indicated	 in	
Western	Province	and	the	post-MDA	follow-up	surveys	were	conducted	there.	
	
2.6.1	Community	sensitization		
Prior	 to	 commencing	 the	 surveys	 conducted	during	 this	 study,	 the	Solomon	 Islands	MHMS	
organized	 a	 radio	 broadcast	 announcing	 the	 survey	 and	 outlining	 which	 regions	 were	
involved.	 In	 each	 community,	 discussions	 were	 held	 with	 village	 leaders	 and	 community	
members.	Knowledge	and	opinions	on	both	yaws	and,	at	the	baseline	survey	trachoma,	were	
discussed,	and	the	aims	of	the	study	and	subsequent	MDA	programme	outlined.	The	study	
was	also	explained	to	household	heads,	participating	individuals	and	their	parents/guardians.		
Opportunities	 for	questions	 to	be	answered	were	given	at	every	 stage	of	 the	process.	 The	
sensitization	process	was	conducted	by	 local	health	staff	 in	appropriate	 local	 languages	 for	
each	community.	
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2.6.2	Participant	inclusion	and	exclusion	criteria	
	
Inclusion	Criteria	
Baseline	survey	
Children	aged	5-14	years	 in	the	target	population	 in	whom	informed	consent	was	obtained	
from	a	guardian	and	assent	was	obtained	from	the	child.	
	
6	Months	follow-up	survey	
Children	aged	5-14	years	 in	the	target	population	 in	whom	informed	consent	was	obtained	
from	a	guardian	and	assent	was	obtained	from	the	child.	
	
18	Months	follow-up	survey	
Children	aged	1-14	years	 in	the	target	population	 in	whom	informed	consent	was	obtained	
from	a	guardian	and	assent	was	obtained	from	the	child.	
	
Exclusion	Criteria:	All	surveys		
Any	participant	who	declined	to	participate	or	was	unable	to	consent	or	participate	in	sample	
collection	due	to	
• Illness	
• Incapacity	
• Inability	to	communicate	
	
Exclusion	from	the	study	did	not	affect	an	individual’s	participation	in	the	azithromycin	MDA	
programme	being	undertaken	as	part	of	the	MHMS	trachoma	elimination	programme.	
	
2.6.3	Informed	consent	
For	all	fieldwork,	initial	consent	for	the	community	to	participate	in	the	study	was	obtained	
from	 the	 village	 elders.	 For	 each	 participating	 household,	 the	 household	 head	 provided	
verbal	consent	for	collection	of	household	level	data.	Where	the	household	head	was	absent	
52
		
	
	
	
at	the	time	of	the	study	visit,	the	most	senior	person	identified	by	household	members	was	
asked	to	provide	consent.	For	skin	examination	and	sample	collection,	the	household	head	or	
senior	 adult	was	 asked	 to	provide	written	 consent	on	behalf	 of	 children	 in	 the	household.	
Children	were	also	asked	to	assent	to	participation	in	the	study.	The	study	aims	and	protocols	
were	explained	to	participants	by	nursing	staff	 fluent	 in	the	 local	dialect.	All	consent	 forms	
were	 witnessed	 by	 a	 member	 of	 the	 study	 team.	 Where	 consent	 was	 not	 obtained,	
households	or	individuals	were	excluded	from	the	study.		
	
2.6.4	Data	and	sample	collection	
Surveys	were	undertaken	between	October	2013	and	November	2015.	Participant	level	data	
were	 collected	 on	 demographics	 (age	 and	 gender)	 and	 clinical	 features	 of	 yaws.	 For	 each	
included	 individual,	 the	 field	 team	 completed	 a	 standardized	 history	 and	 examination,	
collecting	information	on	bone	and	joint	symptoms,	yaws	treatment	history	and	the	number,	
location,	 and	 duration	 of	 skin	 lesions.	 Information	 about	 skin	 lesions	 was	 captured	 in	 a	
standardized	 format.	 All	 information	 was	 recorded	 directly	 into	 a	 purpose-built,	 Android	
smartphone	app,	to	ensure	completeness	and	accuracy	of	data	recorded.		
	
The	survey	team	collected	either	a	serum	sample	(children	aged	5-14	years)	or	a	dried	blood	
spot	 (children	 aged	 1-4	 years)	 from	 all	 individuals,	 regardless	 of	 clinical	 features,	 for	
diagnostic	 testing.	 In	 individuals	with	 skin	 lesions,	 the	 team	 collected	 lesion	 swabs	using	 a	
standardized	 protocol	 developed	 by	 collaborators	 at	 the	 CDC	 [27].	 Clinical	 samples	 were	
transferred	 to	 the	National	 Referral	 Hospital	 in	 Honiara	where	 they	were	 frozen	 to	 -20°C. 
Samples	were	subsequently	transferred	on	dry	ice	for	diagnostic	testing	at	LSHTM.	
	
2.6.5	Laboratory	testing:	
In	 children	 aged	 5-14	 years,	 serum	 was	 tested	 using	 both	 TPPA	 (Mast	 Diagnostics)	 and	
Quantitative	 RPR	 (Deben	 Diagnostics)	 to	 establish	 evidence	 of	 both	 previous	 (TPPA)	 and	
current	infection	(RPR	titre	>1/4).	In	children	aged	1-4	years,	dried	blood	spot	samples	were	
tested	using	TPPA	alone.	
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A	CDC-developed	four-plex	real-time	PCR	was	used	to	establish	the	presence	or	absence	of	
treponemal	DNA	in	lesion	swabs	and	to	allow	differentiation	of	T.	p.	ssp	pertenue	from	other	
pathogenic	treponemes	[27].	Where	treponemal	DNA	was	present,	an	additional	triplex	PCR	
was	 used	 to	 test	 for	 the	 presence	 or	 absence	 of	 the	 A2058G	 and	 A2059G	 23s	 rRNA	 gene	
point	mutations	that	are	associated	with	azithromycin	resistance	[7,8].	
	
2.7	Data	analysis	tools	
Statistical	analyses	for	the	epidemiology	studies	were	conducted	using	STATA	13.1	software	
(Stata	Corporation,	College	Station,	Texas	USA)	and	the	R	statistical	software	package	3.0.2	
(The	 R	 Foundation	 for	 Statistical	 Computing,	 https://www.r-project.org).	 Mathematical	
modelling	was	performed	in	R	using	the	adaptiveTau	package	[28].		Details	of	specific	analysis	
plans	for	each	component	of	the	project	are	provided	in	the	individual	data	chapters	below.	
	
2.8	Ethical	considerations	
All	 elements	 of	 the	 study	were	 conducted	 in	 accordance	with	 the	 Declaration	 of	 Helsinki.	
Ethical	approval	was	obtained	from	the	Solomon	Islands	MHMS	Research	Ethics	Committee	
(HRC	 13/10)	 and	 the	 LSHTM	 Ethics	 Committee	 (6358).	 Written	 (thumbprint	 or	 signature)	
informed	consent	was	obtained	from	the	parents	or	guardians	of	all	children	participating	in	
the	study.	
	
Clinical	examination	and	sample	collection	were	undertaken	by	experienced,	trained	medical	
and	nursing	staff	under	supervision	of	the	candidate.	Venepuncture	and	collection	of	lesion	
swabs	are	routinely	performed	procedures,	which	cause	mild	discomfort.	
	
No	active	intervention	was	undertaken	as	part	of	this	study.	Azithromycin	MDA	for	trachoma	
was	 carried	 out	 by	 the	 Ministry	 of	 Health	 in	 line	 with	 guidance	 from	 WHO.	 Survey	
participants	 with	 non-yaws	 skin	 pathologies	 were	 referred	 to	 local	 health	 services	 as	
appropriate.	 These	 data	 have	 been	 used	 to	 inform	 the	 yaws	 eradication	 strategies	 in	 the	
Solomon	Islands	and	in	other	endemic	countries.	
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2.9	Data	management	
	
For	each	survey,	each	participant	was	given	a	unique	identifier.	These	numbers	were	used	to	
link	 clinical,	 demographic,	 geographic,	 and	 laboratory	 data.	 All	 personal	 identifiers	 were	
removed	from	the	dataset	before	analysis.	All	fieldwork	data	were	collected	directly	into	the	
Opendatakit	 software	 data	 collection	 system	 [29],	 which	 automatically	 links	 all	 non-
laboratory	 data	 to	 the	 individuals’	 unique	 identifier.	 This	 system	 performs	 real-time	 data	
validity	 checks,	 ensures	 all	 data	 are	 automatically	 entered	 into	 the	 database	 in	 a	
predetermined	 coded	 format	 and	 minimizes	 missing	 data.	 Data	 from	 this	 system	 are	
uploaded	directly	to	a	secure	password-protected,	cloud-based	server.	All	data	were	verified	
and	inconsistencies	resolved	prior	to	analysis.	Data	will	be	kept	for	a	minimum	of	seven	years	
after	publication	 (or	 ten	 years	 after	 specimen	 collection,	 if	 no	publication	 results	 from	 the	
work).			
	
2.9.1	Quality	assurance	
	
Quality	 control	measures	have	been	 addressed	 in	 the	 relevant	 sections	of	 the	manuscript.	
These	include:		
	
1. Use	of	ODK	Data	Entry	Forms	on	Android	Smartphones	
a. Avoids	missing	data	
b. Validation	checks	on	data	at	the	time	of	entry	
c. Ensures	data	coded	appropriately	
2. Standardization	of	recording	of	skin	lesions	
3. Labelling	 of	 all	 samples	 with	 a	 unique	 identification	 number	 to	 link	 samples	 to	
individuals,	photographs	and	consent	forms		
4. Laboratory	work	conducted	by	operators	blinded	 to	clinical	data	using	 standardized	
SOPS	
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Chapter	3:	Epidemiology	of	yaws	in	the	Solomon	Islands	
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Abstract. Yaws, a non-venereal treponemal disease, is targeted for eradication by 2020 but accurate epidemiologi-
cal data to guide control programs remain sparse. The Solomon Islands reports the second highest number of cases of
yaws worldwide. We conducted a cluster randomized survey of yaws in two provinces of the Solomon Islands. One
thousand four hundred and ninety-seven (1,497) children 5–14 years of age were examined. Clinical signs of active yaws
were found in 79 children (5.5%), whereas 140 children (9.4%) had evidence of healed yaws lesions. Four hundred and
seventy (470) (31.4%) children had a positive Treponema pallidum particle agglutination assay (TPPA). Two hundred
and eighty-five (285) children (19%) had a positive TPPA and rapid plasma regain assay. Risk of yaws increased with
age and was more common in males. The prevalence of yaws at village level was the major risk factor for infection. Our
findings suggest the village, not the household, should be the unit of treatment in the World Health Organization (WHO)
yaws eradication strategy.
INTRODUCTION
Yaws is a non-venereal, endemic treponemal infection
caused by Treponema pallidum pertenue1 and is closely
related to T.p. pallidum, the causative agent of venereal syph-
ilis.2 Unlike syphilis, yaws is generally a disease of children3
living in poor, rural settings and is found mostly in warm and
humid environments.4 Infection predominantly results in
lesions of the skin and bone.5 Tertiary yaws causes disfiguring
lesions of the face but neurological and cardiovascular mani-
festations (which can appear in advanced syphilis) are not
thought to occur. A major campaign in the 1950s was respon-
sible for a significant reduction in the prevalence of disease
worldwide, but following the dismantling of vertical control
programs, the number of cases subsequently rebounded, and
yaws now represents a significant public health problem in
Africa, South-East Asia, and the Pacific.6–10
In a single-center study in Papua New Guinea, azithromycin
was shown to be equivalent to benzathine-penicillin in the
treatment of both primary and secondary yaws.11 The discov-
ery of an orally effective agent prompted the World Health
Organization (WHO) to plan a renewed effort to eliminate
yaws using community mass treatment.12
Despite optimism, clinical and epidemiological data on
yaws remain sparse. Many countries report only clinical cases
without laboratory confirmation and there are inadequate
data to guide control programs in many countries. Previous
studies have shown that the majority of clinical cases occur in
children < 15 years of age, and have also suggested a prepon-
derance of cases in males.3,8,13 It is also recognized that for
every clinical case there are 5–6 individuals with serological
evidence of infection but no clinical manifestations.8,13
The Solomon Islands, a Pacific archipelago of ~100 inhabited
islands, is endemic for yaws, and in 2010 the country reported
20,635 cases of yaws, the second highest number of cases in the
world after Papua New Guinea, which lies immediately to the
north.5 We conducted a cluster randomized community survey
in two provinces of the Solomon Islands to establish the prev-
alence of yaws infection and disease, and to explore risk fac-
tors associated with infection and disease at community level.
MATERIALS ANDMETHODS
Participant recruitment. The study was undertaken in
Western and Choiseul Provinces of the Solomon Islands in
September and October 2013, alongside programmatic tra-
choma mapping activities.14 The two provinces were consid-
ered as two separate evaluation units. We defined clusters
either as villages or as groups of villages to obtain 50 clusters
of approximately equal size. Twenty-five clusters were
selected at random in each province. In each cluster, a com-
plete census of all households was obtained and 30 house-
holds were selected using simple random sampling. In
selected households children 5–14 years of age were invited
to participate. Where selected households were unoccupied,
an alternative household was randomly selected. Written
informed consent was obtained from the head of each house-
hold by staff fluent in the local dialect. Assent was obtained
from all children. We calculated that a sample size of 1,022
would allow us to detect a prevalence of infection of 10% with
absolute precision of 3% assuming a design effect of 2.5.
Data collection. Household-level data were collected on
location (recorded using the smartphone global positioning
system) and Water, Sanitation and Hygiene (WASH) vari-
ables, including source of water and the presence or absence
of hand washing facilities and latrines.
Participant-level data were collected on demographics and
clinical features of yaws. The survey team completed a stan-
dardized history and examination, collecting information on
bone and joint symptoms, yaws treatment history, and the
number, location, and duration of skin lesions. Skin lesions
were classified using the WHO pictorial yaws classification
scheme. All data were collected using the LINKS software
package on Android smartphones.15
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London School of Hygiene and Tropical Medicine, Keppel Street,
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The survey team performed venipuncture on all individuals,
regardless of clinical features, and obtained a serum sample
for diagnostic testing. Samples were transferred to the National
Referral Hospital in Honiara where they were frozen. Samples
were transferred on dry ice for diagnostic testing at the London
School of Hygiene & Tropical Medicine (LSHTM).
Laboratory studies. Sera were tested using both the Trepo-
nema pallidum particle agglutination assay (TPPA, Mast Diag-
nostics, Merseyside, UK) and a quantitative rapid plasma regain
test (RPR, Deben Diagnostics, Ipswich, UK), at LSHTM, by an
operator masked to clinical findings.
Ethics. Ethical approval for the study was granted by the
ethics committees of the Ministry of Health and Medical Ser-
vices in the Solomon Islands (HRC 13/10) and LSHTM (6358)
in the UK.
Diagnosis. A positive TPPA was taken as evidence of pre-
vious or current infection. A positive TPPA combined with a
quantitative RPR titer of ³ 1/4 was taken to represent dual-
positive serology, suggestive of active infection. Individuals
with a single ulcerative or papillomatous lesion and dual-
positive serology were considered to have primary yaws. Indi-
viduals with skin or bony lesions consistent with secondary yaws
and dual-positive serology were considered to have secondary
yaws. Individuals with late manifestations (gondou, gangosa,
or gummatous lesions) would have been considered to have
tertiary yaws. Individuals with dual-positive serology but no
current clinical signs were considered to have latent yaws.
Analyses. Logistic regression was used to estimate unad-
justed and adjusted odds ratios (ORs) for factors associated
with both TPPA positivity or dual seropositivity. We classi-
fied household size as less than or greater than the national
average (5 residents) according to the 2009 census. There are
no established criteria for classifying yaws endemicity based
on serological findings. We adjusted previous treatment
criteria, based on the number of clinical cases,3 by a factor of
5 to accommodate individuals with latent infection. For the
purpose of analysis villages were classified as hypo-endemic
(0–25% of surveyed individuals dual seropositive), meso-
endemic (26–50% of individuals dual seropositive), or hyper-
endemic (> 50% of individuals dual seropositive). Robust
standard errors were used to calculate all confidence intervals
(CIs) and P values to account for village-level clustering.
All analyses were performed using Stata 13.1 (StataCorp,
College Station, TX).
RESULTS
Clinical findings. One thousand four hundred and ninety-
four (1,494) households in 981 villages were visited; there was
no-one home, or no residents 5–14 years of age, in 656 house-
holds. One thousand four hundred and ninety-seven (1,497)
children were enrolled from 98 villages and 838 households
(Figure 1). Demographic data on these individuals are
shown in Table 1. More children were enrolled in Western
province (N = 889) than Choiseul province (N = 608). Skin
lesions, of any type, were found in 290 children (19.4%, 95%
CI 14.3–25.6%).
In total, clinical signs suggestive of active yaws were found
in 79 (5.5%, 95% CI 4.0–7.5%) children. Of these, 50 children
(3.3%, 95% CI 2.4–4.6%) had skin lesions consistent with
primary yaws, whereas 29 (2.0%, 95% CI 1.1–3.7%) had
signs consistent with secondary yaws. Skin lesions consistent
with secondary yaws were found in 19 (1.3%, 0.6–2.9%),
bone lesions consistent with secondary yaws were found in
Figure 1. Map showing locations of surveyed villages. Villages where the seroprevalence of yaws was 0–25% (hypo-endemic), 25–50% (meso-
endemic), and > 50% (hyper-endemic) are shaded green, yellow, and red, respectively. The predominance of coastal villages reflects the
distribution of communities within the Solomon Islands.
Table 1
Demographics
Western Province Choiseul Province
Number of children 889 (59.4%) 608 (40.6)
Number of households 494 344
Number of villages 45 53
Number clusters 25 25
Age (median, IQR) 9 (7–12) 9 (7–11)
Male 438 (49.3%) 323 (53.1%)
Household size (median, IQR) 5 (4–6) 5 (4–6)
Number positive TPPA individuals 334 (37.6%) 132 (21.9%)
Number dual seropositive individuals 186 (20.9%) 63 (10.4%)
Village classified as endemic 12 (26.7%) 3 (5.7%)
Village classified as highly endemic 4 (8.9%) 2 (3.8%)
Access to hand washing facilities 137 (15.4%) 52 (8.6%)
IQR = interquartile range; TPPA = Treponema pallidum particle agglutination.
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10 (0.7%, 95% CI 0.3–1.5%) children. One hundred and forty
(140) children (9.4%, 95% CI 6.1–14.1%) had evidence of
healed yaws lesions, of whom 7 also had evidence of active
yaws. Two hundred and eighteen (218) children (15.2%, 95%
CI 11.0–20.5%) reported treatment of yaws in the last
12 months.
Serological findings. Four hundred and seventy children
(470) had a positive TPPA, giving a seroprevalence of previ-
ous or current treponemal infection of 31.4% (95% CI 23.6–
41.5%). As expected, the prevalence of TPPA positivity
increased with age (Figure 2). In Western province, seroprev-
alence was 37.6% (95% CI 28.1–51.1%), as compared with
21.7% (95% CI 10.4–40.2%) in Choiseul province; after
adjustment for clustering this difference was not statistically
significant (P < 0.09).
Of individuals with a positive TPPA, 285 (60.6%) had an
RPR ³ 1/4, suggesting active treponemal infection. Dual sero-
positivity was therefore 19.0% overall, but varied significantly
between Western Province (N = 186, 21.7%, 95% CI 14.6–
30.9%) and Choiseul Province (N = 63, 10.4%, 95% CI 4.1–
24.2%) (P = 0.11).
Twenty-four (30.4%) of 79 children with signs of active
yaws and 40 (28.6%) of 140 children with signs of healed yaws
were dually seropositive, compared with 14.8% of children
without signs of active or healed yaws (P < 0.01 for both
comparisons) (Table 2).
Based on serology data we classified 77 (78.6%) villages as
non-endemic, 15 (15.3%) villages as endemic, and 6 (6.1%)
villages as highly endemic. Eighty percent of dual-serologically
positive individuals lived in a meso-endemic or hyper-
endemic village.
Risk factors. In both unadjusted and adjusted analyses, age,
sex, number of dual seropositive household contacts, degree
of village endemicity, and access to hand washing facilities
were all associated with both TPPA positivity and dual sero-
positivity, and active disease. Household size was not a risk
factor for either infection or active disease (Tables 3 and 4).
DISCUSSION
This study confirms that yaws is endemic in the north-west
of the Solomon Islands, with one-third of children in this area
showing evidence of infection by TPPA. In keeping with
national case reporting, we observed a difference in the prev-
alence of clinical signs of yaws and of both TPPA positivity
and dual seropositivity between Western and Choiseul prov-
inces, although this result was not statistically significant after
accounting for clustering. As anticipated, there was significant
clustering of both infection and disease. The degree of ende-
micity at village level was the strongest risk factor for both
TPPA positivity and dual seropositivity, a finding that sug-
gests communities, not households, should be the target of
contact tracing and treatment as part of the WHO yaws erad-
ication campaign in this population. Treatment failure with
penicillin has previously been reported to be associated with
the degree of endemicity at village level.16 Our data support
the theory that reinfection, rather than true treatment failure,
may partially explain this finding.
Seropositivity was strongly associated with the number of
seropositive household contacts. It is possible that this associ-
ation is a consequence of transmission to household contacts
from an actively infected individual rather than a risk factor
for initial infection per se. Longitudinal data would be needed
to better explore this association.
Figure 2. Seroprevalence by age prevalence (and 95% confidence
interval [CI]) of Treponema pallidum particle agglutination (TPPA)
assay and dual seropositivity (TPPA and rapid plasma regain [RPR]
titer ³ 1/4) by age group.
Table 2
Serology results
Overall Western Province Choiseul Province
Clinical evidence of primary yaws n 50 38 12
TPPA positive/RPR negative 1 (2%) 1 (2.6%) 0 (0%)
TPPA positive/RPR < 1/4 3 (6%) 2 (5.3%) 1 (8.3%)
TPPA positive/RPR ³ 1/4 17 (34%) 11 (29.0%) 6 (50%)
Clinical evidence of secondary yaws N 29 28 1
TPPA positive/RPR negative 2 (6.9%) 2 (7.1%) 0 (0%)
TPPA positive/RPR < 1/4 3 (10.3%) 3 (10.7%) 1 (0%)
TPPA positive/RPR ³ 1/4 7 (24%) 6 (21.4%) 1 (100%)
Clinical evidence of previous yaws N 140 135 5
TPPA positive/RPR negative 21 (15%) 21 (15.6%) 0 (0%)
TPPA positive/RPR <1/4 25 (17.9%) 24 (17.8%) 1 (20%)
TPPA positive/RPR ³1/4 40 (28.6%) 40 (29.6%) 0 (0%)
No clinical evidence of active yaws N 1278 688 590
TPPA positive/RPR negative 59 (4.6%) 28 (4.1%) 31 (5.3%)
TPPA positive/RPR < 1/4 122 (9.5%) 75 (10.8/%) 47 (8.0%)
TPPA positive/RPR ³ 1/4 188 (14.8%) 132 (19.2%) 56 (9.5%)
TPPA = Treponema pallidum particle agglutination; RPR = rapid plasma regain.
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As in previous studies, there were several individuals with
serological evidence of infection for every individual with
clinically apparent disease,8,13 and a large number of individ-
uals with typical skin lesions who were not dually seroposi-
tive.17 Lesions not associated with positive serology may
reflect early yaws before conversion, recent treatment of yaws
with declining RPR titers, misclassification of the lesion by
survey personnel, or alternative aetiologies of ulcerative skin
lesions.Haemophilus ducreyi has recently been identified as a
possible causative agent of yaws-like lesions in the Pacific
region.18–20
As expected, the prevalence of TPPA positivity increased
with age within the age group examined, and the study also
confirmed previous reports8,13 that males are at slightly higher
risk than females of both TPPA positivity and dual seroposi-
tivity. The reasons for this association are unclear. It is possi-
ble that the association with gender reflects an earlier onset of
sexual intercourse in boys than girls, with misclassification of
cases of syphilis as yaws in endemic communities. In our
study, the association with gender remained when analyses
were restricted to children < 10 years of age, making this kind
of misclassification less likely.
An unexpected finding was the protective association
between access to hand washing facilities and the risk of
TPPA positivity and dual seropositivity. It is thought that
yaws is spread by skin-to-skin contact when bacteria from a
lesion enter by a breach in the skin.3,21 It is plausible that
access to hand washing facilities promotes better overall skin
health, reducing the number of small abrasions and lesions,
which might serve as portals of entry for T. pallidum ssp.
pertenue. It is also possible that this association is explained
by residual confounding, from better general living conditions
or access to health care facilities.
Although we did not examine adults during this survey, we
did not see any cases of tertiary yaws in the communities we
visited, a finding in keeping with a previous yaws survey in the
Table 3
Risk factors for TPPA positivity
Illustrative prevalence data Unadjusted OR Adjusted OR
Age (years)* 5–9: 27.0%
10–14: 37.9%
1.14 (1.08–1.20) P < 0.001
Sex Male: 35.1%
Female: 28.6%
1.35 (1.11–1.64) P = 0.002
Household size £ 5: 29.8%
> 5: 35.6%
1.30 (0.90–1.88) P < 0.160
Number of household dual
seropositive contacts†
0 22.9%
1 69.1% 7.52 (4.72–12.0) P < 0.001 3.92 (2.16–7.12) P < 0.001
> 1 86.1% 20.80 (9.25–46.76) P < 0.001 10.74 (4.38–26.37) P < 0.001
Household dual seropositive
contacts with skin ulcers‡
Absent: 30.7%
Present 82.4%
10.54 (3.43–32.33) P < 0.001 7.52 (4.72–12.0) P < 0.001
Village§ Hypo-endemic 14.5%
Meso-endemic 67.0% 12.02 (6.99–20.68) P < 0.001 10.22 (6.35–16.42) P < 0.001
Hyper-endemic 74.2% 17.01 (9.50–30.46) P < 0.001 20.51 (12.11–34.75) P < 0.001
Hand washing facilities¶ Absent 33.2%
Present: 23.4%
0.62 (0.35–1.09) P = 0.095 0.62 (0.35–1.09) P = 0.095
*Relative increase in odds per year increase in age.
†TPPA positive with a reactive RPR titer ³ 1/4. Adjusted for age, gender, household size, and village endemicity.
‡TPPA positive with a reactive RPR titer ³ 1/4 and an ulcerative skin lesion. adjusted for age, gender, household size, and village endemicity.
§Adjusted for age, gender, household size, and household contacts.
¶Hand washing facilities reported by family within 15 m of toilet/latrine. Adjusted for age, gender, and household size.
OR = odds ratio; TPPA = Treponema pallidum particle agglutination; RPR = rapid plasma regain.
Table 4
Risk factors for dual seropositivity
Unadjusted OR Adjusted OR
Age* 5–9: 15.4%
10–14:19.1%
1.08 (1.02–1.14) P = 0.006 1.08 (1.03–1.14) P = 0.003
Sex Male: 19.5%
Female: 14.4%
1.44 (1.38–1.83) P = 0.002 1.48 (1.17–1.88) P = 0.001
Household size £ 5: 16.0%
> 5: 18.9%
1.22 (0.79–1.90) P = 0.362
Number of household dual
seropositive Contacts†
0 9.9%
1 46.4% 7.85 (4.12–14.97) P < 0.001 4.18 (2.12–8.25), P < 0.001
> 1 59.3% 13.20 (6.40–27.21) P < 0.001 6.74 (2.72–16.70), P < 0.001
Household dual seropositive
contacts with skin ulcers‡
Absent: 16.2%
Present: 52.9%
5.82 (2.57–13.21) P < 0.001 7.52 (4.72–12.0) P < 0.001
Village§ Non-endemic 4.95%
Endemic 40.11% 12.85 (7.17–23.02) P < 0.0001 8.30 (5.36–12.86) P < 0.001
Highly endemic 51.6% 20.46 (10.79–38.82) P < 0.0001 20.33 (11.88–34.80) P < 0.001
Hand washing facilities¶ Absent: 18.4%
Present: 8.0%
0.39 (0.16–0.90) P = 0.029 0.39 (0.16–0.91) P = 0.029
*Increase in odds per year increase in age.
†TPPA positive with a reactive RPR titer ³ 1/4. Adjusted for age, gender, household size, and village endemicity.
‡Adjusted for age, gender, household size, and village endemicity.
§TPPA positive with a reactive RPR titer ³ 1/4 and an ulcerative skin lesion. adjusted for age, gender, household size, and village endemicity.
¶Hand washing facilities reported by family within 15 m of toilet/latrine. Adjusted for age, gender, and household size.
TPPA = Treponema pallidum particle agglutination; RPR = rapid plasma regain.
132 MARKS AND OTHERS
65
Solomon Islands.17 The reasons why late stage manifestations
are less common than previously reported are unclear, but
improved access to health care and use of antibiotics with
treponemocidal activity for other infections may partially
account for this finding.
In summary, our data confirm that yaws is highly endemic
in the Solomon Islands. Our study confirms previously sug-
gested associations between gender and infection while also
highlighting the need for further studies to examine the asso-
ciation with access to hand washing facilities. Prevalence of
disease at a village level was shown to be the major risk factor
for disease at an individual level, a finding that suggests the
community should be the unit of treatment in response to the
identification of cases of yaws, in the WHO yaws eradication
strategy.12 Further studies are needed to investigate whether
the associations shown in this study remain after community
mass treatment with azithromycin.
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Haemophilus 
ducreyi Associated 
with Skin Ulcers 
among Children, 
Solomon Islands
Michael Marks, Kai-Hua Chi, Ventis Vahi,  
Allan Pillay, Oliver Sokana, Alex Pavluck,  
David C. Mabey, Cheng Y. Chen,  
and Anthony W. Solomon
During a survey of yaws prevalence in the Solomon Is-
lands, we collected samples from skin ulcers of 41 children. 
Using PCR, we identified Haemophilus ducreyi infection in 
13 (32%) children. PCR-positive and PCR-negative ulcers 
were phenotypically indistinguishable. Emergence of H. du-
creyi as a cause of nongenital ulcers may affect the World 
Health Organization’s yaws eradication program.
Bacterial ulcerative skin diseases are a common cause of illness in the developing world (1). Some of these 
diseases, including Buruli ulcer, caused by Mycobacterium 
ulcerans, and yaws, caused by Treponema pallidum sub-
species pertenue, occur only in tropical and subtropical 
climates. Yaws is endemic in the Solomon Islands, where 
≈15,000 cases per year are reported (2). In 2012, the World 
Health Organization (WHO) launched a worldwide yaws 
eradication program based on treatment by mass distribu-
tion of azithromycin and monitoring for skin ulcers (3).
Reports suggest that Haemophilus ducreyi, the caus-
ative organism of chancroid, a sexually transmitted infec-
tion, may be associated with nonsexual transmission of 
nongenital ulcers of the skin in persons from the Pacific 
region (4,5). If this organism is a common cause of skin 
ulcers in the region, this factor has crucial implications 
for the yaws eradication strategy. PCR has been shown to 
be highly sensitive and specific for diagnosing chancroid 
(6). We used real-time PCR to detect H. ducreyi in skin 
ulcer samples collected during a survey for yaws in the 
Solomon Islands.
The Study
We conducted a cross-sectional survey for yaws in the 
Western Province and Choiseul Province of the Solomon 
Islands in 2013. In each province, we chose 25 clusters 
using a probability-proportionate-to-size method. In each 
cluster, we selected 30 houses by random sampling; chil-
dren 5 to 14 years of age living in those houses were invited 
to participate. Informed written consent was obtained from 
the children’s parents. 
Children underwent standardized examination. We 
recorded location, classification, and duration of skin le-
sions and yaws treatment history using the LINKS system 
(7, http://www.linkssystem.org/). Lesions were classified 
by using the WHO pictorial grading scheme for yaws (8). 
Tenderness was classified based on reports by children. 
Blood samples were collected from all children. For chil-
dren with exudative skin lesions, a sample for PCR was 
collected by rolling a sterile cotton-tipped swab across the 
lesion and placing it in a cryotube pre-filled with 1.2 mL of 
AssayAssure solution (Thermo Fisher Scientific, Waltham, 
MA, USA). Samples were transferred to Honiara National 
Referral Hospital within 5 days and stored at –20°C. Serum 
samples were placed on dry ice and shipped to the London 
School of Hygiene & Tropical Medicine and lesion sam-
ples to the US Centers for Disease Control and Prevention.
Serum samples were tested by using T. pallidum par-
ticle agglutination (Mast Diagnostics, Merseyside, UK) at 
the London School of Hygiene & Tropical Medicine. For 
samples with a positive T. pallidum particle agglutination, 
a rapid plasma regain test was performed (Deben Diagnos-
tics, Ipswich, UK). DNA was extracted from lesion sam-
ples in a CDC laboratory by using iPrep PureLink gDNA 
blood kits and the iPrep purification instrument (Life Tech-
nologies, Grand Island, NY, USA). A real-time duplex 
PCR targeting the DNA polymerase I gene (polA, tp0105) 
of pathogenic treponemes (which detects all 3 T. pallidum 
subspecies) and the human RNase P gene (to monitor for 
PCR inhibition) was performed by using a Rotor-Gene-Q 
real-time PCR instrument (QIAGEN Inc., Valencia, CA, 
USA) (9). Negative (no-template) control and positive con-
trols for T. pallidum DNA were included in each PCR run. 
Considering reports of H. ducreyi and the occurrence of M. 
ulcerans in Papua New Guinea, immediately north of the 
Solomon Islands, we performed a second duplex real-time 
PCR for M. ulcerans and H. ducreyi on all samples by us-
ing previously validated targets (10,11).
For the purpose of analysis, lesions were classified as 
acute (<4 weeks) or chronic (>4 weeks). A rapid plasma 
regain titer ≥1/4 was considered positive. Fisher exact test 
was used to compare characteristics of patients whose le-
sions contained H. ducreyi with patients whose lesions did 
not contain H. ducreyi. Analyses were performed by using 
STATA 13.1 (http://www.stata.com/).
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During the survey, 1,497 children were examined. 
Samples for PCR were collected from 41 children who 
had exudative lesions (19 male, median age 8 years). 
Twenty-two children had ulcerative lesions from which a 
sample could not be collected. Twelve (29.3%) children 
had positive results for yaws from serologic testing, but 
no DNA evidence of T. pallidum subsp. pertenue or M. ul-
cerans, causative organisms of yaws and Buruli ulcer, re-
spectively,  was detected in any sample. H. ducreyi DNA 
was amplified from 13 (32%) samples (Figure). PCR 
inhibitors were not found in any samples. Clinical data 
were incomplete for 2 participants. There were no notable 
differences in the recorded characteristics of skin lesions 
or in the serologic status of patients in whose ulcers H 
ducreyi DNA was found compared with those in which H 
ducreyi was not found (Table).
Conclusions
H. ducreyi is frequently present in skin ulcers of chil-
dren in the Solomon Islands, and lesions containing H du-
creyi DNA were similar in location, duration, and tender-
ness to lesions in which H ducreyi was not found. Papua 
New Guinea reported a similar finding (12). Experimental 
models of chancroid have demonstrated that injection of 
H. ducreyi into the epidermis and dermis causes nongenital 
skin disease, suggesting that H. ducreyi may be the cause 
of some ulcers in our survey (13). Similar to results for 
experimental models, H. ducreyi DNA was found more fre-
quently in samples collected from boys (8/13; p = 0.179), 
although this difference was not statistically significant. It 
is possible that the difficulty of collecting samples for mo-
lecular testing, the lack of facilities to enable collection of 
samples for culture in affected areas, and the precise cul-
ture requirements of H. ducreyi have notably delayed rec-
ognition of this association (14).
Lesions associated with H. ducreyi were found in pa-
tients with positive and negative serologic test results for T. 
pallidum subsp. pertenue. It is likely that patients with posi-
tive serologic test results represent latent yaws with an alter-
native etiologic agent causing the current lesion. The possi-
bility that there are alternative causes of childhood skin ulcers 
in the Pacific region could have implications for WHO’s 
yaws eradication strategy, which is based on detection of 
suspected clinical cases. Although azithromycin is effective 
in treating genital strains of H. ducreyi and experimental 
nongenital lesions (15), further studies are needed to con-
firm efficacy in nongenital lesions in a clinical setting. The 
emerging data suggest that surveillance strategies should 
routinely require molecular diagnostics. 
A causative agent was not identified in a large pro-
portion of lesion samples. A variety of possible reasons 
exist for this, including the fact that some lesions were 
noninfectious, such as insect bites, some numbers of or-
ganisms were below current limits of detection of real-
time-PCR, or that other organisms, such as staphylococci, 
for which PCR was not performed, caused these lesions. 
The sample collection/transport media and PCR assays 
we used varied from those used by Mitjà et al (12), but it 
is unclear to what extent this effected our results. A single 
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Figure: Example of lesion from which sample was obtained and 
Haemophilus ducreyi DNA was amplified, Solomon Islands, 2013. 
Photograph 2014 Michael Marks.
 
Table. Comparison of skin ulcer samples from 41 patients tested for Haemophilus ducreyi, Solomon Islands, 2013* 
Characteristic 
No. (%) samples tested for H. ducreyi by real-time-PCR, 95% CI 
p value Positive, n = 13 Negative, n = 28 
Male sex 8 (62), 32%–86% 10 (36), 19%–56% 0.179 
Location of lesion on leg 12 (92), 64%–99% 21 (96), 80%–99% 0.561 
Duration <4 weeks 7 (54), 25%–81% 14 (54), 33%–73% 0.632 
Painful lesion 8 (62), 32%–86% 17 (65), 44%–83% 0.542 
Sample TPPA-positive 6 (46), 19%–75% 17 (61), 41%–78% 0.503 
Sample TPPA- and RPR-positive 5 (38), 14%–68% 7 (25), 11%–45% 0.469 
*TPPA, Treponema pallidum particle agglutination; RPR, rapid plasma regain test. 
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sample was collected per patient, but several patients (n = 
8, 19.5%) had >1 skin lesion. Swabbing every lesion may 
have increased the diagnostic yield for H. ducreyi and/
or T. pallidum subsp. pertenue. Further studies to explore 
causes of skin ulcers in this community are needed to bet-
ter inform disease control efforts.
Because it was not anticipated that H. ducreyi DNA 
would be found in nongenital skin lesions, we did not pro-
spectively collect data on regional lymphadenopathy; how-
ever, we did not notice marked lymphadenopathy or bubo 
formation. Collection of samples for culture and sequenc-
ing of the H. ducreyi genome are needed to inform our un-
derstanding of relatedness of these strains to genital strains.
This study has 2 main limitations. First, the number 
of samples tested was small. Second, lesion samples were 
tested for only 3 organisms, raising the possibility that other 
organisms caused a large proportion of skin ulcers. Despite 
these limitations, this study clearly demonstrates that H. du-
creyi is frequently present in childhood skin ulcers in this 
yaws-endemic community. Further studies of the epide-
miology, microbiology, and response to treatment for this 
newly described pathogen–disease association are required.
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Abstract
Background
Community mass treatment with 30mg/kg azithromycin is central to the newWHO strategy
for eradicating yaws. Both yaws and trachoma— which is earmarked for elimination by
2020 using a strategy that includes mass treatment with 20mg/kg azithromycin—are
endemic in the Pacific, raising the possibility of an integrated approach to disease control.
Community mass treatment with azithromycin for trachoma elimination was conducted in
the Solomon Islands in 2014.
Methods
We conducted a study to assess the impact of mass treatment with 20mg/kg azithromycin
on yaws. We examined children aged 5-14 years and took blood and lesion samples for
yaws diagnosis.
Results
We recruited 897 children, 6 months after mass treatment. There were no cases of active
yaws. Serological evidence of current infection was found in 3.6% (95% CI= 2.5-5.0%). This
differed significantly between individuals who had and had not received azithromycin (2.8%
vs 6.5%, p=0.015); the prevalence of positive serology in 5-14 year-olds had been 21.7%
(95% CI=14.6%-30.9%) 6 months prior to mass treatment. Not receiving azithromycin was
associated with an odds of 3.9 for infection (p=0.001). National figures showed a 57%
reduction in reported cases of yaws following mass treatment.
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Discussion
Following a single round of treatment we did not identify any cases of active yaws in a previ-
ously endemic population. We found a significant reduction in latent infection. Our data sup-
port expansion of the WHO eradication strategy and suggest an integrated approach to the
control of yaws and trachoma in the Pacific may be viable.
Author Summary
Yaws is a bacterial infection closely related to syphilis. The WHO has launched a world-
wide campaign to eradicate yaws by 2020. This strategy relies on mass treatment of the
whole community with the antibiotic azithromycin. Mass treatment with the same antibi-
otic is also recommended by WHO to treat the eye condition trachoma but the dose used
for this is lower. In this study we assessed the impact of a trachoma control programme in
the Solomon Islands on yaws. Following a single round of mass treatment the number of
yaws cases fell significantly compared to before treatment. We also saw fewer new cases of
yaws being reported to the Ministry of Health. Our findings suggest that mass treatment
with the lower dose of azithromycin is also effective as a treatment for yaws. In countries
where both yaws and trachoma are found it may be possible to develop an integrated strat-
egy for both conditions.
Introduction
Yaws, caused by Treponema pallidum subsp pertenue, is a non-venereal infection closely
related to syphilis that predominantly affects children living in remote, rural communities in
tropical countries[1]. Infection manifests as lesions of the skin, bone and cartilage and,
untreated, may progress to destructive tertiary lesions[2]. Yaws was once widespread through-
out the tropics. Previous yaws control efforts in the middle of the twentieth century were based
on treatment with injectable long-acting penicillin[3], and resulted in significant reductions in
the burden of disease worldwide[4]. Despite these initial successes, the disease subsequently
rebounded in a number of countries and it is currently thought to be endemic in at least 12
countries across West Africa, South East Asia and the Pacific[1].
In 2012, treatment with azithromycin was shown to be highly effective for yaws[5], and com-
munity mass treatment became the foundation of the newWHOMorges yaws eradication strat-
egy[6]. Azithromycin has a number of advantageous characteristics as a mass treatment agent,
including oral route of administration, long tissue half-life, and an acceptable side-effect profile.
Community mass treatment with azithromycin is also central to the control of trachoma[7],
but the recommended dose used in trachoma control (20mg/kg, max 1g) is lower than that rec-
ommended for yaws (30mg/kg, max 2g). The International Task Force for Disease Eradication
highlighted the need to investigate the effect of lower dose azithromycin for the treatment of
yaws, and the possibility of synergies with trachoma control programmes in countries where
the two diseases are co-endemic. In some areas of Ghana in which azithromycin mass drug
administration was previously used for trachoma control, yaws is currently undetectable[8],
supporting the hypothesis that lower dose azithromycin may be effective.
Unexpectedly, several recent studies have demonstrated thatHaemophilus ducreyi[9,10] is a
common cause of non-genital ulcerative skin lesions in children in yaws endemic communities.
This is a finding which can present difficulties for clinical case identification. Community
Impact of Trachoma MDA on Yaws
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perceptions of the value of mass treatment campaigns may be affected by the impact of azithro-
mycin on other common skin infections. Genital strains ofH. ducreyi are responsive to azithro-
mycin[11], so it is possible that mass treatment with azithromycin may have a synergistic
benefit on non-yaws ulcerative skin lesions in these communities.
Both yaws and trachoma are endemic in the Solomon Islands[12], which routinely reports
the third highest number of cases of yaws among all countries worldwide[13]. In 2014, the Sol-
omon Islands Ministry of Health and Medical Services (MHMS) undertook community mass
treatment with azithromycin as part of the SAFE strategy for trachoma elimination. We per-
formed a prospective study in the Western Province of the Solomon Islands to assess the
impact of azithromycin used against trachoma on the prevalence of active and latent yaws.
Methods
As previously described [12], in September and October 2013, we conducted a pre-mass treat-
ment survey in Western and Choiseul Provinces of the Solomon Islands, and documented a
high prevalence of active and latent yaws. In mid 2014, mass antibiotic treatment was under-
taken for trachoma by the Ministry of Health, in Western Province only, Choiseul Province
not qualifying for mass treatment on the basis of a lower prevalence of active trachoma. Azi-
thromycin was administered at 20mg/kg (max 1g) with dose determined by body weight, mea-
sured using analogue scales. Due to the death of a local religious leader in June 2014, some
communities in the province were in mourning and did not receive treatment with azithromy-
cin. For the purposes of this study, we randomly selected a subset of Western Province commu-
nities known to have received treatment with azithromycin. At each household, we collected
data on number of residents and whether no, some, or all members of the household had
received treatment with azithromycin as part of the mass treatment campaign for trachoma.
We enrolled children aged 5–14 years for assessment, collecting individual level data on age,
gender, the presence or absence of clinical signs and symptoms of yaws, yaws treatment his-
tory, and whether the individual reported having received treatment with azithromycin. We
categorized skin lesions using the WHO yaws pictorial guide[14]. All data were entered directly
into Android smartphones using the ODK software package[15].
Venepuncture was performed and a serum sample collected from each individual. In indi-
viduals with ulcerative or papillomatous skin lesions, we also collected a swab sample of lesion
exudate. Exudate was transferred to a FTA Elute Micro Card (GE Healthcare, Buckingham-
shire, UK) using three firm side-to-side passes of the swab across the card. We placed each
card in its own re-sealable plastic packet with a sachet of desiccant. All samples were trans-
ferred to the National Referral Hospital, Honiara, where they were frozen at -20°C, and shipped
on dry ice to the London School of Hygiene & Tropical Medicine (LSHTM), UK and the Cen-
ters for Disease Control and Prevention (CDC), USA for diagnostic testing.
Laboratory testing
Serum samples were tested at LSHTM with the Treponema pallidum particle agglutination test
(TPPA, Mast Diagnostics, Merseyside UK). On samples that were TPPA-positive, a quantita-
tive plasma reagin test (RPR, Deben Diagnostics, Ipswich, UK) was performed. Lesion swabs
were tested at the CDC using a multiplex real-time (RT) PCR for the identification of Trepo-
nema pallidum sub-species DNA[16]. If the T pallidum PCR was positive, we intended to use a
second multiplex RT PCR to detect mutations in the 23S rRNA gene associated with azithro-
mycin resistance. Regardless of the result of the T. pallidum PCR, we performed an additional
duplex RT PCR for the detection ofHaemophilus ducreyi andMycobacterium ulcerans DNA
[9]. All laboratory testing was performed by individuals masked to the clinical findings.
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Routine reporting of yaws incidence data
Suspected cases of yaws are reported via the MHMS Health Information System. We extracted
data on the number of cases of yaws seen, per month, across all clinics in the Western Province
of the Solomon Islands during the period 2011 to 2014 to allow an assessment of the impact of
community mass treatment on the incidence of disease presentation.
Statistical analysis
A positive TPPA was taken as evidence of previous or current infection. Individuals with clini-
cal signs of yaws, a positive TPPA and an RPR titre of!1:4 (dual-seropositivity) were consid-
ered to have active yaws. Individuals without clinical signs of yaws and with a positive TPPA
and an RPR titre of!1:4 were considered to have latent yaws. An RPR titre of!1:16 was con-
sidered to be a high-titre positive. We classified household size as"5 or>5 residents, 5 house-
holders being the national average according to the most recent census[17]. Household
treatment with azithromycin was categorized as complete, incomplete (at least 1 individual not
treated) or none. The prevalence of active and latent yaws was compared between individuals
who had and had not received treatment with azithromycin. Multivariable logistic regression
was used to estimate unadjusted and adjusted odds ratios (ORs) for factors associated with
both TPPA- and dual-seropositivity. Robust standard errors were used to calculate all confi-
dence intervals (CIs) and P values, to account for village-level clustering[18]. The impact of
mass treatment on cases reported to the MHMS was analysed by fitting a linear regression
model to the time series on incident yaws cases, controlling for known seasonal variations and
trend in yaws incidence. To account for autocorrelation, the error in the model was assumed to
follow an autoregressive process, with a lag of one. All analyses were performed using Stata
13.1 (Statacorp, Texas).
Sample size
Our pre-mass drug administration (MDA) survey had shown that the prevalence of dual-sero-
positivity in these communities was approximately 20%[12]. Assuming that treatment with azi-
thromycin is 90% effective, the prevalence in people who receive treatment would be
anticipated to be approximately 2% post treatment. The prevalence of yaws in untreated indi-
viduals was also predicted to fall due to reduced community transmission, although there were
no data to guide the likely magnitude of this effect. Assuming, conservatively, that prevalence
amongst untreated individuals would fall by 25%, 72 individuals receiving azithromycin and
72 individuals who did not receive azithromycin would have 90% power to detect a difference
in the prevalence of yaws. Given anticipated community coverage of 90%, a total survey sample
of 720 individuals would therefore be required.
Ethical approval
Written informed consent was obtained from each participating child’s parent or guardian by
a member of staff fluent in the local dialect. Assent was obtained from all children. Ethical
approval for the study was granted by the ethics committees of the Solomon Islands MHMS
and the LSHTM (6358).
Results
We enrolled 897 children from 441 households in 11 communities. The median age of children
was 9 years, and 466 (52%) were male. 717 children (80%) reported having been treated with
azithromycin as part of the trachoma control programme (Table 1) (S1 File).
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Two hundred and thirty seven children (26%) had a clinically apparent skin lesion. Twenty-
eight children (3.1%) had a skin lesion clinically consistent with yaws. Lesions were more com-
mon in individuals who had not received MDA, but this difference was not statistically signifi-
cant. (4.9% vs 2.6%, p = 0.101). No individual with a skin lesion consistent with active yaws had
dual-positive serology. Bone swelling consistent with secondary yaws was rare, occurring in
only 4 subjects (0.5%). Sixty children (6.7%) had skin lesions consistent with healed yaws. Other
skin lesions including ringworm and bacterial infections were common (158 children, 17.6%).
Two hundred and twenty eight children (25%, 95% CI 23–28%) had a positive TPPA. The
prevalence did not differ significantly between individuals who had and had not received treat-
ment with azithromycin (24% vs 26%, p = 0.598). Thirty two children (3.5%, 95% CI 2.5–4.9%)
had a positive TPPA and an RPR titre of! 1:4; the prevalence of this differed significantly
between individuals who had and had not received treatment with azithromycin (2.8% vs 6.6%,
p = 0.015). 11 children (1.2%, 95% CI 0.06–2.2%) had a high titre positive RPR and this also
differed significantly between individuals who had and had not received azithromycin (0.8% vs
2.7%, p = 0.046) (Fig 1). We collected lesion swabs from twenty individuals. Swabs could not
be collected from eight ulcerative lesions as they were dry. No sample tested positive for T. p
subsp. pertenue, but 7 swabs (35%) were positive for H. ducreyi.
Given the small number of individuals with dual sero-positivity these subjects were com-
bined into a single group for the purpose of further analysis. People who had not taken azithro-
mycin had higher odds of dual sero-positivity than those who had (OR = 2.49, 95% CI 1.2–5.2,
p = 0.015), and after adjusting for confounding due to age, gender, and community of resi-
dence, the odds ratio was 3.8 (95% CI 1.8–8.5, p = 0.001) (Tables 2 and 3). Increasing age was
associated with TPPA positivity, but no other variable was associated with dual sero-positivity.
In the pre-mass treatment period (n = 36 months) the mean monthly number of cases of
yaws reported by clinicians in the Western Province was 184. In the interrupted time series
analysis, the number of cases was 183 in the dry season and 158 in the wet season (p = 0.440),
and mass treatment was followed by a reduction in the mean number of cases reported per
month of 101 case (relative reduction 57%, p = 0.044) (Fig 2).
Discussion
In this study, a single round of community mass treatment with 20mg/kg azithromycin, given
for trachoma elimination, resulted in a significant reduction in the prevalence of both active
and latent yaws, from 1.5% and 20.2% pre-treatment[12], to 0.0% and 3.6% post-treatment
(p = 0.002 and<0.001, respectively). The prevalence of infection declined both in individuals
who had received treatment and in those who had not, suggesting that a single round of
Table 1. Demographics of study subjects.
Number of children 897
Number of households 441
Household size (Median, IQR) 6 (4–7)
Household MDA Coverage Complete 59%
Incomplete 28%
None 13%
Age (Median, IQR) 9 (7–12)
Male 466 (52%)
Received treatment with azithromycin 717 (80%)
Reported treatment for yaws in last year 93 (10%)
doi:10.1371/journal.pntd.0003988.t001
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treatment may have reduced transmission, resulting in a population level benefit that extended
to individuals who were not themselves treated. Consistent with this, the impact of azithromy-
cin appeared particularly marked in reducing the prevalence of high-titre positive individuals,
who are thought to drive transmission at community level. Our results are mirrored in the rou-
tine reporting data for incident yaws cases, which showed a profound drop following mass
treatment with azithromycin. There was also a reduction in the prevalence of any ulcerative
skin lesion since our previous survey (6.0% vs 3.1%, p = 0.004). Taken together, these data sug-
gest that a single round of 20mg/kg azithromycin mass treatment given for trachoma may have
interrupted yaws transmission, resulting in a reduction of both prevalent and incident yaws
cases, and reducing the prevalence of skin lesions due to other bacteria.
Table 2. Risk factors for TPPA Positivity.
Variable Indicative prevalence data Unadjusted Odds Ratio 95% CI p-value
Age* 5–10: 21% 1.1 1.1–1.1 <0.001
11–14: 32%
Male Male: 27% 1.2 0.9–1.6 0.247
Female: 24%
Household size !5: 25% 1.0 0.8–1.4 0.836
>5: 26%
Reported taking Yes: 26% 0.9 0.6–1.3 0.598
azithromycin No: 24%
Household MDA Complete: 25% 0.8 0.5–1.4 0.472
Incomplete: 25%
None: 28% 0.9 0.5–1.3
*Risk associated with a 1 year increase in age
doi:10.1371/journal.pntd.0003988.t002
Fig 1. Prevalence of dual sero-positivity in individuals who did and did not receive treatment with azithromycin.
doi:10.1371/journal.pntd.0003988.g001
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The results of this study are concordant with recently published data from Papua New
Guinea, which also demonstrated that a single round of azithromycin mass treatment, albeit at
a higher dose of 30mg/kg, significantly reduced the prevalence of active and latent yaws[19]. In
our study, effectiveness was demonstrated with a lower dose of azithromycin (20mg/kg), evi-
dence that facilitates integration of yaws control into national trachoma elimination plans. The
absence of any lesions which were positive by PCR for T. p subsp. pertenue is consistent with
the marked effect seen on serological markers of infection. Our failure to detect treponemal
DNA is somewhat reassuring in the context of the theoretical potential for lower dose azithro-
mycin to select for macrolide resistance[20]. Integrated, synergistic control efforts are likely to
result in increased efficiencies and decreased costs for programmes and ministries of health,
which will be vital in helping countries achieve elimination targets by 2020.
Table 3. Risk factors for dual sero-positivity.
Variable Indicative prevalence data Unadjusted Odds Ratio 95% CI p-value
Age 5–10: 3% 1.1 0.9–1.2 0.291
11–14: 4%
Male Male: 4% 1.4 0.7–2.8 0.394
Female: 3%
Household size !5: 4% 0.8 0.4–1.7 0.5980
>5: 3%
Reported taking azithromycin Yes: 2.8% 2.5 1.2–5.2 0.015
No: 6.7%
Household MDA Complete: 3.0% 0.097
Incomplete: 3.2% 1.1 0.5–2.6
None: 6.8% 2.4 0.9–5.7
doi:10.1371/journal.pntd.0003988.t003
Fig 2. Yaws clinical case reporting in Western Province, 2011–2014. The rainy season is indicated in
blue and the dry season in yellow. In the pre-mass treatment period there is evidence of seasonal variation in
the incidence of yaws, which is well recognized. Following mass treatment there was a profound drop in the
number of cases reported.
doi:10.1371/journal.pntd.0003988.g002
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In this population, individual level coverage with azithromycin was about 80%, which is in
line with that commonly achieved by trachoma elimination programmes. Our findings suggest
that an initial mass treatment round with high coverage can significantly reduce the burden of
infection. Whether subsequent treatment would be best delivered through community mass
treatment or the detection of cases and contacts remains unclear and should be studied further
using both observational and modeling approaches. In view of the extremely low positive pre-
dictive value of clinical signs for the diagnosis of yaws seen here, the call for point of care sero-
logical tests to be made available within the health care system[21] must be redoubled, in order
to strengthen surveillance and guide post-mass treatment case detection and treatment.
In trachoma control programmes in sub-Saharan Africa the use of height-based dosing
algorithms commonly results in children receiving doses of azithromycin closer to 30mg/kg
than 20mg/kg[22] which might make it difficult to detect meaningful differences in outcomes
between the two dosing strategies. As there were limited anthropometric data to guide
height-based dosing in the Pacific, weight-based dosing was used in the Solomon Islands,
and children therefore received a dose as close as possible to 20mg/kg body weight, to a maxi-
mum of 1g. This study therefore provides the first prospective data supporting the effective-
ness of lower dose azithromycin against yaws. This information is of particular value for
countries where yaws and trachoma are co-endemic and which may therefore benefit from
existing trachoma elimination activities.
The most notable limitation of this study is its observational nature. Whilst a randomized
design may have been desirable, this would have be unethical, given the need to implement
international guidelines for trachoma elimination[23], which mandate treatment of the whole
population. A stepped-wedge design could have been considered[24] but may have been uneth-
ical, for the same reason. Follow-up in this study was limited to 6 months, and it is possible
that longer observation would have revealed a more marked difference between the two groups.
We relied on reported receipt of azithromycin, which may have introduced an element of recall
bias. However it is likely that this would, in fact, have reduced any difference seen between
individuals who did and did not receive azithromycin, and therefore would not affect the over-
all finding of our study. RPR titres normally fall rapidly in individuals successfully treated for
yaws and, in the original randomized control trial of azithromycin conducted in Papua New
Guinea[5], combined clinical and serological cure was 96% at 6 months. It seems likely there-
fore that we have observed the greater part of the effect that might be expected to be derived
from azithromycin mass treatment.
Our findings support the roll out of mass treatment with azithromycin as an effective inter-
vention for the simultaneous elimination of trachoma and yaws in co-endemic areas, and pro-
vide further observational data to recommend the WHOMorges strategy where yaws alone is
endemic. The reduction in the prevalence of latent yaws following community mass treatment
is a particularly important result, as a failure to adequately treat these individuals is thought to
have contributed to the failure of previous yaws eradication efforts. Community mobilization,
ongoing surveillance and lasting political support will be necessary to translate these findings
into the ambitious goal of yaws eradication.
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Abstract:	
Introduction:		
Both	yaws	and	trachoma	are	endemic	in	the	Pacific.	Mass	treatment	with	azithromycin	is	the	
mainstay	 of	 the	 WHO	 strategy	 for	 both	 the	 eradication	 of	 yaws	 and	 the	 elimination	 of	
trachoma	as	a	public	health	problem,	but	the	dose	recommended	for	trachoma	is	lower	than	
that	for	yaws.	In	countries	where	both	diseases	are	endemic,	there	is	a	potential	for	synergy	
between	 yaws	 and	 trachoma	 control	 programs,	 if	mass	 treatment	with	 the	 lower	 dose	 of	
azithromycin	was	 shown	 to	 be	 effective	 for	 the	 treatment	 of	 yaws.	 In	 an	 earlier	 study	we	
demonstrated	 a	 profound	 reduction	 in	 the	 clinical	 and	 serological	 prevalence	 of	 yaws	
following	a	 single	 round	of	mass	 treatment	with	azithromycin	20mg/kg	undertaken	 for	 the	
purposes	of	trachoma	elimination.	
Methods:	
This	 survey	 was	 conducted	 18	 months	 following	 a	 single	 round	 of	 azithromycin	 mass	
treatment	 in	 the	 same	 communities	 in	 which	 we	 had	 conducted	 our	 previous	 six	 month	
follow-up	survey.	We	examined	children	aged	1-14	years	and	took	blood	and	lesion	samples	
for	yaws	diagnosis	using	the	Treponema	pallidum	particle	agglutination	assay	(TPPA)	and	the	
non-treponemal	Rapid	Plasma	Reagin	(RPR)	test	.		
Results:	
A	total	of	1,284	children	were	enrolled	in	the	study.		Amongst	children	aged	5-14	years,	223	
had	a	positive	TPPA	(27.5%,	95%	CI	13.6-47.7%).	The	TPPA	seroprevalence	amongst	this	age	
group	 did	 not	 differ	 significantly	 from	 either	 our	 pre-mass	 treatment	 survey	 or	 our	 initial	
follow-up	survey.	Thirty-five	children	had	positive	TPPA	and	positive	RPR	(4.3%,	95%	CI	2.1-
8.7%),	and	this	did	not	differ	significantly	from	our	initial	post-MDA	follow-up	survey	(4.3%	vs	
89
		
	
	
	
3.5%,	 p	 =	 0.43)	 but	 remained	 significantly	 lower	 than	 our	 initial	 pre-MDA	 survey	 (4.3%	 vs	
21.7%,	 p	 <0.0001).	 Village	 level	 MDA	 coverage	 was	 strongly	 associated	 with	 dual-
seropositivity	 (p	 =	0.005).	Amongst	 children	aged	1-4	 years,	 16	had	a	positive	 TPPA	 (3.5%,	
95%	CI	1.6-7.1%).	This	did	not	differ	significantly	from	the	seroprevalence	 in	this	age	group	
that	 had	 been	 predicted	 based	 on	 our	 previous	 surveys	 (3.5%	 vs	 5%,	 p	 =	 0.11).	 Fourteen	
children	 (1.1%)	 were	 considered	 to	 have	 a	 skin	 lesion	 clinically	 consistent	 with	 yaws,	 but	
none	of	 these	 individuals	was	 seropositive	 for	 yaws.	Of	nine	 cases	where	a	 swab	could	be	
collected	for	PCR,	all	were	negative	for	Treponema	pallidum	subsp.	pertenue	DNA.		
Discussion	
In	 this	 study	 we	 have	 shown	 that	 the	 benefit	 of	 a	 single	 round	 of	 mass	 treatment	 with	
azithromycin	20mg/kg	appears	to	extend	to	18	months	without	any	further	intervention.	The	
lack	 of	 a	 significant	 change	 in	 seroprevalence	 from	 6	 to	 18	months	 after	mass	 treatment	
might	suggest	that	interventions	could	be	spaced	at	yearly	intervals	without	a	significant	loss	
of	impact,	and	that	this	might	facilitate	integration	of	yaws	eradication	with	other	neglected	
tropical	disease	 (NTD)	control	programmes.	MDA	coverage	above	90%	was	associated	with	
significantly	 better	 outcomes	 than	 coverages	 lower	 than	 this	 threshold,	 and	 strategies	 to	
improve	coverage	at	all	stages	of	yaws	eradication	efforts	should	be	investigated.		
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Author	Summary	
	
Yaws	 is	 a	neglected	 tropical	 disease	 caused	by	 a	bacterium	closely	 related	 to	 the	 agent	of	
syphilis.	 Mass	 treatment	 is	 recommended	 by	WHO	 for	 the	 control	 of	 both	 yaws	 and	 the	
blinding	 eye	 disease	 trachoma,	 but	 the	 dose	 used	 for	 trachoma	 is	 lower	 (20mg/kg	 vs	
30mg/kg).	 We	 have	 previously	 shown	 that	 a	 single	 round	 of	 mass	 treatment	 with	
azithromycin	 for	 trachoma	 had	 a	 significant	 impact	 on	 the	 number	 of	 cases	 of	 yaws	 in	 a	
community,	suggesting	that	the	lower	dose	of	azithromycin	might	be	effective	for	yaws	and	
that	 trachoma	and	 yaws	programmes	 in	 the	Pacific	might	be	 integrated.	We	 repeated	our	
survey	18	months	following	the	initial	round	of	mass	treatment	to	see	if	the	benefit	seen	at	6	
months	had	persisted.	In	this	study,	the	number	of	yaws	cases	remained	significantly	lower	
than	before	mass	treatment	even	without	any	additional	public	health	 interventions	taking	
place	 in	 the	 18	months	 between	MDA	 and	 this	 follow-up.	 This	might	 suggest	 that	 annual	
mass	 treatment	 could	 be	 used	 rather	 than	 the	 current	 recommendation	 of	 six-monthly	
treatment.	An	annual	treatment	strategy	might	facilitate	integrating	yaws	eradication	efforts	
with	other	NTD	control	programmes.		
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Introduction	
Yaws	is	an	endemic	treponemal	disease	caused	by	Treponema	pallidum	subsp	pertenue	[1].	
Most	cases	of	yaws	are	seen	in	rural	communities	in	tropical	countries[2]	and	are	manifest	as	
lesions	of	the	skin,	bones	and	joints.	 In	2012,	single	dose	azithromycin	was	shown	to	be	an	
effective	 treatment	 for	 yaws[3],	 and	mass	 treatment	 with	 azithromycin	 was	 subsequently	
adopted	by	WHO	as	the	cornerstone	of	a	new	yaws	eradication	campaign	[4].	Active	yaws	is	
usually	seen	in	children	aged	5-14	years,	and	examination	of	this	age	group	has	been	used	in	
many	 studies	 to	 assess	 the	 prevalence	 of	 active	 yaws	 [5–7].	 WHO	 also	 recommends	
surveillance	by	 serology	of	 children	aged	1-4	years	 to	determine	whether	 transmission	has	
been	interrupted	[4].		
	
The	Pacific	is	a	particular	focus	for	yaws	with	a	large	number	of	cases	reported	in	Papua	New	
Guinea,	 the	 Solomon	 Islands	 and	 Vanuatu	 [2].	 Trachoma,	 caused	 by	 ocular	 infection	 with	
Chlamydia	 trachomatis,	 is	 also	 endemic	 in	 the	 Pacific.	 As	 community	mass	 treatment	with	
azithromycin	is	also	central	to	the	control	of	trachoma	[8],	there	is	the	potential	for	synergies	
between	trachoma	and	yaws	programmes	in	the	Pacific	[9].	A	challenge	is	the	difference	in	
the	dose	of	azithromycin	recommended	for	trachoma	(20mg/kg,	max	1g)	compared	to	yaws	
(30mg/kg,	max	 2g).	We	 previously	 demonstrated	 that	 the	 prevalence	 of	 active	 and	 latent	
yaws	declined	markedly	six	months	after	a	single	round	of	mass	treatment	with	azithromycin	
given	as	part	of	a	trachoma	control	program	in	the	Solomon	Islands	[10],	providing	the	first	
evidence	that	low	dose	azithromycin	is	effective	in	the	treatment	of	yaws.		
The	 optimal	 number	 and	 timing	 of	 rounds	 of	 mass	 treatment	 needed	 to	 interrupt	
transmission	 of	 yaws	 are	 unknown	 [11],	 although	 pilot	 data	 from	 other	 countries	 suggest	
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that	a	single	round	is	inadequate	[7].	In	2015	a	decision	was	made	not	to	undertake	a	second	
round	 of	 azithromycin	 mass	 treatment	 in	 the	 Solomon	 Islands	 in	 light	 of	 a	 low	 reported	
prevalence	 of	 trachomatous	 trichiasis	 and	 a	 low	 prevalence	 of	 ocular	 infection	 with	 C.	
trachomatis	[12].	This	provided	an	opportunity	to	assess	any	potential	rebound	in	active	and	
latent	yaws	in	the	absence	of	further	control	measures.	It	was	hoped	that	these	data	might	
inform	 expansion	 of	 yaws	 control	 efforts	 and,	 in	 particular,	 any	 potential	 for	 synergy	
between	yaws	and	trachoma	control	programs	in	the	Pacific.	
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Methods	
This	 survey	 was	 conducted	 18	 months	 following	 a	 single	 round	 of	 azithromycin	 mass	
treatment	 conducted	by	 the	Solomon	 Islands	Ministry	of	Health	and	Medical	 Services.	 The	
study	was	conducted	in	the	same	communities	in	which	we	had	conducted	our	previous	six	
month	 follow-up	 survey	 [10].	 	 No	 further	 rounds	 of	 mass	 treatment	 (or	 other	 specific	
interventions	against	yaws)	had	been	conducted	in	these	communities	since	then.	
For	each	household	we	collected	data	on	the	number	of	residents.	We	enrolled	children	aged	
1-14	 years	 for	 assessment,	 collecting	 individual-level	 data	on	 age,	 gender,	 the	presence	or	
absence	of	clinical	signs	and	symptoms	of	yaws	and	yaws	treatment	history.	We	categorized	
skin	 lesions	 using	 the	WHO	 yaws	 pictorial	 guide	 [13].	 All	 data	 were	 entered	 directly	 into	
Android	smartphones	using	the	ODK	software	package	[14].		
For	children	aged	5-14	years,	venepuncture	was	performed	and	a	serum	sample	collected.	In	
children	aged	1-4	years	a	 finger-prick	blood	sample	was	collected	onto	a	 filter	paper.	Filter	
papers	were	air-dried	and	stored	in	sealed	bags	with	desiccant	sachets.	From	individuals	with	
ulcerative	or	papillomatous	skin	lesions,	we	also	collected	a	swab	sample	of	lesion	exudate.	
Exudate	was	 transferred	 to	 a	 FTA	 Elute	Micro	 Card	 (GE	 Healthcare,	 Buckinghamshire,	 UK)	
using	three	firm	side-to-side	motions	of	the	swab	across	the	card.	Each	card	was	placed	in	its	
own	 re-sealable	 plastic	 packet	 with	 an	 individual	 desiccant	 sachet.	 The	 samples	 were	
transferred	 to	 the	National	 Referral	Hospital	 in	Honiara,	where	 they	were	 frozen	 at	 -20°C,	
and	 shipped	 to	 the	 London	 School	 of	 Hygiene	 &	 Tropical	Medicine	 (LSHTM),	 UK,	 and	 the	
Centers	for	Disease	Control	and	Prevention	(CDC),	USA,	on	dry-ice	for	testing.	
	
Laboratory	Testing	
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Blood	samples	were	tested	at	LSHTM.	Filter	paper	samples	were	eluted	and	tested	using	the	
Treponema	pallidum	particle	agglutination	test	 (TPPA,	Mast	Diagnostics,	Merseyside	UK)	as	
previously	 described	 [15].	 For	 serum	 samples	 a	 TPPA	 test	 was	 performed	 initially	 and	 for	
samples	 that	 were	 TPPA-positive,	 a	 quantitative	 rapid	 plasma	 reagin	 test	 (RPR,	 Deben	
Diagnostics,	Ipswich,	UK)	was	performed.		
Lesion	swab	samples	were	tested	at	the	CDC	using	a	number	of	multiplex	real-time	(RT)	PCR	
assays.	 Initially,	 samples	 were	 tested	 using	 an	 assay	 for	 the	 identification	 of	 T.	 pallidum	
subspecies	DNA	[5].	If	the	PCR	was	positive	for	T.	pallidum	subsp.	pertenue	this	was	followed	
by	a	second	multiplex	RT	PCR	to	detect	mutations	in	the	23S	rRNA	gene	which	are	associated	
with	 azithromycin	 resistance.	 All	 samples	 were	 also	 tested	 with	 a	 duplex	 RT	 PCR	 for	 the	
detection	 of	Haemophilus	 ducreyi	 and	Mycobacterium	 ulcerans	 [16].	 All	 laboratory	 testing	
was	performed	by	individuals	masked	to	the	clinical	findings.	
	
Statistical	Analysis	
In	children	aged	1-4	years,	a	positive	TPPA	was	taken	as	evidence	of	exposure	to	yaws.	For	
children	aged	5-14	years,	a	positive	TPPA	was	considered	as	evidence	of	previous	or	current	
yaws	 infection.	 	We	 considered	 individuals	 with	 clinical	 signs	 of	 yaws	 and	 both	 a	 positive	
TPPA	 and	 an	 RPR	 titre	 of	 ≥1:4	 (dual-seropositivity)	 to	 have	 active	 yaws.	 We	 considered	
individuals	who	were	dual-seropositive	but	without	clinical	signs	of	yaws	to	have	latent	yaws.	
For	 the	 purpose	 of	 the	 analysis	 an	 RPR	 titre	 of	 ≥1:16	 was	 considered	 to	 be	 a	 high-titre	
positive.	 We	 classified	 household	 size	 as	 ≤5	 or	 >5	 residents,	 5	 householders	 being	 the	
national	 average	 according	 to	 the	most	 recent	 census	 [17].	 For	 each	 community,	we	 used	
village	level	estimates	of	treatment	coverage	obtained	during	our	previous	six	month	follow	
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up	survey	[10].	We	classified	village	level	coverage	as	low	(<80%),	high	(80-90%)	or	very	high	
(>90%).	We	calculated	the	prevalence	of	latent	and	active	yaws	in	older	children	(aged	5-14	
years)	 and	 the	 sero-prevalence	 of	 exposure	 to	 yaws	 in	 younger	 children	 (aged	 1-4	 years).	
Logistic	 regression	 was	 used	 to	 estimate	 unadjusted	 and	 adjusted	 odds	 ratios	 (ORs)	 for	
factors	associated	with	both	TPPA-	and	dual-seropositivity.	Robust	standard	errors	were	used	
to	calculate	all	confidence	intervals	(CIs)	and	p-values,	to	account	for	village-level	clustering.	
All	analyses	were	performed	using	Stata	13.1	(Statacorp,	Texas).		
	
Sample	size	
In	our	previous	follow-up	survey,	the	seroprevalence	of	active	yaws	was	3.6%.	We	calculated	
that	 a	 sample	 size	 of	 738	was	 need	 to	measure	 a	 seroprevalence	 of	 4%	with	 a	 degree	 of	
absolute	 precision	 of	 3%,	 assuming	 a	 design	 effect	 of	 4.5	 (estimated	 using	 data	 from	 the	
baseline	survey)	 in	children	aged	5-14	years.	Based	on	previous	data	we	hypothesized	that	
the	 seroprevalence	 amongst	 children	 aged	 1-4	 years	 would	 be	 approximately	 1%	 if	
transmission	had	been	interrupted	following	the	earlier	community	mass	treatment	and	5%	
if	 transmission	had	not	been	 interrupted.	We	calculated	 that	a	sample	size	of	432	children	
aged	1-4	years	was	required	to	detect	a	prevalence	of	1%	with	a	precision	of	2%	and	a	design	
effect	of	4.	
	
Ethical	Approval	
Written	informed	consent	was	obtained	from	each	participating	child’s	parent	or	guardian	by	
a	 member	 of	 staff	 fluent	 in	 the	 local	 dialect.	 Assent	 was	 obtained	 from	 children.	 Ethical	
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approval	for	the	study	was	granted	by	the	ethics	committees	of	the	Solomon	Islands	MHMS,	
the	CDC,	and	LSHTM.	
	
Results	
A	total	of	1,284	children	were	enrolled	from	519	households	in	10	communities.		
811	 children	were	 aged	 5-14	 years	 (median	 9	 years),	 of	 whom	 401	 (49.4%)	were	male.	 A	
serum	sample	was	collected	from	770	children	(94.9%).	Thirty-one	children	(3.8%)	declined	
collection	 of	 a	 serum	 sample	 but	 assented	 to	 collection	 of	 a	 dried-blood	 spot,	 whilst	 10	
children	(1.2%)	assented	to	examination	but	not	to	sample	collection.	473	children	aged	1-4	
years	 (median	3	years)	were	also	enrolled,	of	whom	248	(52.4%)	were	male.	A	dried	blood	
spot	was	collected	from	451	children	(95.3%)	 in	this	age	group.	Seven	children	(1.5%)	aged	
under	5	 incorrectly	had	a	serum	sample	(rather	than	a	DBS)	collected.	No	dried	blood	spot	
was	collected	from	15	children	aged	under	5	(3.2%).		
	
Four	 hundred	 and	 thirty	 seven	 children	 (34.0%)	 had	 at	 least	 one	 skin	 lesion.	 14	 children	
(1.1%)	had	lesions	considered	to	be	clinically	consistent	with	yaws.	The	most	common	non-
yaws	 lesions	 were	 scabies	 and	 impetigo,	 as	 previously	 reported	 (A	 Steer,	 Personal	
Communication).	As	in	our	initial	6	month	follow-up	survey,	no	individual	with	a	skin	lesion	
consistent	with	yaws	had	dual-positive	 serology.	 Swabs	were	obtained	 from	nine	yaws-like	
lesions.	Swabs	could	not	be	obtained	from	the	other	three	lesions	as	they	were	dry/crusted.	
Of	these	 lesion	samples,	all	were	negative	on	RT-PCR	for	T.p	subsp	pertenue	and	two	were	
positive	for	H.	ducreyi.	
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Amongst	 5-14	 year-old	 children,	 223	had	 a	 positive	 TPPA	 (27.5%,	 95%	CI	 13.6-47.7%).	 The	
TPPA	seroprevalence	amongst	this	age	group	did	not	differ	significantly	from	either	our	pre-
MDA	survey	or	our	 initial	 follow-up	survey	 (31.4%	and	25.0%	respectively,	p>0.05	 for	both	
comparisons).	 	 In	both	the	crude	and	adjusted	analyses,	only	age	was	associated	with	TPPA	
positivity	(Table	2).	Thirty-five	children	had	dual	positive	serology	(4.3%,	95%	CI	2.1-8.7%),	of	
whom	8	had	high-titre	positive	serology.	This	did	not	differ	significantly	from	our	initial	post-
MDA	 follow-up	 survey	 (4.3%	 vs	 3.5%,	 p	 =	 0.43)	 but	 remained	 significantly	 lower	 than	 our	
initial	pre-MDA	survey	(4.3%	vs	21.7%,	p	<0.0001).	The	level	of	MDA	coverage	was	strongly	
associated	with	dual-seropositivity	(p	=	0.005).	Compared	to	an	MDA	coverage	above	90%,	a	
village	 level	 coverage	 below	 80%	 was	 strongly	 associated	 with	 an	 increased	 risk	 of	 dual-
seropositivity	 (aOR	6.95,	95%	CI	1.2-38.3,	p	=	0.03)	 (Table	3).	Coverage	of	between	80-90%	
was	also	associated	with	an	increased	risk	of	dual-seropositivity	compared	to	coverage	>90%,	
but	this	difference	was	not	statistically	significant	(aOR	3.99,	95%	CI	0.66-24.0,	p	=	0.12).		
	
Amongst	children	aged	1-4	years,	16	had	a	positive	TPPA	(3.5%,	95%	CI	1.6-7.1%)	 including	
two	 children	 aged	 less	 than	 two	 years	 (0.9%,	 95%	 CI	 0.2	 –	 4.0%).	 This	 did	 not	 differ	
significantly	from	the	seroprevalence	in	this	age	group	that	had	been	predicted	based	on	our	
previous	surveys	(3.5%	vs	5%,	p	=	0.11).	 In	villages	where	very	high	(>90%)	mass	treatment	
coverage	was	 achieved,	 there	were	 no	 young	 children	with	 a	 positive	 TPPA,	 compared	 to	
3.8%	 and	 4.4%	 TPPA	 positivity	 in	 villages	 with	 low	 (<80%)	 and	 high	 (80-90%)	 coverage	 of	
mass	treatment,	respectively,	although	these	differences	were	not	statistically	significant	(p	=	
0.08	 and	 0.06	 respectively).	 Age	 was	 the	 only	 variable	 significantly	 associated	 with	 TPPA	
seropositivity	amongst	children	aged	1-4	years	(Table	4).		
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Discussion	
We	have	previously	demonstrated	that	a	single	round	of	mass	treatment	with	azithromycin	
at	 20mg/kg,	 given	 for	 the	 purposes	 of	 trachoma	 control,	 has	 a	 significant	 impact	 on	 the	
prevalence	of	yaws-like	skin	 lesions	and	sero-positivity	 for	yaws	[10].	 In	this	study	we	have	
shown	 that	 the	 benefit	 appears	 to	 extend	 to	 18	months	without	 any	 further	 intervention.	
The	 WHO	 yaws	 eradication	 strategy	 [4]	 suggests	 that,	 following	 initial	 mass	 treatment,	
follow-up	surveys	with	targeted	treatment	of	cases	and	contacts	should	take	place	every	3-6	
months.	 This	 requirement	 for	 at	 least	 biannual	 intervention	 is	 a	 potential	 barrier	 to	
integrating	 yaws	 eradication	 efforts	 with	 other	 NTD	 control	 programmes,	 including	
trachoma,	where	annual	mass	treatment	is	recommended.	The	lack	of	a	significant	change	in	
seroprevalence	from	6	to	18	months	after	mass	treatment	might	suggest	that	interventions	
could	 be	 spaced	 at	 yearly	 intervals	 without	 a	 significant	 loss	 of	 impact.	Modelling	 studies	
exploring	these	questions	are	under	way,	and	 initial	 results	suggest	 that	such	decisions	are	
highly	 dependent	 on	 the	basic	 reproductive	 number	 (R0)	 of	 yaws.	Where	R0	 is	 low	 (<1.45)	
then	annually	spaced	treatment	may	be	sufficient	to	achieve	interruption	of	transmission	(M	
Marks	–	Manuscript	submitted).	
Of	particular	 interest,	 the	village-level	 treatment	coverage	was	the	strongest	 risk	 factor	 for	
dual-seropositivity	18	months	after	mass	treatment.	When	the	coverage	was	below	80%,	the	
risk	for	seropositivity	was	more	than	6	times	greater	compared	to	villages	where	coverage	of	
greater	 than	90%	was	achieved.	Consistent	with	 these	 findings	 in	older	children,	we	noted	
that	 in	 villages	where	 very	high	 (>90%)	 coverage	was	achieved	 there	were	no	 seropositive	
children	 aged	 1-4	 years,	 which	 may	 indicate	 that	 transmission	 was	 interrupted	 in	 these	
communities.	Ongoing	presumed	seroconversion,	 including	 in	children	aged	2	years	or	 less,	
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was	 documented,	 however,	 in	 villages	 with	 coverage	 below	 90%.	We	 cannot	 exclude	 the	
possibility	 that	 positive	 serology	 in	 children	 aged	 1-4	 years	 was	 due	 to	 mother-to-child	
transmission	of	 syphilis.	However,	 in	 the	context	of	ongoing	 transmission	of	yaws	amongst	
older	children	in	these	communities,	we	consider	it	likely	that	seropositivity	amongst	children	
aged	 1-4	 years	 does	 reflect	 ongoing	 transmission	 of	 yaws	 in	 this	 age	 group.	 These	 two	
findings	emphasize	the	need	for	extremely	high	coverage	during	mass	treatment.	Given	the	
difficulties	 that	can	be	 faced	 in	achieving	 such	high	coverage	at	a	programmatic	 level	 [18],	
innovative	strategies	should	be	considered	to	augment	yaws	eradication	efforts.	This	might	
include	additional	school-based	mass	treatment	alongside	community-based	approaches,	or	
use	 of	 multiple	 rounds	 of	 mass	 treatment	 before	 transitioning	 to	 the	 total	 targeted	
treatment	phase	of	the	yaws	eradication	strategy	[4].	
	
Our	data	add	to	the	literature	supporting	a	lower	dose	of	azithromycin	(20mg/kg	max	1g	vs	
30mg/kg	max	2g)	for	the	treatment	of	yaws.	If	a	lower	dose	is	proven	effective,	this	may	help	
achieve	programmatic	synergies,	especially	in	the	Pacific	where	several	countries	have	a	high	
prevalence	of	yaws,	and	trachoma	is	also	endemic.	A	WHO	sponsored	trial	(NCT02344628)	is	
being	undertaken	in	Ghana	and	Papua	New	Guinea	to	formally	compare	the	efficacy	of	these	
two	 doses	 in	 both	 active	 and	 latent	 yaws,	 and	 it	 is	 hoped	 that	 this	 study	 will	 provide	 a	
definitive	answer	on	the	efficacy	of	the	lower	dose	of	azithromycin.	
	
The	major	 limitation	of	our	study	 is	the	observational	design.	A	study	of	mass	treatment	 in	
Papua	New	Guinea	found	only	44	serologically	confirmed	active	cases	in	a	total	population	of	
13,166	individuals	seen	at	six	months	follow-up.	Given	the	smaller	sample	size	of	this	study,	
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we	may	have	been	underpowered	to	detect	 rare	active	cases	 following	 the	 initial	 round	of	
mass	treatment.		
	
Our	data	show	that	 the	 impact	of	a	 single	 round	of	mass	 treatment	on	yaws	prevalence	 is	
profound,	and	appears	to	last	for	at	least	18	months	following	mass	treatment,	even	in	the	
absence	 of	 further	 interventions.	 We	 have	 demonstrated	 that	 mass	 treatment	 coverage	
above	90%	is	associated	with	significantly	better	outcomes	than	 lower	coverage.	Strategies	
to	improve	coverage	at	all	stages	of	yaws	eradication	efforts	should	be	investigated.	
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Table	1:	Demographics	of	study	subjects	
Number	of	Children	 1284	
Number	of	Households	 519	
Household	Size	
[Number	of	residents]	
(Median,	IQR)	
6	(4-8)	
Age	[years]	(Median,	IQR)	 6	(3-10)	
Village	Level	azithromycin	
Coverage	
Low	(<80%)	 536	(41.7%)	
High	(80-90%)	 501	(39.0%)	
Very	High	(>90%)	 247	(19.2%)	
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Table	2:	Risk	factors	for	TPPA	positivity	amongst	children	aged	5-14	years	
Variable	 Indicative	
Prevalence	Data	
Unadjusted	
Odds	Ratio	
(95%	CI)	
Adjusted	
Odds	Ratio#	
(95%	CI)	
p-value	
Age	[years]	 5-9:	19%	 1.22	*	
(1.13-1.32)	
1.22	
(1.13-1.32)	
<0.001	
	 10-14:	38.5%	 	 	 	
Male	 Male:	28.4%	 1.09	
(0.77-1.57)	
1.19	
(0.87-1.63)	
0.24	
	 Female:	26.6%	 	 	 	
Household	
Size	
[number	of	
residents]	
≤5:	30.21%	 1	 	 	
	 >5:	25.6%	 0.8	
(0.48-1.31)	
0.75	
(0.46-1.23)	
0.23	
Village	Level	
azithromycin	
coverage¶	
Low	Coverage	
(<80%):	
24.1%	
1.13	
(0.23-5.48)	
1.28	
(0.26-6.39)	
0.73	
	 High	Coverage	(80-
90%):	
33.4%	
1.83	
(0.34-10.09)	
1.96	
(0.31-12.56)	
0.44	
	 Very	High	
Coverage	(>90%):	
21.9%	
1	 	 	
*	Increased	odds	associated	with	each	one	year	increase	in	age	
#	Adjusted	for	age	and	gender	
¶	Compared	to	very	high	coverage	(>90%)	
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Table	3:	Risk	factors	for	dual-seropositivity	amongst	children	aged	5-14	years	
Variable	 Indicative	
Prevalence	Data	
Unadjusted	
Odds	Ratio	
(95%	CI)	
Adjusted	
Odds	Ratio#	
(95%	CI)	
p-value	
Age	[years]	 5-9:	3.3%	 1.18*	
(1.05-1.34)	
1.19	
(1.08-1.35)	
0.009	
	 10-14:	5.7%	 	 	 	
Male	 Male:	3.2%	 1.77	
(0.85-3.71)	
1.91	
(0.93-3.94)	
0.07	
	 Female:	5.5%	 	 	 	
Household	Size	
[number	of	
residents]	
≤5:	5.7%	 1	 	 	
	 >5:	3.3%	 0.57	
(0.14-2.32)	
0.53	
(0.13-2.14)	
0.33	
Village	Level	
azithromycin	
coverage¶	
Low	Coverage	
(<80%):	
6.2%	
5.5	
(0.97-31.22)	
6.95	
(1.27-38.3)	
0.03	
	 High	Coverage	
(80-90%):	
4.1%	
3.6	
(0.58-21.67)	
3.99		
(0.66-24.0)	
0.12	
	 Very	High	
Coverage	
(>90%):	
1.2%	
1	 	 	
*	Increased	odds	associated	with	each	one	year	increase	in	age	
#	Adjusted	for	age	and	gender	
¶	Compared	to	very	high	coverage	(>90%)	
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Table	4:	Risk	factors	for	TPPA	positivity	amongst	children	aged	1-4	
Variable	 Indicative	
Prevalence	
Data	
Unadjusted	
Odds	Ratio	
(95%	CI)	
Adjusted	Odds	
Ratio#	
(95%	CI)	
p-value	
Age	[years]	 1-2:	0.87%	 1	 	 	
	 3-4:	5.8%	 2.21*	
(1.55-3.15)	
2.23	
(1.51-3.29)	
0.001	
Male	 Male:	4.0%	 1.53	
(0.58-4.06)	
1.64	
(0.56-4.82)	
0.33	
	 Female:	2.7%	 1	 	 	
Household	
Size	
[number	of	
residents]	
≤5:	4.0%	 0.72	
(0.25-2.08)	
0.78	
(0.25-2.35)	
0.62	
	 >5:	2.9%	 1	 	 	
*	Increased	odds	associated	with	each	one	year	increase	in	age	
#	Adjusted	for	age	and	gender	
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STROBE	 2007	 (v4)	 Statement—Checklist	 of	 items	 that	 should	 be	 included	 in	 reports	 of	
cross-sectional	studies	
	
Section/Topic	 Item	
#	 Recommendation	
Reported	 on	
page	of	thesis	#	
Title	and	abstract	 1	 (a)	 Indicate	 the	 study’s	 design	 with	 a	
commonly	 used	 term	 in	 the	 title	 or	 the	
abstract	
87-88	
(b)	Provide	in	the	abstract	an	informative	and	
balanced	 summary	 of	 what	 was	 done	 and	
what	was	found	
89-91	
Introduction	 	
Background/rationale	 2	 Explain	 the	 scientific	 background	 and	
rationale	for	the	investigation	being	reported	
92-93	
Objectives	 3	 State	 specific	 objectives,	 including	 any	 pre-
specified	hypotheses	
92-93	
Methods	 	
Study	design	 4	 Present	key	elements	of	study	design	early	in	
the	paper	
94	
Setting	 5	 Describe	 the	 setting,	 locations,	 and	 relevant	
dates,	 including	 periods	 of	 recruitment,	
exposure,	follow-up,	and	data	collection	
94	
Participants	
	
6	
	
(a)	 Give	 the	 eligibility	 criteria,	 and	 the	
sources	 and	 methods	 of	 selection	 of	
participants	
94-95	
Variables	 7	 Clearly	 define	 all	 outcomes,	 exposures,	
predictors,	potential	confounders,	and	effect	
modifiers.	 Give	 diagnostic	 criteria,	 if	
applicable	
95-96	
Data	 sources/	
measurement	
8*	 	For	each	variable	of	interest,	give	sources	of	
data	 and	 details	 of	 methods	 of	 assessment	
95-96	
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(measurement).	 Describe	 comparability	 of	
assessment	 methods	 if	 there	 is	 more	 than	
one	group	
Bias	 9	 Describe	 any	 efforts	 to	 address	 potential	
sources	of	bias	
95-96	
Study	size	 10	 Explain	how	the	study	size	was	arrived	at	 95-96	
Quantitative	
variables	
11	 Explain	 how	 quantitative	 variables	 were	
handled	 in	 the	 analyses.	 If	 applicable,	
describe	 which	 groupings	 were	 chosen	 and	
why	
95-96	
Statistical	methods	 12	 (a)	Describe	all	statistical	methods,	including	
those	used	to	control	for	confounding	
95-96	
	
	
	
	
(b)	 Describe	 any	 methods	 used	 to	 examine	
subgroups	and	interactions	
N/A	
(c)	Explain	how	missing	data	were	addressed	 N/A	
(d)	 If	applicable,	describe	analytical	methods	
taking	account	of	sampling	strategy	
95-96	
(e)	Describe	any	sensitivity	analyses	 N/A	
Results	 	 	 	
Participants	 13*	 (a)	 Report	 numbers	 of	 individuals	 at	 each	
stage	 of	 study—e.g.	 numbers	 potentially	
eligible,	 examined	 for	 eligibility,	 confirmed	
eligible,	 included	 in	 the	 study,	 completing	
follow-up,	and	analyzed	
97	
	 	 (b)	Give	reasons	for	non-participation	at	each	
stage	
97-98	
	 	 (c)	Consider	use	of	a	flow	diagram	 N/A	
Descriptive	data	 14*	 (a)	 Give	 characteristics	 of	 study	 participants	
(e.g.	 demographic,	 clinical,	 social)	 and	
information	 on	 exposures	 and	 potential	
97-98+	Table	1	
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confounders	
	 	 (b)	 Indicate	 number	 of	 participants	 with	
missing	data	for	each	variable	of	interest	
97-98	
Outcome	data	 15*	 Report	 numbers	 of	 outcome	 events	 or	
summary	measures	
97-98	
Main	results	 16	 (a)	 Give	 unadjusted	 estimates	 and,	 if	
applicable,	 confounder-adjusted	 estimates	
and	 their	 precision	 (e.g.,	 95%	 confidence	
interval).	 Make	 clear	 which	 confounders	
were	 adjusted	 for	 and	 why	 they	 were	
included	
97-98	 and	 Table	
2	&	3	&	4			
	 	 (b)	 Report	 category	 boundaries	 when	
continuous	variables	were	categorized	
97-98	 and	 Table	
2	&	3	&	4			
	 	 (c)	 If	relevant,	consider	translating	estimates	
of	 relative	 risk	 into	 absolute	 risk	 for	 a	
meaningful	time	period	
N/A	
Other	analyses	 17	 Report	 other	 analyses	 done—eg	 analyses	 of	
subgroups	 and	 interactions,	 and	 sensitivity	
analyses	
N/A	
Discussion	 	 	 	
Key	results	 18	 Summarize	 key	 results	 with	 reference	 to	
study	objectives	
99	
Limitations	 19	 Discuss	 limitations	 of	 the	 study,	 taking	 into	
account	 sources	 of	 potential	 bias	 or	
imprecision.	 Discuss	 both	 direction	 and	
magnitude	of	any	potential	bias	
99-100	
Interpretation	 20	 Give	 a	 cautious	 overall	 interpretation	 of	
results	 considering	 objectives,	 limitations,	
multiplicity	 of	 analyses,	 results	 from	 similar	
studies,	and	other	relevant	evidence	
99-100	
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99-100	
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Abstract
Yaws is a non-venereal treponemal infection caused by Treponema pallidum ssp. pertenue. The WHO has launched a
worldwide control programme, which aims to eradicate yaws by 2020. The development of a rapid diagnostic test (RDT) for
serological diagnosis in the isolated communities affected by yaws is a key requirement for the successful implementation
of the WHO strategy. We conducted a study to evaluate the utility of the DPP test in screening for yaws, utilizing samples
collected as part of a community prevalence survey conducted in the Solomon Islands. 415 serum samples were tested
using both traditional syphilis serology (TPPA and quantitative RPR) and the Chembio DPP Syphilis Screen and Confirm RDT.
We calculated the sensitivity and specificity of the RDT as compared to gold standard serology. The sensitivity of the RDT
against TPPA was 58.5% and the specificity was 97.6%. The sensitivity of the RDT against RPR was 41.7% and the specificity
was 95.2%. The sensitivity of the DPP was strongly related to the RPR titre with a sensitivity of 92.0% for an RPR titre of .1/
16. Wider access to DPP testing would improve our understanding of worldwide yaws case reporting and the test may play
a key role in assessing patients presenting with yaws like lesions in a post-mass drug administration (MDA) setting.
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Introduction
Yaws is a non-venereal treponemal infection caused by Trepo-
nema pallidum ssp. pertenue (T. pertenue) [1] which is currently
thought to be endemic in fourteen countries [2]. The emergence
of azithromycin as an effective oral agent in the treatment of yaws
[3] has prompted renewed calls for a coordinated worldwide
programme to eradicate the disease by 2020 [4].
Despite this optimism there are significant barriers still to be
overcome. The differential diagnosis of yaws can be broad [5] and
serological testing is necessary to help establish a diagnosis. As with
syphilis, latent infection occurs, and it is recognized that for every
clinical case there may be 5–6 individuals with serological
evidence of infection but no clinical manifestations [6,7]. Failure
to adequately treat latent cases was one of the reasons for the
failure of previous attempts to eliminate yaws [8]. Detection and
treatment of these latent cases will be extremely important if the
WHO eradication programme is to achieve its target.
Traditional syphilis serology includes a treponemal specific test,
such as the Treponema pallidum particle agglutination assay
(TPPA) or the fluorescent treponemal antibody test, and a non-
treponemal test, such as the Rapid Plasma Reagin (RPR) or
Venereal Disease Research Laboratory (VDRL) assays. The
former tests are highly specific but normally remain positive for
life following infection. The latter tests are non-specific but the
RPR titre more accurately reflects disease activity and falls
following successful treatment. Low-titre false-positive RPRs may
occur in a number of conditions including acute viral infections,
malaria and connective tissue diseases. Testing therefore requires
combined treponemal and non-treponemal assays to give a more
accurate diagnostic result.
The development of a rapid diagnostic test (RDT) that can be
used to improve access to serological diagnosis in the isolated
communities affected by yaws has been highlighted as a major
research question [9] to be addressed. RDTs allow wider access to
diagnostic testing in remote communities where laboratory
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facilities are not available, with results available at the point of
care to inform clinical decision making. As yaws is serologically
indistinguishable from syphilis [10], the recent development of
syphilis RDTs with high sensitivity and specificity [11] prompts
evaluation of their use for the diagnosis of endemic treponemal
diseases.
The required role(s) of an RDT may vary depending on the
progress of the eradication programme in a given country. The
test may have utility to confirm the diagnosis in patients presenting
with skin lesions, to detect ongoing transmission of infection after
mass drug administration has been conducted, or to conduct
community surveillance in areas previously known to be endemic.
The target product profiles of the RDTs required in each of these
settings are likely to vary.
The Dual Path Platform (DPP) Syphilis Screen and Confirm
(Chembio, Medford, NY, USA) provides both a ‘‘treponemal’’
result (analogous to a Treponema Pallidum Particle Agglutination
(TPPA) assay (T1 line)) and a ‘‘non-treponemal’’ result (analogous
to a qualitative Rapid Plasma Reagin (RPR) assay (T2 line)) [12].
We conducted a study to evaluate the utility of the DPP test in
screening for yaws in the general population, utilizing samples
collected as part of a community prevalence survey for yaws and
trachoma conducted in the Solomon Islands.
Methods
Participant Recruitment
This study was embedded in a larger study investigating the
epidemiology of yaws in the Solomon Islands. Briefly, we
undertook a survey in Western and Choiseul provinces of the
Solomon Islands in September and October 2013. Twenty-five
clusters were randomly selected in each province. In each cluster,
thirty households were visited, and children aged five to fourteen
were enrolled in the study. The study team collected information
on yaws symptoms, signs and treatment history. Venepuncture
was performed and a serum sample was collected from all
participants. Sera were kept on wet ice (4uC) in the field and
transferred within 5 days of collection to the National Referral
Hospital, Honiara, where they were frozen. Samples were shipped
on dry-ice to the London School of Hygiene & Tropical Medicine
(LSHTM).
Sample Size
We assumed that the prevalence of yaws sero-positivity by the
gold standard assay would be 30%. We therefore calculated that a
sample size of 415 was required to be 80% confident that the true
sensitivity of the DPP, compared to the gold standard, was 85% or
greater [13]. For the purposes of this study, simple random
sampling was used to select samples to undergo parallel testing
with both the DPP kit and traditional serology.
Laboratory Testing
Sera were tested using both the TPPA (Mast Diagnostics,
Merseyside UK) and a quantitative RPR (Deben Diagnostics,
Sheffield UK) at LSHTM by an operator masked to clinical
findings. A second operator, masked to clinical findings and gold
standard serology, tested samples using the DPP test kit. Samples
for which the control line did not appear were repeated. The
manufacturer’s instructions were followed for all test kits.
Statistical Analysis
The sensitivity, specificity, positive and negative predictive
values of the DPP test kit were calculated using traditional serology
as the gold standard. The DPP-T1 line was assessed against TPPA
and the DPP-T2 line was assessed against RPR. Secondary
analyses estimated these performance characteristics by RPR titre
and presence or absence of clinical signs of yaws. Confidence
intervals were calculated using robust standard errors to allow for
clustering. Findings are reported in line with the STARD checklist
for studies of diagnostic accuracy [14].
Ethics
Written, informed consent was obtained from the head of each
household, who was the parent or guardian of children enrolled in
Author Summary
Yaws is a bacterial infection closely related to syphilis. The
WHO has launched a worldwide campaign to eradicate
yaws by 2020. If this goal is to be achieved, programme
managers and clinical staff will need access to a rapid
diagnostic test (RDT) for yaws that can be used in the
remote communities where the disease is found. In this
study, we present data evaluating one possible RDT for
yaws as part of a community survey in the Solomon
Islands. The test performed reasonably well—there were
some false negatives but few false positives. The perfor-
mance of the test was best in individuals with more active
disease suggesting the test may be most appropriately
used for confirming clinically diagnosed cases. These
findings should prompt consideration of the use of this
RDT as part of worldwide yaws control efforts.
Table 1. Participant characteristics.
Number of children 415
Gender: Male(%) 216 (52.1%)
Age (yrs): Median (IQR) 9 (7–11)
Clinical signs of primary yaws 12 (2.9%)
Clinical signs of secondary yaws 7 (1.7%)
Clinical signs of healed yaws 34 (8.2%)
Recent treatment for yaws 54 (13.0%)
doi:10.1371/journal.pntd.0003156.t001
Figure 1. Clinical lesions of yaws. a) Primary yaws ulcer. b) Healed
yaws lesion. Images credit: Michael Marks.
doi:10.1371/journal.pntd.0003156.g001
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the study, and assent was obtained from all children. Ethical
approval for the study was granted by the ethics committees of the
Ministry of Health and Medical Services in the Solomon Islands,
and LSHTM in the UK.
Results
Participant Characteristics
Four hundred and fifteen samples were randomly selected. The
median age was 9, and 52.1% of participants were male.
Individuals selected for this study did not differ significantly from
the larger prevalence survey population with regards to demo-
graphic or clinical features (data not shown). Clinical findings
consistent with active and healed yaws were found in 19 (4.7%)
and 34 (8.2%) respectively of the 415 participants (Table 1 and
Figure 1).
Laboratory Testing
123 (29.6%) individuals had a reactive TPPA. 120 (28.9%)
individuals had a reactive RPR at any titre. By gold standard
serology there were 18 individuals with a false positive RPR
(defined as a positive RPR and negative TPPA). All false positive
RPRs in our study had an RPR titre of 1:2. The overall prevalence
of true RPR reactivity was therefore 102/415 (24.6%). The
distribution of RPR titres in the study population is given in
Figure 2.
79 individuals (19.0%) had a positive T1(treponemal) line on the
DPP kit. 64 (15.4%) individuals had a positive T2 (non-
treponemal) line on the DPP kit. There were ten individuals with
a positive T2 line but a negative T1 line. The overall prevalence of
dual-positivity was therefore 54/415 (13.0%).
The sensitivity of the T1 line against TPPA was 58.5% and the
specificity was 97.6%. The positive predictive value was 91.1%
and the negative predictive 84.5%. The sensitivity of the T2 line
against RPR was 41.7% and the specificity was 95.2%. The
positive predictive value was 78.1% and the negative predictive
value was 79.9%. The sensitivity of combined T1 and T2 against
combined TPPA and RPR was 47.1% and the specificity was
98.1%. The sensitivity of the DPP was strongly related to the RPR
titre (Tables 2 and 3)
In individuals with clinical signs of active yaws the sensitivity of
the T1 line, compared to TPPA, was 81.8% and the specificity was
100%. The sensitivity of the T2, compared to RPR, was 55.6%
and the specificity was 83.3%. A similar association was seen
between T2 sensitivity and RPR titre as in the overall population
(data not shown).
Discussion
In this study, we found that in a community surveillance setting,
the sensitivity and specificity of the DPP rapid diagnostic test were
markedly lower than in the only previous evaluation of the assay
for use in clinically active yaws [15]. There was a strong
association between the sensitivity of both the T2 line (against
gold standard RPR) and RPR titre and also between the T1 line
(against gold standard TPPA) and RPR titre. This finding might
suggest that the apparent reduced sensitivity of the test reflects, at
least in part, lower antibody titres in this population (where
positive serology predominantly reflected asymptomatic latent
cases) compared to populations in which the assay has previously
been evaluated (where there were greater numbers of patients with
active clinical disease), rather than a difference in test character-
istics per se. Despite the reduced sensitivity and specificity the
positive predictive values of the test remained relatively high,
reflecting the high prevalence of treponemal infection in this
endemic setting.
An association between the sensitivity of the T2 line and the
RPR titre has previously been noted [12], but an association
between RPR titre and T1 sensitivity has not been described
before. It is possible that, in keeping with its lower pathogenicity
compared to syphilis, yaws elicits less vigorous antibody produc-
tion than does its venereal cousin, affecting both the non-specific
(non-treponemal) and specific (treponemal) components of that
response. ‘Attenuated yaws’ has previously been described in the
Solomon Islands [16] with less florid clinical manifestations than
noted elsewhere. Widespread use of antibiotics with treponemo-
cidal activity has been postulated as one possible explanation for
Figure 2. RPR titre distribution.
doi:10.1371/journal.pntd.0003156.g002
Table 2. Test characteristics.
Positive by Gold
Standard DPP Sensitivity
DPP Positive
Predictive Value DPP Specificity
DPP Negative
Predictive Value
T1 (Treponemal Line) vs TPPA 123 58.5% (43.4–72.2%) 91.1% 97.6%(95.2–98.8%) 84.5%
T2 (Non-Treponemal Line) vs RPR 120 41.7% (28.0–56.8%) 95.2% 95.2%(92–95%) 79.9%
Dual Positive DPP (T1+T2) vs nDual
Positive Gold-Standard Serology
(TPPA+RPR)
102 47.1%(31.1–63.6%) 88.9% 98.1%(95.2–99.2%) 85.0%
doi:10.1371/journal.pntd.0003156.t002
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this postulated clinical entity. It is conceivable that this phenom-
enon could also contribute to the predominantly low-titre range of
antibody responses seen in this study.
The setting in which this evaluation was carried out varies
markedly from previous evaluations of the DPP test. In the largest
published study, which evaluated the test in the diagnosis of
syphilis, Yin and colleagues [11] evaluated the test in a population
of 1,323 individuals presenting to a sexual health clinic in China,
and found it to have a sensitivity of approximately 95% against
TPPA and 86% against RPR. An association between RPR titre
and sensitivity was also found in this study, although the
performance of the test was better at titres of 1:4 and 1:8 than
reported here.
Our study has a number of limitations. First, relatively few
individuals tested had clinical evidence of active yaws, reflecting
the community surveillance setting in which the test was evaluated.
Whilst this limits our ability to comment on the value of the test for
the purpose of case-confirmation, the aim of this study was to
evaluate the DPP’s use in screening whole communities at risk of
yaws, and for this context we provide the first published data.
Second, testing was performed in a central laboratory facility not
in the field. Although the test can be performed rapidly
(approximately 15–20 minutes per RDT), field-testing was not
practical alongside the other activities being performed in our
study, for which teams had to move house-to-house. Evaluations of
the test elsewhere show that test performance is unaffected by
whether venepuncture or finger-prick samples are used [11].
Further evaluations of the test in the field are warranted.
This study has implications for the use of the DPP RDT in yaws
surveillance and control. Whilst the sensitivity of the test was lower
than previously reported, the specificity remained high, and the
negative and positive predictive values of the test were also high.
Our data suggest that the DPP test can be used as part of a
community surveillance strategy to identify individuals who are
dually sero-positive with high-titre RPRs. These individuals are
most likely to represent the major source of ongoing transmission.
Identification of communities in which such individuals live is vital
to allow adequate community targeted treatment to be undertaken
[4]. The performance of the test in individuals with clinical
evidence of yaws was better than in those without clinical evidence
of disease, an association that is likely to be explained by the higher
RPR titres found in individuals with clinically active disease.
Because of inadequate access to point-of-care diagnostics, many
national yaws surveillance systems only report clinically suspected
cases. Wider access to DPP testing could allow a larger proportion
of these cases to be evaluated serologically, which would both
critically refine understanding of global yaws epidemiology as it
evolves towards the eradication endpoint, but also provide a vital
clinical aid in the post-MDA setting, where many conditions
mimicking yaws will continue to present to health-care facilities.
Further evaluation of the DPP in other yaws surveillance settings
would be welcomed to provide the basis for guideline develop-
ment.
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Supplementary	Figure	1:	STARD	flowchart	
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STARD	checklist	for	reporting	of	studies	of	diagnostic	accuracy	
(version	January	2003)	
	
	
Section	and	Topic	 Item	
#	
	 On	page	#	
TITLE/ABSTRACT/	
KEYWORDS	
1	 Identify	the	article	as	a	study	of	diagnostic	
accuracy	 (recommend	 MeSH	 heading	
'sensitivity	and	specificity').	
1	
INTRODUCTION	 2	 State	 the	 research	 questions	 or	 study	
aims,	 such	 as	 estimating	 diagnostic	
accuracy	or	comparing	accuracy	between	
tests	or	across	participant	groups.	
1-2	
METHODS	 	 	 	
Participants	 3	 The	 study	 population:	 The	 inclusion	 and	
exclusion	 criteria,	 setting	 and	 locations	
where	data	were	collected.	
2	
	 4	 Participant	 recruitment:	Was	 recruitment	
based	 on	 presenting	 symptoms,	 results	
from	 previous	 tests,	 or	 the	 fact	 that	 the	
participants	 had	 received	 the	 index	 tests	
or	the	reference	standard?	
2	
	
	 5	 Participant	 sampling:	 Was	 the	 study	
population	 a	 consecutive	 series	 of	
participants	 defined	 by	 the	 selection	
criteria	 in	 item	 3	 and	 4?	 If	 not,	 specify	
how	participants	were	further	selected.	
2	
	 6	 Data	 collection:	 Was	 data	 collection	
planned	 before	 the	 index	 test	 and	
reference	 standard	 were	 performed	
(prospective	study)	or	after	(retrospective	
study)?	
2	
	
Test	methods	 7	 The	reference	standard	and	its	rationale.	 2	
	 8	 Technical	 specifications	 of	 material	 and	
methods	 involved	 including	 how	 and	
when	measurements	were	 taken,	 and/or	
cite	 references	 for	 index	 tests	 and	
reference	standard.	
2	
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	 9	 Definition	 of	 and	 rationale	 for	 the	 units,	
cut-offs	and/or	categories	of	the	results	of	
the	 index	 tests	 and	 the	 reference	
standard.	
2	
	 10	 The	number,	training	and	expertise	of	the	
persons	 executing	 and	 reading	 the	 index	
tests	and	the	reference	standard.	
2	
	 11	 Whether	 or	 not	 the	 readers	 of	 the	 index	
tests	 and	 reference	 standard	 were	 blind	
(masked)	 to	 the	 results	 of	 the	 other	 test	
and	 describe	 any	 other	 clinical	
information	available	to	the	readers.	
2	
Statistical	methods	 12	 Methods	 for	 calculating	 or	 comparing	
measures	of	diagnostic	accuracy,	and	 the	
statistical	 methods	 used	 to	 quantify	
uncertainty	 (e.g.	 95%	 confidence	
intervals).	
2	
	 13	 Methods	 for	 calculating	 test	
reproducibility,	if	done.	
N/A	
RESULTS	 	 	 	
Participants	 14	 When	 study	 was	 performed,	 including	
beginning	and	end	dates	of	recruitment.	
3	
	 15	 Clinical	 and	 demographic	 characteristics	
of	 the	 study	 population	 (at	 least	
information	 on	 age,	 gender,	 spectrum	 of	
presenting	symptoms).	
3	
	 16	 The	number	of	participants	 satisfying	 the	
criteria	 for	 inclusion	 who	 did	 or	 did	 not	
undergo	 the	 index	 tests	 and/or	 the	
reference	 standard;	 describe	 why	
participants	 failed	 to	 undergo	 either	 test	
(a	 flow	 diagram	 is	 strongly	
recommended).	
Supplementary	
Figure	1		
Test	results	 17	 Time-interval	between	the	index	tests	and	
the	 reference	 standard,	 and	 any	
treatment	administered	in	between.	
N/A	
	 18	 Distribution	of	 severity	of	disease	 (define	
criteria)	 in	 those	 with	 the	 target	
condition;	other	diagnoses	 in	participants	
without	the	target	condition.	
3	
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	 19	 A	 cross	 tabulation	 of	 the	 results	 of	 the	
index	 tests	 (including	 indeterminate	 and	
missing	 results)	 by	 the	 results	 of	 the	
reference	 standard;	 for	 continuous	
results,	the	distribution	of	the	test	results	
by	the	results	of	the	reference	standard.	
Table	2	and	Table	3	
	 20	 Any	 adverse	 events	 from	 performing	 the	
index	tests	or	the	reference	standard.	
N/A	
Estimates	 21	 Estimates	 of	 diagnostic	 accuracy	 and	
measures	 of	 statistical	 uncertainty	 (e.g.	
95%	confidence	intervals).	
3	
Table	2	and	3	
	 22	 How	 indeterminate	 results,	 missing	 data	
and	 outliers	 of	 the	 index	 tests	 were	
handled.	
3	
	 23	 Estimates	 of	 variability	 of	 diagnostic	
accuracy	 between	 subgroups	 of	
participants,	readers	or	centers,	if	done.	
N/A	
	 24	 Estimates	of	test	reproducibility,	if	done.						N/A	
DISCUSSION	 25	 Discuss	 the	 clinical	 applicability	 of	 the	
study	findings.	
3-4	
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Chapter	6:	Mathematical	modeling	 to	 inform	programmatic	
requirements	for	yaws	eradication	
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Abstract	
	
Yaws	 is	 targeted	 for	eradication	by	2020.	The	mainstay	of	 the	eradication	 strategy	 is	mass	
treatment	 followed	 by	 case	 finding.	 Modelling	 has	 been	 used	 to	 inform	 programmatic	
requirements	 for	 other	 NTDs	 and	 has	 the	 potential	 to	 provide	 insights	 into	 the	 yaws	
eradication	strategy.	We	developed	a	model	of	yaws	transmission	varying	the	coverage	and	
number	 of	 rounds	 of	mass	 treatment.	 R0	was	 estimated	 to	 be	 between	 1.08	 and	 3.32.	 To	
have	 an	 80%	 probability	 of	 achieving	 eradication	 eight	 rounds	 of	 treatment	 with	 80%	
coverage	were	 required	 at	 low	 estimates	 of	 R0.	 	This	 rose	 to	 95%	 at	 high	 estimates	 of	 R0.	
Extending	 the	 interval	 between	 treatments	 to	 12	 months	 significantly	 increased	
programmatic	 requirements	 at	 all	 estimates	 of	 R0.	 At	 high	 estimates	 of	 R0	 and	 when	
treatment	 rounds	 were	 spaced	 12	 months	 apart	 no	 combination	 of	 variables	 achieved	
eradication.	Models	should	be	used	to	guide	the	scale	up	of	the	eradication	program.		
Background	
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Yaws	 is	 a	 bacterial	 infection	 caused	 by	Treponema	pallidum	 subsp.	 pertenue1.	 The	 disease	
predominantly	affects	children	 living	 in	poor,	 remote	communities	and	 results	 in	 lesions	of	
the	skin,	bone	and	cartilage.	Previously,	yaws	was	widespread	throughout	the	tropics2,	but	in	
the	20th	century	a	series	of	control	efforts	based	on	mass	treatment	and	case	finding	led	by	
WHO	 is	estimated	 to	have	 reduced	 the	burden	of	 cases	worldwide	by	up	 to	95%3.	Despite	
these	efforts,	the	disease	has	resurged	in	a	number	of	countries	in	West	and	Central	Africa,	
the	Pacific	and	South-East	Asia.		
	
In	2012	 it	was	demonstrated	that	a	single	dose	of	azithromycin	was	an	effective	treatment	
for	yaws4.	The	availability	of	a	well-tolerated	oral	agent	has	prompted	WHO	to	develop	a	new	
eradication	 strategy,	 the	 ‘Morges	 Strategy’,	 based	 on	 community	 mass	 azithromycin	
treatment5.	 The	 strategy	 combines	 an	 initial	 round	 of	 total	 community	 treatment	 (TCT)	
followed	 by	 subsequent	 active	 case	 finding	 and	 total	 targeted	 treated	 (TTT)	 of	 newly	
identified	cases	and	their	contacts.	Pilot	studies	have	shown	that	community	mass	treatment	
with	 azithromycin	 is	 a	 highly	 effective	 strategy	 for	 reducing	 the	 community	 prevalence	 of	
yaws6,7.			
	
There	are	 limited	data	 to	 inform	the	optimum	coverage	and	number	of	TCT	or	TTT	 rounds	
that	are	required	to	achieve	elimination	(interruption	of	transmission)	of	yaws	at	a	local	level	
to	 facilitate	 country-level	 elimination	and	ultimately	 global	 eradication.	 In	 India,	 a	national	
yaws	 elimination	 campaign	 conducted	 between	 1996	 and	 2004	 resulted	 in	 significant	
reduction	 in	 the	 prevalence	 of	 yaws,	 sustained	 interruption	 of	 transmission	 and	 national	
elimination8.	 This	 programme	 consisted	 of	 six-monthly	 case	 finding	 surveys	 and	 treatment	
with	 parenteral	 penicillin.	Whilst	 this	 approach	 did	 not	 include	 the	 initial	 mass	 treatment	
round	 now	 recommended	 as	 part	 of	 the	Morges	 strategy,	 its	 success	 indicates	 that	 serial	
rounds	of	high	coverage	treatment	may	achieve	local	elimination.	
	
A	 recent	 review	 of	 important	 research	 questions	 facing	 the	 global	 yaws	 eradication	
programme	has	highlighted	the	need	for	more	accurate	data	to	inform	the	optimum	number	
and	coverage	of	 rounds	of	TCT	and	TTT	 that	will	be	 required	 to	achieve	yaws	eradication9.	
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Mathematical	 modelling	 has	 been	 used	 to	 inform	 control	 efforts	 for	 a	 number	 of	 other	
Neglected	 Tropical	 Diseases	 (NTDs)10–12	 which	 are	 also	 managed	 using	 community	 mass	
treatment	strategies,	and	such	approaches	could	be	of	value	for	yaws	eradication	efforts.	In	
particular,	 this	 approach	may	 allow	 a	 comparison	 of	 the	 differential	 impact	 of	 alternative	
mass	 treatment	 strategies,	 which	 would	 be	 difficult	 to	 assess	 by	 empirical	 randomized	
controlled	 trials	 due	 to	 the	 size	 and	 cost	 of	 implementing	 large-scale	 cluster	 randomized	
studies.	
	
Previous	 mathematical	 models	 for	 yaws13	 have	 assessed	 the	 cost-effectiveness	 of	 yaws	
eradication,	 but	 have	 not	 directly	 addressed	 the	 feasibility	 of	 achieving	 this	 goal	 or	 the	
number	of	rounds	of	treatment	that	would	be	required.	In	this	study,	we	aimed	to	determine	
whether	 the	eradication	of	 yaws	 is	 feasible	based	on	 the	Morges	 strategy	 and,	 if	 it	 is,	 the	
number	and	coverage	of	mass	treatment	rounds	needed	to	achieve	the	goal.	
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Methods	
	
We	developed	a	stochastic	Markov	model	of	community-level	 transmission	of	yaws	 (Figure	
1).	 Upon	 infection,	 susceptible	 (S)	 individuals	 develop	 primary	 disease	 (I1)	 at	 a	 rate	
proportional	to	the	transmission	rate	β	and	the	total	number	of	infectious	individuals	(I1	+	I2).	
Individuals	with	primary	disease	can	further	transition	to	secondary	disease	(I2)	at	rate	α,	and	
both	those	with	primary	and	secondary	disease	can	transition	to	latent	disease	(L)	at	rate	η.	
Lastly,	 those	with	 latent	 disease	 can	 relapse	 back	 to	 I2	 at	 rate	 ρ.	 Infected	 individuals	with	
primary	or	secondary	disease	are	treated	(and	become	susceptible	again)	at	rate	τI,	and	those	
with	latent	disease	at	rate	τL.	Unlike	previous	mathematical	models	of	yaws13	,	tertiary	yaws	
was	 not	 included	 in	 the	 model	 as	 these	 cases	 are	 believed	 not	 to	 contribute	 to	
transmission14.		As	individuals	may	be	re-infected	many	times	we	did	not	consider	individuals	
to	obtain	protective	immunity	following	infection	or	treatment.		
	
Although	there	is	some	evidence	that	there	may	be	a	non-human	primate	reservoir	for	yaws	
in	Africa15	we	did	not	include	such	infections	in	our	model	as	there	is	currently	no	definitive	
evidence	 that	 the	 organism	 responsible	 for	 these	 infections	 is	 the	 same	 one	 that	 causes	
human	yaws,	or	that	zoonotic	transmission	occurs	in	the	real	world.	We	therefore	considered	
the	epidemiological	significance	of	this	possible	reservoir	as	minimal	when	constructing	our	
model.	
	
Population	Size	
Estimates	 of	 the	 starting	 population	 for	 each	 compartment	 were	 derived	 from	 published	
population-based	 yaws	 prevalence	 studies6,16.	 We	 modelled	 a	 discrete,	 closed	 population	
without	addition	or	reduction	via	births	or	deaths.	
	
Disease	characteristic	variable	estimates	(Table	1)	
We	estimated	values	for	the	rates	of	disease	progression	between	different	stages	of	yaws,	
including	development	of	and	relapse	from	latent	yaws,	using	expert	opinion,	published	data	
and	 estimates	 used	 in	 other	models1,13,16.	 	We	 defined	 three	 transmission	 scenarios	 (low,	
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medium	 and	 high)	 using	 published	 age-specific	 treponemal	 seroprevalence	 data16,	 expert	
opinion,		and	values	used	in	other	yaws	models13.	Based	on	these	data	we	generated	initial	
estimates	of	R0	of	between	1.25	(low),	1.83	(medium)	and	2.4	(high).	These	were	converted	
to	estimates	of	β,	taking	in	to	account	the	average	duration	of	infection	and	the	size	of	the	
population	compartments	in	the	model.	The	basic	reproduction	number	R0	taking	account	of	
the	full	structure	of	our	model	is	1.96	resulting	in	a	mean	R0	of	1.45	(95%	1.01-2.14)	for	the	
low	 transmission	 settings,	 1.95	 (1.38-2.91)	 for	 medium	 and	 2.47	 for	 high	 (1.7-3.68)	
transmission	 settings.	 We	 included	 a	 variable	 to	 represent	 the	 likelihood	 of	 an	 individual	
receiving	 treatment	 for	 yaws	 in	 the	 absence	 of	 public	 health	 interventions	 based	 on	
published	data16.	
	
	
Mass	drug	administration	variables	estimates	
	
We	 performed	 simulation	 experiments	 to	 estimate	 the	 impact	 of	 a	 yaws	 eradication	
intervention	on	disease	transmission.	 In	 line	with	the	Morges	strategy5,	we	considered	two	
programme	 components.	 In	 the	 first	 component,	 Total	 Community	 Treatment	 (TCT),	 all	
individuals	were	 considered	 to	 have	 an	 equal	 chance	 of	 receiving	 treatment	 regardless	 of	
their	 infection	 status.	 In	 the	 second	 component	 of	 the	 intervention,	 Total	 Targeted	
Treatment	(TTT),	we	considered	that	the	coverage	achieved	amongst	active	and	latent	cases	
might	differ.	 Intervention	coverage	was	modelled	 independently	 for	TCT,	TTT	pertaining	 to	
active	cases,	and	TTT	pertaining	to	latent	cases	over	a	range	of	plausible	estimates	(65%	to	
95%	 population	 coverage).	 Mass	 treatment	 compliance	 was	 simulated	 as	 a	 random,	 non-
systematic	process;	i.e.,	each	individual	had	the	same	chance	of	receiving	treatment,	with	the	
likelihoods	of	any	one	individual	receiving	treatment	being	independent.	
	
We	varied	the	number	of	treatment	rounds	of	both	TCT	(between	1-3)	and	TTT	(between	0-
6).	Where	one	or	more	 rounds	of	 TTT	were	 implemented	 these	 commenced	 following	 the	
final	round	of	TCT.	In	line	with	the	Morges	strategy	and	real-world	pilot	implementations5,6	,	
rounds	of	mass	treatment	were	spaced	at	six-monthly	intervals.	
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We	 derived	 estimates	 of	 the	 efficacy	 of	 single	 dose	 treatment	 with	 azithromycin	 from	
randomized	controlled	trials	of	azithromycin	for	the	treatment	of	yaws	(Table	1).4	Following	
successful	 treatment,	 yaws	 lesions	 become	 non-infectious	within	 24	 hours1,	 and	 therefore	
we	considered	treatment	to	be	immediately	efficacious	at	the	time	of	MDA,	with	individuals	
reverting	to	a	susceptible	state	following	treatment.		
	
Implementing	the	model	
The	Markov	model	was	run	with	an	optimized	tau-leap	algorithm	to	approximate	Gillespie’s	
algorithm	for	exactly	simulating	stochastic	systems17,18.	
We	 used	 the	 adaptiveTau	 package	 for	 R	 (the	 R	 Project	 for	 Statistical	 Computing)19.	 We	
performed	repeated	simulations	across	a	range	of	disease	transmission	assumptions	(β,	n=3)	
and	 treatment	 assumptions,	 varying	 both	 the	 coverage	 and	 number	 of	 mass	 treatment	
rounds	undertaken	(Table	1).		
For	 each	 combination	 of	 disease	 and	 intervention	 parameters	 we	 performed	 1,000	
simulation	experiments.	Within	each	combination	we	utilized	latin-hypercube	sampling	using	
the	 lhs	R	package20	to	vary	other	disease	specific	variables	(rate	of	progression	and	relapse,	
treatment	 in	 the	 absence	 of	 intervention)	 across	 the	 range	 of	 parameter	 estimates.	 We	
included	 an	 initial	 burn-in	 time	 of	 50	 months	 prior	 to	 the	 commencement	 of	 any	 yaws	
eradication	intervention.	The	model	then	ran	for	a	further	100	months.		
	
Assessing	outcomes	
We	recorded	for	each	run	of	the	model	whether	eradication	was	achieved.	Eradication	was	
defined	as	no	cases	of	infectious	or	latent	yaws	at	the	end	of	the	model	run.	The	eradication	
probability	 was	 defined	 as	 the	 percentage	 of	 runs	 within	 each	 permutation	 of	 model	
characteristics	where	extinction	was	achieved.	All	analyses	were	performed	using	R	version	
3.2.2.	
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Results:	
The	 model	 generated	 a	 total	 of	 6,174	 simulations	 of	 variable	 MDA	 strategies.	 As	 each	
strategy	was	implemented	across	a	range	(n	=	3)	of	assumptions	about	the	force	of	infection	
a	total	of	18,522	simulations	were	created.		
The	 probability	 of	 achieving	 local	 interruption	 of	 transmission	 varied	 substantially	 across	
estimates	of	the	force	of	infection	and	MDA	characteristics.		
	
At	 the	 lowest	 estimates	 of	 the	 force	 of	 infection,	 the	 minimum	 treatment	 thresholds	
required	to	have	a	transmission	interruption	probability	of	80%	or	higher	were	a	coverage	of	
greater	 than	 75%	 of	 all	 populations,	 and	 8	 or	 more	 rounds	 of	 treatment.	 Increasing	 the	
coverage	to	85%	reduced	the	total	number	of	rounds	required	to	5.	For	comparison,	when	
the	gap	between	treatment	rounds	was	extended	from	6	to	12	months	a	total	of	7	rounds	of	
85%	coverage	were	required.	
	
At	medium	estimates	of	the	force	of	infection	(R0	=	1.95),	the	equivalent	thresholds	were	90%	
coverage	and	a	total	of	7	rounds	of	treatment.	When	the	gap	between	rounds	of	treatment	
was	increased	to	12	months,	no	combination	of	treatment	variables	was	predicted	to	have	a	
transmission	interruption	probability	of	80%	or	more.	
	
At	 the	 highest	 estimates	 of	 the	 force	 of	 infection	 (R0	=	3.32)	 a	 total	 of	 8	 rounds	with	 95%	
coverage	were	required	for	a	greater	than	80%	likelihood	of	interrupting	transmission.	When	
the	 gap	 between	 rounds	 of	 treatment	 was	 increased	 to	 12	 months,	 no	 combination	 of	
treatment	variables	was	predicted	to	have	a	probability	of	interrupting	transmission	of	80%	
or	more	(Figure	2).	
	
It	was	considered	plausible	that,	under	field	conditions,	the	coverage	of	 latent	cases	would	
not	exceed	70%	 in	any	given	 round	of	TTT,	because	 such	cases	are	not	 clinically	apparent,	
and	adequate	coverage	may	not	be	achieved	by	treating	the	 immediate	contacts	of	clinical	
cases.	At	 lower	estimates	of	the	force	of	 infection,	a	total	of	three	rounds	of	TCT	with	85%	
coverage	and	 three	 rounds	of	TTT	 (each	with	a	coverage	of	active	cases	of	85%	and	 latent	
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cases	 of	 65%)	 was	 associated	 with	 a	 greater	 than	 80%	 probability	 of	 interrupting	
transmission.	If	only	1	round	of	TCT	was	conducted,	then	coverage	during	TCT	needed	to	be	
90%	 and	 a	 total	 of	 5	 rounds	 of	 TTT	 (each	 with	 90%	 coverage	 of	 active	 cases	 and	 65%	
coverage	of	 latent	cases)	were	 required.	For	medium	estimates	of	 the	 force	of	 infection,	a	
total	of	8	rounds	of	treatment	(3xTCT	and	5xTTT)	with	a	coverage	of	90%	were	required.	 If	
only	1	round	of	TCT	was	undertaken,	then	95%	coverage	was	required,	followed	by	5	rounds	
of	 TTT	with	 a	 95%	 coverage	 of	 active	 cases	 and	 70%	 coverage	 of	 latent	 cases.	 Under	 the	
highest	 estimate	 of	 the	 force	 of	 infection	 no	 combination	 of	 treatment	 variables	 was	
associated	with	a	high	probability	of	interrupting	transmission.		 	
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Discussion:	
Our	study	has	demonstrated	that,	with	implementation	of	the	Morges	strategy,	interruption	
of	transmission	and,	therefore,	eradication	of	yaws	 is	achievable,	although	not	guaranteed.	
The	probability	 of	 success	would	be	 strongly	 dependent	on	 the	 transmission	 rate	of	 yaws,	
and	 further	 studies	 to	 obtain	 better	 estimates	 of	 the	 basic	 reproduction	 number	 (R0)	 in	 a	
range	 of	 countries	 where	 yaws	 is	 endemic	 would	 be	 of	 value	 to	 inform	 both	 improved	
models	 and	 programmatic	 planning.	 A	minimum	of	 eight	 rounds	with	 coverage	 of	 at	 least	
75%	seems	to	be	required	for	a	high	likelihood	of	achieving	eradication,	although	this	would	
prove	 inadequate	at	our	highest	estimates	of	possible	 values	 for	R0.	The	predictions	of	our	
model	are	broadly	in	keeping	with	the	real-world	findings	of	the	successful	yaws	elimination	
programme	in	India8	where	7	years	of	consecutive	case	finding	and	treatment	(analogous	to	
14	rounds	of	TTT	with	75%	coverage)	were	conducted.	In	our	model,	the	coverage	achieved	
amongst	 latent	 cases	 during	 TTT	 has	 a	 profound	 impact	 on	 the	 likelihood	 of	 achieving	
eradication.	 When,	 in	 our	 model,	 coverage	 was	 limited	 to	 70%	 or	 below,	 the	 required	
number	of	rounds	of	treatment	to	interrupt	transmission	increased	considerably.	
There	are	relatively	few	data	available	on	the	transmission	rate	of	yaws.	Even	within	endemic	
countries,	 the	 prevalence	 of	 yaws	 varies	 markedly.	 Studies	 in	 the	 Pacific	 have	 found	 a	
seroprevalence	 of	 anti-treponemal	 antibodies	 of	 more	 than	 30%	 in	 a	 number	 of	
communities6,16	and	a	prevalence	of	clinical	yaws	of	between	2.5-5%	in	pre-mass	treatment	
communities.	 The	 prevalence	 of	 yaws	 is	 significantly	 lower	 in	 many	 endemic	 countries	 in	
West	Africa21	but	there	are	limited	community	based	seroprevalence	data	available	to	inform	
our	 understanding	 of	 disease	 transmission	 there.	We	modeled	 a	 range	 of	 estimates	 of	 R0	
between	 1.08	 and	 3.32	 based	 on	 seroprevalence	 data	 and	 expert	 opinion.	 Given	 the	
significant	 influence	 of	 these	 estimates	 of	 R0	 on	 the	 likely	 outcome	 of	 community	 mass	
treatment,	 further	 studies	 to	 better	 understand	 disease	 transmission	 and	 how	 this	 varies	
within	 and	 between	 endemic	 communities	would	 be	 of	 value.	 Ideally	 these	 studies	would	
obtain	community	level	age-specific	seroprevalence	data	that	could	be	used	to	calculate	the	
force	 of	 infection.	 There	 is	 no	 perfect	 serological	 marker	 that	 can	 be	 used	 for	 this	 task.	
Traditional	 treponemal	 serology	 combines	 a	 treponemal	 test,	 which	 reflects	 lifetime	
136
		
	
	
	
exposure	but	 remains	positive	 for	 life,	with	a	non-treponemal	 test,	 the	 titre	of	which	 rises	
and	 falls	 following	 treatment.	 It	 is	 therefore	 not	 possible	 to	 use	 seroprevalence	 data	 to	
distinguish	 individuals	 who	 have	 been	 infected	 many	 times	 from	 those	 who	 have	 been	
infected	once,	 and	 seroprevalence	estimates	are	 likely	 to	under-estimate	 the	 true	 force	of	
infection.	For	this	study	we	calculated	the	force	of	infection	relying	on	treponemal	serology	
alone,	which	 should	provide	a	more	accurate	estimate	of	 the	 force	of	 infection	 than	 if	we	
used	dual	positive	serology.	It	remains,	however,	an	imperfect	measure.		
Our	model	predicts	that	high	coverage	 is	required	 in	all	rounds	of	treatment	to	make	yaws	
eradication	 feasible.	 Data	 from	 the	 previous	WHO	 and	 UNICEF	 mass	 treatment	 campaign	
have	 highlighted	 the	 importance	 of	 achieving	 high	 coverage	 of	 latent	 cases22	 and	 that	
treatment	of	active	cases	alone	 is	 insufficient	to	 interrupt	transmission.	These	factors	were	
important	considerations	in	the	adoption	as	part	of	the	Morges	strategy	of	an	initial	round	of	
total	 community	 treatment	 regardless	of	 the	prevalence	of	 active	disease	 in	a	 community.	
Given	 the	 high	 coverage	 requirement,	 particularly	 of	 latent	 cases,	 and	 the	 relatively	 high	
fixed-costs	of	reaching	endemic	communities13	when	compared	to	the	relatively	low	costs	of	
generic	azithromycin,	 it	may	be	preferable	 to	conduct	multiple	 rounds	of	Total	Community	
Treatment	prior	to	the	switch	to	Total	Targeted	Treatment.	Indeed	such	a	recommendation	
would	be	 in	 line	with	 the	original	Morges	 Strategy23	 ,	which	 recommended	 that	 additional	
rounds	of	TCT	could	be	considered	if	the	coverage	achieved	in	the	initial	round	of	treatment	
was	<90%	or	if	access	to	endemic	communities	was	difficult.	A	switch	to	multiple	rounds	of	
community	 mass	 treatment	 might	 also	 facilitate	 integration	 with	 other	 NTD	 MDA	
programmes	 in	 countries	 which	 are	 also	 frequently	 based	 on	 whole	 community	 mass	
treatment24,	 although	 it	 should	 be	 noted	 that	 our	model	 predicted	 a	 higher	 probability	 of	
achieving	 eradication	 with	 biannual	 treatment.	 Further	 studies	 to	 help	 determine	 the	
optimum	 strategy	 for	 achieving	 high	 coverage	 of	 latent	 cases	 during	 the	 TTT	 phase	 of	
eradication	 efforts	 should	 be	 considered	 –	 for	 example,	 to	 better	 understand	 the	 spatial	
epidemiology	 of	 latent	 yaws	 cases	 in	 relation	 to	 active	 cases	 in	 both	 pre	 and	 post-MDA	
settings	or	whether	additional	mass	treatment	rounds	specifically	targeting	children	might	be	
beneficial.	
137
		
	
	
	
Our	 study	 has	 a	 number	 of	 limitations.	 Most	 notably,	 we	 lack	 accurate	 estimates	 for	 a	
number	of	disease	parameters.	The	disease	parameters	used	in	this	study	are	broadly	in	line	
with	 those	 used	 by	 other	 models	 of	 yaws	 transmission13.	We	 tested	 a	 range	 of	 coverage	
estimates	for	community	mass	treatment,	but	we	did	not	factor	in	the	possibility	that	some	
individuals	may	be	systematically	missed	during	mass	treatment	campaigns,	a	phenomenon	
that	has	been	seen	in	control	efforts	for	other	NTDs25.	The	current	Morges	strategy	does	not	
include	 adjunctive	 elements,	 such	 as	WASH	 interventions,	 in	 addition	 to	 mass	 treatment,	
although	 some	 studies	 suggest	 that	 improved	 access	 to	water	 and	 sanitation	 is	 associated	
with	a	decreased	risk	of	yaws16.	We	did	not	include	a	secular	trend	in	our	model,	and	such	a	
trend	 could	 be	 anticipated	 to	 further	 increase	 the	 likelihood	 of	 yaws	 eradication	 being	
achieved.	Our	model	was	designed	to	assess	the	feasibility	of	achieving	yaws	eradication	in	
the	near	future,	driven	by	the	current	WHO	strategy,	and	in	those	conditions	any	effect	of	a	
secular	trend	could	be	expected	to	be	minimal	when	compared	to	the	significant	 impact	of	
community	mass	treatment.	Previous	models	have	shown	that	secular	trends	are	unlikely	to	
significantly	 affect	 the	 cost-effectiveness	 of	 mass	 treatment13.	 It	 is	 important	 to	 note,	
however,	 that	 those	models	were	based	on	an	assumption	of	 90-99%	coverage	 in	 a	 single	
TCT	round	and	100%	coverage	of	index	cases	and	their	contacts	in	the	TTT	round.	
Our	 study	 is	 the	 first	 to	assess	 the	 theoretical	achievability	of	worldwide	yaws	eradication,	
and	 represents	 an	 important	 milestone	 in	 reaching	 WHO’s	 eradication	 target.	 We	 have	
defined	programmatic	thresholds	that	may	need	to	be	met	to	achieve	yaws	eradication,	and	
identified	key	research	questions	to	be	addressed	to	inform	both	refinements	of	the	model	
and	worldwide	roll-out	of	treatment	strategies.	
		
	
	 	
138
		
	
	
	
Table	1:	Model	Parameters	
Parameter	 Parameter	Estimate	 Comments	
Epidemiological	Parameters	 	
R0	 1.08	–	3.32	 The	average	number	of	
new	 cases	 occurring	
from	 a	 single	 index	
case	 in	 a	 fully	
susceptible	population	
Monthly	 probability	 of	
Progression	from	Primary	to	
Secondary	 Disease	 without	
Treatment	
2.78-5.56%	 Untreated	 all	
individuals	 with	
primary	 disease	 either	
develop	 secondary	 or	
latent	 stage	 disease	
and	 this	 occurs	 over	 a	
period	of	2-6	months.	
Monthly	 probability	 of	
Progression	 from	 Infectious	
to	 Latent	 Disease	 without	
Treatment	
13.9-27.8%	
Monthly	 probability	 of	
relapse	 from	Latent	Disease	
to	 Infectious	 stage	 without	
treatment	
1-3%	 Untreated	 latent	 cases	
may	 relapse	 for	 a	
period	 of	 at	 least	 5	
years	 and	 become	
actively	 infectious	
again	
Population	Parameters	 	
Susceptible	at	baseline	 64%	 Data	 derived	 from	
multiple	 pre-MDA	
surveys	 conducted	 in	
yaws	 endemic	
communities.		
Primary	yaws	at	baseline	 1.5%	
Secondary	yaws	at	baseline	 1.5%	
Latent	yaws	at	baseline	 33%	
Mass	Treatment	Parameters	 	
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TCT	Coverage	 65-95%	 Coverage	 estimates	
were	 chosen	 to	 reflect	
the	 range	 achieved	 in	
real-world	 MDA	
programmes	 for	 other	
NTDs		
TTT	 Coverage	 of	 Active	
Cases	
65-95%	
TTT	 Coverage	 of	 Latent	
Cases	
65-95%	
Number	of	Rounds	of	TCT	 1-3	 	
Number	of	Rounds	of	TTT	 0-5	 	
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Figure	1:	Markov	model	of	yaws	transmission	
	
Susceptible	 individuals	 (S)	 become	 infected	 at	 a	 rate	 dependent	 on	 both	 the	 transmission	
probability	 (β)	and	the	number	of	 individuals	with	 infectious	primary	(I1)	and	secondary	(I2)	
yaws.	Without	treatment	individuals	progress	from	primary	disease	to	either	latent	yaws	(L)	
or	 secondary	 yaws	 (I2).	 Latent	 cases	may	 relapse	 to	 generate	 further	 infectious	 secondary	
cases	of	yaws.			
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Figure	2:	Probability	of	achieving	eradication	given	different	coverage	estimates	
The	 graphs	 show	 the	 predicted	 probability	 of	 achieving	 eradication	 given	 variations	 in	 the	
estimate	 of	 R0,	 the	 coverage	 of	 TCT	 (lower-X-axis)	 the	 number	 of	 rounds	 of	 TCT	 (upper-X-
axis),	 the	 coverage	of	 TTT	 (left-Y-axis),	 the	number	of	 rounds	of	 TTT	 (right-Y-axis).	 For	 this	
graph	 we	 only	 show	 simulations	 where	 the	 coverage	 of	 latent	 cases	 is	 the	 same	 as	 the	
coverage	of	active	cases	during	TTT.	This	may	over-represent	the	true	likelihood	of	achieving	
eradication,	as	the	coverage	of	latent	cases	is	likely	to	be	lower	than	the	coverage	of	active	
cases	during	TTT.  
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Chapter	7:	Discussion		
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7.	1	Summary	of	research	findings	
	
This	section	provides	a	brief	overview	of	the	findings	of	the	study	in	relation	to	the	objectives	
of	 the	thesis.	For	each	objective,	 the	Research	Paper	 in	which	a	detailed	description	of	the	
study	findings	are	reported,	is	highlighted.	
	
Objective	1:	Establish	accurate	data	on	epidemiology	of	yaws	in	Solomon	Islands	
(Research	Paper	-	Chapter	3)		
	
The	pre-MDA	study	conducted	in	2013	provided	accurate	prevalence	estimates	for	both	yaws	
infection	 and	 disease	 in	 the	 two	 provinces	 of	 the	 Solomon	 Islands	 where	 the	 study	 was	
conducted	[1].	Almost	one	in	three	children	(31.4%)	had	evidence	of	exposure	in	the	form	of	
a	 positive	 TPPA.	 The	 prevalence	 of	 both	 infection	 and	 disease	 was	 found	 to	 be	 higher	 in	
Western	province	than	in	Choiseul	province,	which	 is	consistent	with	clinical	case	reporting	
through	 the	 national	 surveillance	 system.	 Significant	 clustering	 of	 infection	 was	
demonstrated	at	the	sub-province	level,	a	finding	which	has	also	been	reported	from	other	
endemic	 settings	 [2].	 The	 study	 was	 not	 able	 to	 identify	 clear	 drivers	 of	 geographical	
clustering	and	further	studies	to	explore	this	would	aid	mapping	and	surveillance	strategies.		
Haemophilus	 ducreyi	 was	 identified	 as	 a	 common	 cause	 of	 skin	 ulcers	 in	 this	 study	 in	
individuals	 who	 were	 both	 seropositive	 and	 seronegative	 for	 yaws	 [3].	 This	 finding,	 along	
with	similar	data	from	Papua	New	Guinea	and	Ghana	[4,5],	has	been	used	to	propose	case	
definitions	for	yaws	that	vary	at	the	different	stages	of	an	eradication	effort	[2].	In	a	pre-MDA	
setting,	 serology	 and	 clinical	 features	 are	 considered	 adequate,	 but	 in	 a	 post-MDA	 setting	
molecular	tools	are	now	recommended	to	supplement	clinical	and	serological	data.	
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Objective	2:	Identify	risk	factors	in	pre-MDA	setting	for	both	yaws	disease	and	infection	
(Research	Paper	-	Chapter	3)		
	
The	 risk	 factor	 analysis	 conducted	 on	 the	 pre-MDA	 survey	 data	 demonstrated	 that	 the	
presence	of	other	infected	individuals	at	both	the	household	and	village	level	are	the	major	
factors	associated	with	the	risk	of	 infection	[1],	which	is	consistent	with	the	study’s	a	priori	
hypothesis.	
	
Consistent	with	other	 studies,	 an	 increased	 risk	of	 infection	 in	boys	 compared	 to	 girls	was	
noted	[6].	As	yaws	and	syphilis	are	serologically	indistinguishable,	one	explanation	would	be	
that	these	findings	are	due	to	early	cases	of	sexually	acquired	syphilis	amongst	the	males	in	
the	 study.	 The	 association	 between	 gender	 and	 infection	 remained	 statistically	 significant	
even	 in	 the	 sub-group	of	 children	 aged	under	 10	 years,	which	makes	 this	 explanation	 less	
likely.	An	alternative	hypothesis	is	that	the	additional	risk	in	boys	reflects	increased	traumatic	
damage	 to	 the	 skin,	 through	 rougher	 playing,	 which	 then	 serves	 as	 a	 portal	 of	 entry	 for	
infection	by	T.	p.	pertenue.		
	
A	possible	protective	effect	from	improved	access	to	water	and	sanitation	was	noted,	which	
might	 reflect	 improved	 skin	 integrity	 and	 a	 decreased	 risk	 of	 infection.	 This	 was	 a	 novel	
association,	which	had	not	previously	been	assessed	in	epidemiological	studies	of	yaws	and	
warrants	 further	exploration.	Further	 studies	 to	better	delineate	 the	determinants	of	 yaws	
epidemiology	and	guide	appropriate	survey	design	and	health	care	interventions	would	be	of	
value.	
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Objective	3:	Assess	impact	of	azithromycin	MDA	on	yaws	prevalence	
(Research	Paper	–	Chapter	4)		
	
The	 two	 follow-up	 studies	 conducted	during	 the	PhD	demonstrated	a	marked	 reduction	 in	
both	clinical	and	serological	evidence	of	yaws	 infection	and	disease.	The	seroprevalence	of	
infection	declined	from	21.7%	prior	to	MDA	to	3.6%	at	six	months	and	at	eighteen	months	
was	4.3%;	no	individual	with	both	clinical	and	serological	evidence	of	active	yaws	was	found	
in	either	of	the	post-MDA	surveys.	These	findings	are	consistent	with	the	a	priori	hypothesis	
that	treatment	with	20mg/kg	of	azithromycin	would	effectively	treat	yaws	and	would	result	
in	a	decreased	prevalence	of	both	active	and	 latent	yaws	 in	 the	community.	The	results	of	
this	 study	 are	 the	 first	 evidence	 to	 support	 the	 use	 of	 the	 lower	 dose	 of	 azithromycin	 for	
yaws,	and	provide	 important	evidence	 for	potential	 synergies	between	trachoma	and	yaws	
control	programmes	in	the	Pacific	[7].	These	studies	also	add	to	data	from	other	settings	that	
mass	treatment	for	yaws	is	a	highly	effective	intervention	for	the	control	of	yaws	[8].		
	
Objective	4:	Identify	risk	factors	for	treatment	failure	following	MDA	
(Research	Paper	–	Chapter	4)		
	
The	 six-	 and	 eighteen-month	 follow-up	 surveys	 identified	 non-receipt	 of	 treatment	 at	 the	
individual	level	and	low	coverage	at	the	community	level	as	the	major	factors	associated	with	
the	 risk	 of	 infection	 following	 mass	 treatment.	 At	 six	 months,	 individuals	 who	 had	 not	
received	 azithromycin	 were	 significantly	 more	 likely	 to	 have	 serological	 evidence	 of	
compared	to	those	who	had	received	treatment	(aOR	3.9).	In	the	eighteen	month	follow-up	
survey,	the	coverage	achieved	at	the	village	level	remained	strongly	associated	with	the	risk	
of	infection,	with	individuals	in	a	village	where	coverage	was	below	80%	having	an	adjusted	
odds	ratio	of	6	compared	to	individuals	living	in	villages	where	a	coverage	of	more	than	90%	
was	achieved.	Taken	 together	with	 the	 findings	 summarized	below	 from	 the	mathematical	
modelling	studies,	these	data	suggest	that	multiple	high	coverage	(ideally	>	90%)	rounds	of	
mass	treatment	will	be	required	to	interrupt	transmission	of	yaws.		
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Objective	5:	Evaluate	diagnostic	tests	for	use	in	yaws	eradication	programmes	
(Research	Paper	–	Chapter	5)		
Current	 rapid	 syphilis	 tests	have	 limitations	as	 they	only	detect	 treponemal	antibodies	and	
can	 therefore	 not	 distinguish	 between	 past	 and	 current	 infection.	 In	 this	 study,	 the	 DPP-
Syphilis	 Screen	 &	 Confirm	 RDT	 was	 shown	 to	 have	 high	 specificity	 (>95%)	 for	 both	
treponemal	and	non-treponemal	antibodies	[9].	The	sensitivity	of	the	test	varied	significantly	
with	the	reference	RPR	titre.	For	samples	with	an	RPR	titre	of	≥1:16,	the	sensitivity	of	the	RDT	
was	 92%,	 but	 this	 decreased	 to	 below	 70%	 for	 samples	 with	 a	 RPR	 titre	 of	 <1:8.	 These	
variations	in	sensitivity	will	need	to	be	accounted	for	when	considering	the	role	of	the	RDT	in	
yaws	eradication	campaigns.	The	greater	sensitivity	at	higher	titres	suggests	the	RDT	may	be	
of	use	in	mapping	surveys	and	in	active	case	finding	during	an	intervention,	but	will	be	of	less	
value	 in	 surveillance	 post-MDA,	 when	 lower	 titre	 disease	 will	 be	more	 common	 and	 high	
sensitivity	 will	 be	 needed	 to	 ensure	 all	 cases	 are	 identified.	 Alternative	 strategies	 such	 as	
repeat	testing	of	negative	samples	may	be	of	value	 in	 increasing	the	sensitivity	of	the	RDT.	
The	 finding	 that	 alternative	 organisms	 such	 as	 Haemophilus	 ducreyi	 may	 cause	
phenotypically	similar	ulcers	highlights	the	fact	 that	additional	diagnostic	 tools	such	as	PCR	
are	 likely	 to	 also	 play	 a	 central	 role	 in	 post-MDA	 surveillance	 [10,11].	 Future	 evaluations	
should	consider	 the	optimum	diagnostic	 strategy	 for	each	of	 the	mapping,	 implementation	
and	surveillance	stages	of	yaws	eradication.	
	
Objective	6:	Identify	programmatic	requirements	for	yaws	eradication	programmes	
(Research	Paper	–	Chapter	6)		
Current	 recommendations	 about	 yaws	 eradication	were	 developed	 on	 the	 basis	 of	 expert	
opinion	and	data	from	previous	yaws	eradication	efforts	conducted	in	the	twentieth	century	
[12–14].	Only	one	previous	study	had	used	mathematical	modelling	to	address	the	question	
of	 yaws	 eradication,	 and	 the	 study	was	 designed	 to	measure	 the	 cost-effectiveness	 of	 an	
intervention,	 not	 its	 feasibility	 or	 programmatic	 requirements	 [15].	 In	 this	 study,	
programmatic	 thresholds	 were	 identified	 to	 interrupt	 transmission	 under	 different	
epidemiological	assumptions.	At	a	coverage	of	85%,	the	model	predicted	that	five	rounds	of	
treatment	 would	 have	 a	 greater	 than	 80%	 chance	 of	 achieving	 yaws	 eradication.	 The	
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coverage	thresholds	predicted	are	in-keeping	with	the	marked	effect	of	differential	coverage	
demonstrated	 in	 the	 post-MDA	 follow-up	 surveys.	 Together,	 these	 data	 suggest	 that	 a	
strategy	of	administering	multiple	rounds	of	mass	treatment	before	switching	to	active	case	
finding	may	 be	more	 effective	 than	 use	 of	 a	 single	 round	 of	mass	 treatment	 prior	 to	 that	
switch.	 Trials	 of	 this	 approach	 should	 be	 conducted.	 There	 is	 considerable	 uncertainty	
surrounding	 estimates	 of	 the	R0	 of	 yaws	 and	 this	 should	 be	 a	 priority	 for	 further	 research	
studies.	
	
7.2	Study	limitations	
	
Many	of	the	findings	in	the	study	were	derived	from	cross-sectional	studies.	This	design	has	
inherent	limitations	as	it	provides	only	a	snapshot	of	the	current	epidemiology	of	the	disease	
of	 interest	 at	 a	 specific	point	of	 time.	 There	were	 limited	data	available	 to	explore	 factors	
that	might	 explain	 the	marked	 clustering	 that	was	 observed	 in	 the	 pre-MDA	 survey.	 Data	
were	not	collected	on	alternative	foci	of	transmission	such	as	schools	or	places	of	worship,	or	
on	 other	 variables	 such	 as	 local	 climatic	 factors,	 which	 might	 be	 in	 part	 responsible	 for	
disease	 clustering.	 Fine-scale	 mapping	 capturing	 a	 wider	 range	 of	 environmental,	
infrastructure,	 and	personal	 variables	 should	be	 conducted	 to	more	accurately	explore	 the	
determinants	of	clustering.		
	
The	assessment	of	the	impact	of	mass	treatment	in	this	study	was	a	before-and-after	study	
design,	which	 does	 not	 provide	 evidence	 that	would	 be	 as	 robust	 for	 proving	 causality	 as	
evidence	derived	from	a	randomized	trial.	Whilst	the	findings	from	this	study	are	consistent	
with	other	pilot	implementations	of	azithromycin	MDA	for	yaws,	they	do	not	provide	direct	
evidence	as	 to	whether	MDA	with	 the	higher	dose	of	 azithromycin	would	have	been	even	
more	effective.	A	randomized	controlled	trial	was	not	felt	to	be	appropriate	in	the	context	of	
this	 study,	 where	 the	 MDA	 was	 being	 conducted	 by	 the	 Ministry	 of	 Health	 for	 a	
programmatic	 indication,	but	an	RCT	 is	being	undertaken	to	provide	definitive	evidence	on	
the	comparative	efficacy	of	the	lower	and	higher	doses	of	azithromycin	(Chapter	9	–	Future	
Studies).	
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Only	one	rapid	diagnostic	 test	was	assessed	 in	 this	study.	The	evaluation	conducted	 in	 this	
study	 was	 conducted	 in	 a	 lab	 setting.	 The	 performance,	 quality	 control	 and	 use	 of	 rapid	
diagnostic	tests	can	differ	significantly	in	the	field	setting	compared	to	in	a	lab.	More	detailed	
studies	 of	 the	 use	 of	 these	 test	 kits	 in	 ‘real-world’	 settings	 are	 planned	 to	 allow	 a	 more	
detailed	 exploration	 of	 the	 optimal	 use	 of	 RDTs	 for	 yaws	 diagnostics	 (Chapter	 9	 –	 Future	
Studies).	The	role	of	alternative	RDTs	and	diagnostic	tests,	including	point	of	care	nucleic	acid	
amplification	 tests	 such	 as	 LAMP	 assays,	 warrants	 evaluation,	 as	 they	may	 have	 a	 role	 in	
different	stages	of	yaws	eradication	efforts.	
	
The	mathematical	model	only	explored	a	 limited	number	of	treatment	strategies,	based	on	
current	WHO	recommendations,	and	did	not	explore	whether	alternative	approaches	such	as	
MDA	targeted	to	children	only,	would	be	more	efficient.	The	data	were	also	derived	from	a	
limited	set	of	data	from	the	Pacific	and	use	of	other	datasets	to	refine	and	validate	the	model	
should	be	considered.		
	
7.3	Conclusions	
	
Yaws	is	a	significant	public	health	problem	in	the	Solomon	Islands.	In	terms	of	the	number	of	
cases	 reported	 annually	 to	 WHO,	 the	 country	 is	 consistently	 amongst	 the	 three	 highest	
burden	countries	 in	the	world	[16].	The	aim	of	this	study	was	to	establish	accurate	data	on	
the	 epidemiology	 of	 yaws	 in	 the	 Solomon	 Islands,	 assess	 the	 impact	 of	 community	 mass	
treatment	with	azithromycin	for	trachoma	on	the	prevalence	of	yaws,	and	generate	data	to	
support	yaws	eradication	efforts.		
	
Cross-sectional	 surveys	 were	 conducted	 before	 and	 after	 mass	 treatment	 to	 establish	
accurate	 estimates	 of	 the	prevalence	of	 infection	 and	disease,	 and	 identify	 risk	 factors	 for	
disease	before	and	after	mass	treatment.		
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In	pre-mass	treatment	surveys	exposure	[1],	 latent	 infection	and	active	disease	were	found	
to	 be	 extremely	 common.	 Household	 and	 village-level	 risk	 factors	 were	 the	major	 factors	
associated	with	 risk	 at	 an	 individual	 level.	 A	 new	protective	 association	 between	 reported	
access	 to	 water	 and	 sanitation	 and	 risk	 of	 infection	 was	 noted.	 Significant	 clustering	 of	
disease	 was	 noted	 within	 endemic	 communities	 and	 future	 studies	 are	 required	 to	
understand	 the	 drivers	 of	 this	 clustering	 and	 their	 implications	 for	 both	 mapping	 and	
implementation	 of	 yaws	 eradication	 programmes.	 The	 pre-MDA	 studies	 demonstrated	 the	
weakness	of	clinical	diagnosis	 for	yaws.	Many	yaws-like	 lesions	were	found	 in	seronegative	
individuals,	 and	 amongst	 seropositive	 cases,	 Haemophilus	 ducreyi	 was	 identified	 as	 an	
alternative	aetiology	 in	a	 large	proportion	of	 lesions	 [3].	The	 findings	of	 these	studies	have	
significant	 implications	 for	 global	 yaws	 eradication	 efforts	 and	 highlight	 that	 point-of-care	
serological	tests,	augmented	by	molecular	diagnostics,	will	be	required.	
	
This	 study	 provided	 the	 first	 data	 that	 a	 lower	 dose	 of	 azithromycin	 (20mg/kg)	 might	 be	
effective	 as	 a	 treatment	 for	 yaws.	 The	 study	 demonstrated	 a	 sustained	 reduction	 in	
prevalence	 following	 a	 single	 round	 of	 mass	 treatment,	 whilst	 also	 demonstrating	 that	
further	 interventions	will	be	required	to	 interrupt	 transmission.	MDA	coverage	of	90%	was	
associated	 with	 significantly	 lower	 risk	 of	 infection	 being	 present	 in	 a	 community	 at	 18	
months	of	 follow-up.	These	 findings	were	consistent	with	 the	 findings	of	 the	mathematical	
modelling	study	and	confirm	the	need	for	new	approaches	to	increase	the	coverage	achieved	
during	treatment	campaigns	[17].	
	
In	summary,	this	PhD	has	addressed	several	key	questions	about	the	epidemiology	of	yaws.	
Even	within	endemic	populations,	the	disease	is	highly	focal.	 Integration	of	rapid	diagnostic	
tests	 into	 routine	 surveillance	may	 help	 improve	 data	 quality	 and	 guide	 yaws	 elimination	
efforts	at	a	national	level.	Given	the	strong	association	between	coverage	of	mass	treatment	
and	 risk	 of	 infection,	 demonstrated	 in	 this	 study,	 new	 strategies	 to	 increase	 coverage	 are	
needed.	 Mathematical	 modelling	 may	 be	 of	 use	 in	 informing	 the	 design	 of	 these	
interventions.		
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Chapter	8:	Progress	towards	yaws	eradication	
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cases than yaws. A rapid serological test has been validated for
yaws but, as H.ducreyi has been found both in sero-positive and
sero-negative individuals, serological diagnosis alone is unlikely
to be sufﬁcient. Access to serological diagnostics, and in the cer-
tiﬁcation phase molecular diagnostics, will need to be scaled-up
signiﬁcantly if the eradication target is to be achieved.
A key requirement for disease eradication is the absence of
an animal reservoir. An emerging body of evidence suggests
there may be a non-human primate (NHP) reservoir for yaws.
Serological and molecular evidence for a disease caused by
T.pallidum has now been documented in NHPs across a range of
countries in Africa, which are currently or formerly endemic for
yaws.8 Alongside this ecological data, there is evidence that
experimental infection of humans with NHPs strains is possible,
and vice versa. Whether zoonotic transmission occurs in the
wild remains an open but vital question.
Social and political factors
Social and political support is of fundamental importance for the
success of any eradication campaign. The WHA resolution is an
important step towards galvanising international political sup-
port for yaws eradication. As a disease predominantly of morbid-
ity not mortality, yaws may not be perceived as a public health
priority even in the countries where it is endemic. Maintaining
political support is likely to become an increasing challenge as
WHO scales up eradication efforts, global case numbers fall but
the costs of on-going eradication efforts remain high.
Modelling work suggests that yaws eradication is cost-
effective in the long term and it is hoped that this will help con-
vince donors to support yaws eradication.9 These ﬁndings are
based on a number of assumptions, which may not hold true.
Firstly, the model assumed that transmission would be inter-
rupted everywhere by a limited number of rounds of high cover-
age treatment (90–99% coverage), although there are limited
empirical data to support this. Secondly, data from NTD pro-
grammes shows that such high coverage is rarely achieved in
the real world.10 Finally, the model assumed that only surveil-
lance would be required in all of the formerly endemic countries.
If any of these countries were found to be currently endemic
then the overall costs of yaws eradication may rise sharply.
Finally, many other NTD elimination/eradication programmes
have beneﬁtted from the creation of donation schemes to sup-
port drug and implementation costs. At present no such
donation programme exists for yaws and this represents a sig-
niﬁcant barrier to the scaling up of yaws eradication efforts.
Conclusions
There are four years remaining until the 2020 target for yaws
eradication. At this point it seems unlikely that this target will
be met. The ﬁrst phases of yaws eradication have already
revealed a number of unexpected ﬁndings and it seems likely
that further obstacles will emerge on the road to eradication.
Despite these obstacles, progress has been made in the devel-
opment of new diagnostic tools and pilot studies demonstrating
the effectiveness of azithromycin mass treatment. A sustained
commitment from the WHO, countries and the academic com-
munity will be required if the goal of yaws eradication is to be
achieved.
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Chapter	9:	Future	studies	
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The	 findings	 of	 this	 PhD	 and	 other	 studies	 conducted	 over	 the	 same	 time	 period	 are	
informing	the	design	of	future	studies.	As	part	of	the	PhD	I	have	helped	to	draft	the	research	
priorities	for	achieving	yaws	eradication	[1].	
	
Further	mapping	 studies	are	being	planned	 in	a	number	of	 yaws	endemic	 countries	where	
there	are	currently	inadequate	epidemiological	data	to	guide	programmatic	decision-making.	
Data	from	these	studies	will	feed	in	to	refinements	of	mathematical	models	including	spatial	
modelling	and	 into	 the	design	of	optimum	sampling	 strategies	 for	both	pre	and	post-MDA	
yaws	surveys.	On-going	work	is	exploring	how	integrated	surveillance	for	multiple	NTDs	can	
be	 undertaken,	 either	 by	 use	 of	 shared	 sampling	 methodologies,	 or	 by	 testing	 a	 single	
sample,	such	as	a	dried	blood	spot,	for	multiple	targets	simultaneously	[2].	The	finding	that	
other	 organisms	 may	 be	 responsible	 for	 yaws-like	 lesions	 in	 endemic	 communities	 has	
profound	 implications	 for	 surveillance	 [3].	More	detailed	molecular	epidemiological	 studies	
are	 required	 to	 explore	 the	 relative	 importance	 of	 these	 organisms	 and	 understand	 their	
relevance	within	the	context	of	yaws	eradication	efforts.	
	
Emerging	 epidemiological	 data	 suggests	 that	 non-human	 primates	 may	 be	 a	 possible	
reservoir	 for	yaws	[4].	Whilst	not	relevant	 in	 the	Pacific,	 this	 finding	would	have	significant	
implications	for	global	yaws	eradication	efforts.	Collaborations	are	planned	with	groups	with	
expertise	 in	 zoonotic	 infections	 in	 both	 Africa	 and	 Asia	 to	 explore	 the	 relevance	 of	 these	
findings	to	human	yaws.	
	
A	number	of	future	studies	are	planned	to	investigate	how	mass	treatment	for	yaws	can	be	
optimized.	These	 include	studies	of	 the	optimum	dose	of	azithromycin,	alternative	delivery	
strategies	 for	MDA	 and	whether	MDA	 for	 yaws	 can	 be	 integrated	with	 other	NTD	 control	
programmes.		
	
In	 line	 with	 our	 finding	 that	 a	 lower	 dose	 of	 azithromycin	 appears	 to	 be	 effective	 in	 the	
treatment	 of	 yaws,	 a	 formal	 randomized	 controlled	 non-inferiority	 study	 comparing	 the	
lower	dose	(20mg/kg)	and	higher	dose	(30mg/kg)	of	azithromycin	 in	the	treatment	of	both	
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active	and	latent	yaws	(NCT02344628)	has	been	commenced.	The	study	will	recruit	patients	
in	both	Ghana	and	Papua	New	Guinea,	and	aims	to	provide	definitive	data	on	the	efficacy	of	
the	lower	dose	of	azithromycin.	
	
Informed	by	the	findings	from	both	the	fieldwork	and	modelling	studies	of	this	PhD,	a	cluster-
randomized	 study	 is	 being	 designed	 to	 assess	 different	 strategies	 to	 improve	 the	
effectiveness	 of	 yaws	 eradication	 strategies.	 The	 trial	 will	 compare	 a	 control	 arm	 of	 the	
standard	WHO	strategy	with	two	alternative	strategies;	the	first	experimental	arm	will	utilize	
multiple	 rounds	of	community	mass	drug	administration	prior	 to	active	case	 finding,	whilst	
the	 second	experimental	arm	will	 add	 school	based	mass	drug	administration	 to	 the	 initial	
community	 based	mass	 drug	 administration.	 These	 studies	will	 help	 inform	more	 detailed	
mathematical	models	and	guide	scale	up	of	yaws	eradication	efforts.		
	
Co-administration	is	an	attractive	strategy	to	potentially	increase	coverage	and	efficiency	of	
NTD	 MDA	 programmes.	 A	 lack	 of	 large	 field	 studies	 on	 the	 feasibility	 and	 safety	 of	 co-
administration	 remains	 a	 barrier	 to	 its	 implementation.	 Working	 with	 colleagues	 at	 the	
University	 of	 Melbourne	 and	 the	 University	 of	 New	 South	 Wales,	 I	 am	 investigating	 the	
safety,	feasibility	and	efficacy	of	co-administration	of	azithromycin	and	ivermectin	as	part	of	
combined	 intervention	 for	 trachoma	 and	 scabies.	 	 A	 combined	 approach	 would	 be	 of	
particular	 value	 in	 the	 Pacific	 where	 scabies,	 yaws	 and	 trachoma	 are	 all	 endemic	 [5,6].	 A	
further	study	of	co-administration	of	azithromycin,	albendazole	and	ivermectin	is	planned	in	
Ethiopia.	 Taken	 together,	 these	 studies	 should	 form	 the	 basis	 for	 generating	 scientific	
consensus	about	co-administration.		
	
An	 impact	 of	 mass	 drug	 administration	 on	 ‘off-target’	 organisms	 has	 previously	 been	
demonstrated.	 In	 the	 setting	 of	 azithromycin	 MDA	 for	 trachoma	 an	 increase	 in	 resistant	
pneumococcus	has	been	demonstrated	in	nasopharyngeal	samples	[7].	There	are	no	current	
data	 on	 the	 impact	 of	 azithromycin	 MDA	 on	 other	 skin	 organisms.	 Both	 Streptococcus	
pyogenes	 and	 Staphylococcus	 aureus	 are	 common	 causes	 of	 skin	 disease	 in	 the	 tropics,	
particularly	where	scabies	is	endemic	[6].	Mass	drug	administration	with	azithromycin	might	
163
		
	
	
	
have	a	beneficial	impact	in	reducing	the	prevalence	of	impetigo	but	could	also	prove	harmful	
if	it	results	in	an	increase	in	resistant	organisms.	A	study	to	assess	the	impact	of	azithromycin	
on	 common	 skin	 organisms	 using	 both	 culture	 and	 molecular	 based	 diagnostics	 is	 being	
planned	and	will	be	undertaken	in	Malaita	province	of	the	Solomon	Islands.	
	
Studies	are	planned	to	operationalize	the	use	of	the	DPP-RDT	in	yaws	endemic	communities.	
These	studies	are	designed	both	to	design	quality	control	measures	that	can	be	implemented	
in	a	resource	poor	setting	and	to	use	mixed	methods	to	assess	the	acceptability	of	the	test	to	
both	healthcare	providers	and	patients.		
	
The	development	of	an	integrated	approach	to	Neglected	Tropical	Diseases	is	a	major	focus	
of	future	work.	Consolidating	vertical	programmes	is	important	to	help	support	fragile	health	
systems,	maximise	efficiency	and	realise	crosscutting	programmatic	benefits.	It	is	hoped	that	
the	work	 presented	 in	 this	 thesis	 and	 the	 future	 studies	 outlined	 above	will	 contribute	 to	
making	this	a	reality.		
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Chapter	10:	Appendices	
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Appendix	10.1:	Skin	lesion	appearance	coding	
	
1. Papilloma:	single	or	multiple	yellow	bumps	on	the	skin.	
2. Ulcer	
3. Painful	Ulcer	
4. Painless	Ulcer	
5. Squamous	Macule:	Scaly,	thickened	or	discoloured	skin	patches	
6. Palmar/Plantar	Lesion:	holes,	cracks,	discolouration	on	soles	of	feet	or	palms	of	hands	
7. Healed	lesion:	re-epithelized	or	healed	lesion	
8. Non-Yaws	Lesion:	Free	Text	Comment	
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Appendix	10.2:	Skin	lesion	location	coding	
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Appendix	10.3:	Sampling,	storage	and	transport	of	samples	for	yaws	testing	
	
Samples	 should	be	 submitted	 for	 laboratory	 testing	 in	 accordance	with	 the	procedures	 for	
collection,	storage	and	transportation	described	below.	
	
Lesions	
	
1. Use	 one	 or	 two	 sterile	 dacron-	 or	 cotton-tipped	 swabs	 to	 collect	 material	 from	
primary	or	secondary	lesions.	
2. Gently	press	and	roll	the	swab	along	the	lesion	taking	care	to	collect	exude	and	skin.		
3. Suspend	one	swab	in	a	cyrotube	containing	1ml	transport	medium	(AssayAssure			 	 	 ,	
http://www.sierramolecular.com/products	).	Press	and	roll	the	swab	along	the	side	of	
the	tube	to	express	the	clinical	material	and	excess	fluid.	Discard	the	swab.	
4. 	Place	the	second	swab	onto	the	Indicating	FTA	Elute	MicroCard	(GE	Healthcare)	using	
3	side-to-side	motions,	90	degrees	each	way	while	pressing	onto	the	card.	Discard	the	
swab	and	allow	the	card	to	air	dry	at	room	temperature	completely	(approximately	3	
hours).	
	
Venepuncture	samples	
1. Clean	the	skin	with	an	alcohol	swab	and	allow	to	dry.	
2. Perform	venepuncture	using	aseptic	non-touch	technique.	
3. Collect	1	mL	of	blood	in	a	serum	tube	(red	top)	for	serology.		
4. Discard	the	syringe	in	to	an	appropriate	sharps	container.	
	
Dried-Blood	Spots	
1. Clean	the	finger	to	be	pricked	with	an	alcohol	swab	and	allow	to	dry.	
2. Prick	 the	 internal	 side	 of	 the	 finger	 using	 a	 sterile	 lancet.	 Discard	 the	 lancet	 into	 a	
sharp’s	container.	
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3. After	pricking	the	finger,	collect	the	blood	directly	onto	each	extension.	Be	sure	the	
extensions	are	completely	red	on	both	sides	(no	white	showing).		
4. Place	the	labelled	disk	onto	a	pencil	inserted	into	a	styrofoam	drying	rack.	Completely	
air–dry	the	disks	at	room	temperature	overnight	if	possible	or	for	at	least	2	hours.	To	
avoid	contamination,	disks	should	not	touch	each	other	while	drying.	
5. When	 the	disk	has	dried	completely,	place	 it	 in	a	 small	plastic	bag	with	a	desiccant	
sachet.	
	
Conservation	and	transport	of	samples	
Samples	collected	in	to	AssayAssure	transport	medium	can	be	stored	at	room		temperature	
for	a	maximum	of	two	weeks	but	should	ideally	be	stored	in	a	refrigerator		(4oC)	or	freezer	(-
20oC).	Filter	paper	samples	(dried	blood	samples	and	FTA	Elute	Microcards)	should	be	stored	
in	a	sealed	bag	along	with	a	desiccant	sachet.		
	
Frozen	specimens	should	be	packaged	appropriately	and	shipped	on	dry	ice	to	the	laboratory	
for	 testing.	 If	dry	 ice	 is	not	available,	samples	should	be	placed	with	 frozen	cold	packs	 in	a	
tightly	 sealed	 Styrofoam	 box.	 Filter	 paper	 cards	 can	 be	 shipped	 either	 frozen	 or	 at	 room	
temperature.	
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Appendix	10.4:	LSHTM	lab	protocol	
V1.0	(14/01/2014)	
	
	
This	 standard	 operating	 procedure	 outlines	 the	 approach	 to	 testing	 of	 serum	 samples	
collected	as	part	of	the	research	project	“Yaws	in	the	Solomon	Islands:	impact	of	a	national	
trachoma	control	programme	on	yaws	clinical	disease,	seroprevalence	and	drug	resistance.”	
	
Samples	will	be	tested	with	TPPA	and	RPR.	
	
Initial	testing	will	be	
• TPPA	
• RPR	at	½	Dilution	
	
Additional	 RPR	 dilutions	 will	 be	 completed	 on	 samples	 that	 are	 TPPA	 positive	 and	 RPR	
reactive	at	½.	
	
Sample	Preparation	
	
Samples	are	prepared	to	test	in	blocks	of	94	specimens	at	a	time.	
	
Preparation	of	a	Master	Plates	
• Samples	are	plated	into	a	96	deep	well	plate	
• Spaces	A1/B1	are	left	blank.		
• Defrost	serum	sample	
• Vortex	the	sample	
• Pipette	160	microlitres	into	the	well	
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TPPA	Protocol	
	
• Reconstitute	 sensitized	 and	 unsensitized	 TPPA	 particle	 kits	 with	 reconstitution	
solution	–	30	minutes	before	needed	
• Put	100	microlitres	of	diluent	in	rows	1,	5	and	9	
• Put	25	microlitres	of	diluent	in	row	2	to	4,	6	to	8	and	10	to	12.	
• Add	25	microlitres	of	sample	to	wells	1,	5	and	9	and	mix	
• Transfer	25	microlites	from	row	1	to	2,	2	to	3	and	3	to	4	mixing	at	each	step	
• Add	1	drop	of	25	microlitres	of	unsensitized	particles	to	wells	3,	7	and	11	
• Add	1	drop	of	25	microlitres	of	sensitized	particles	to	wells	4,	8	and12	
• Cover	the	plate	
• Gently	shake	the	plate	
• Cover	for	2	hours	
• Read	result	at	2	hours	
• Repeat	testing	on	any	indeterminate	samples	
	
RPR	Protocol	
	
Initial	Testing:	
Each	 card	 has	 ten	 spaces.	 We	 will	 use	 8	 for	 testing	 samples	 and	 2	 for	 positive/negative	
controls.	We	will	be	testing	½	dilutions.	
	
1. For	each	sample	
a. Prepare	a	½	dilution	sample	of	total	volume	50	microlites	
i. Pipette	25	microlitres	of	specimen	in	circle	
ii. Pipette	25	microlitres	of	isotonic	saline	in	circle	
b. Add	one	drop	of	antigen	to	each	circle	
c. Spread		within	circle	
2. Add	Positive	and	Negative	controls	to	appropriate	spaces	on	the	test	card	
3. Rotate	test	card	for	8	minutes	
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4. Read	result	immediately	
5. Repeat	testing	on	any	indeterminate	samples	
	
Quantitative		
1. Prepare	 a	 plate	 containing	 dilutions	 of	 each	 sample	 across	 the	 range	½	 through	 to	
1/512		
2. Test	each	dilution	as	per	RPR	protocol	
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